Mitochondria containing anticancer drugs and their applications
By combining anticancer agents with modified mitochondria, and utilizing the mitochondrial-specific binding to antibodies on the surface of tumor cells, the problems of large side effects and low efficiency of existing anticancer agents are solved, achieving highly efficient targeted delivery of compounds and specific killing of cancer cells.
Patent Information
- Application Number
- CN202180072536.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-10-22
- Filing Date
- 2021-10-22
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-10-22
AI Technical Summary
Existing anticancer agents have problems such as large side effects and low efficiency in treating cancer. Moreover, cancer cells have different energy metabolism than normal cells, making it difficult for traditional methods to effectively target and kill cancer cells.
By combining anticancer agents with modified mitochondria, and utilizing the mitochondrial-specific binding to antibodies or fragments of them on the surface of tumor cells, the compounds are delivered in a targeted manner, forming mitochondria containing anticancer agents, which can be used to prepare pharmaceutical compositions for the treatment of cancer.
It achieves efficient delivery and targeting of compounds, significantly improves anti-cancer effects, reduces side effects, and specifically kills cancer cells.
Smart Images

Figure CN116249557B_ABST
Abstract
Description
Technical Field
[0001] The present invention provides a compound capable of modifying mitochondria, mitochondria containing the compound, and a pharmaceutical composition containing the mitochondria as an active ingredient. Background Technology
[0002] Mitochondria are organelles in eukaryotic cells, involved in the synthesis and regulation of adenosine triphosphate (ATP), the cell's energy source. Mitochondria are involved in various metabolic pathways within the body, such as cell signaling, cell differentiation, cell death, and the control of the cell cycle and cell growth. Mitochondria have their own genome and play a central role in cellular energy metabolism. They produce energy through electron transport and oxidative phosphorylation and play a crucial role in apoptosis signaling pathways.
[0003] It has been reported that decreased energy production due to declining mitochondrial function can trigger various diseases. When the function of the electron transport chain reaction declines due to changes in the mitochondrial genome and proteome, it leads to reduced ATP production, excessive production of reactive oxygen species, and decreased calcium regulation. In this situation, mitochondrial membrane permeability changes, apoptosis may occur abnormally, and cancer and incurable diseases may result.
[0004] Therefore, reported human diseases caused by mitochondrial dysfunction include mitochondrial-related genetic diseases, diabetes, heart disease, Alzheimer's disease (Parkinson's or Alzheimer's), and the development of various cancers and cancer metastases. Furthermore, impaired apoptosis, increased inflammatory responses, and increased abnormal metabolism are common features in more than 200 different cancers. All these processes are closely related to mitochondrial function, and the correlation between cancer and mitochondria has attracted considerable attention.
[0005] On the other hand, it is known that normal cells produce 36 ATP molecules per glucose molecule through the electron transport system. However, cancer cells differ from normal cells; under sufficient oxygen conditions, they produce only 2 ATP molecules per glucose molecule through glycolysis (aerobic glycolysis). Therefore, it can be concluded that cancer cells, unlike normal cells, utilize the inefficient process of glycolysis to produce the amino acids, lipids, and nucleic acids necessary for rapid cell proliferation. For this reason, cancer cells require less oxygen and produce a larger amount of lactic acid than normal cells.
[0006] Therefore, abnormal metabolism in cancer cells leading to changes in the cancer microenvironment, inhibition of apoptosis due to mitochondrial dysfunction, and increased inflammatory responses, along with other abnormal metabolic reactions in cancer cells, play a crucial role in cancer proliferation. Thus, developing metabolism-related anticancer agents utilizing these characteristics may be a good way to address the side effects and economic problems of traditional anticancer drugs. On the other hand, there have recently been attempts to directly administer or develop mitochondria as drugs (Korean Patent Registration No. 10-2111321). Summary of the Invention
[0007] Technical issues
[0008] Therefore, in the process of studying the anticancer activity of mitochondria, the inventors completed this invention by demonstrating that mitochondria have excellent anticancer effects when used in combination with conventionally used anticancer agents.
[0009] Technical solution
[0010] In one aspect of the invention, a mitochondrial comprising an anticancer agent and a pharmaceutical composition comprising the same for the prevention or treatment of cancer are provided.
[0011] In another aspect of the invention, a method for preparing mitochondria containing an anticancer agent is provided, comprising mixing the anticancer agent and isolated mitochondria.
[0012] In another aspect of the invention, a modified anticancer agent is provided, wherein TPP is chemically combined with the anticancer agent.
[0013] In another aspect of the invention, a method for preventing or treating cancer is provided, comprising administering to a subject a pharmaceutical composition comprising mitochondria containing an anticancer agent.
[0014] Invention Effects
[0015] It has been confirmed that mitochondria containing compounds with anticancer effects according to the present invention can efficiently deliver the compounds to tumors, and the anticancer effects of mitochondria containing the compounds have been demonstrated. Specifically, the compounds can be specifically delivered to tumors when tumor-specific antibodies or fragments thereof bind to the mitochondrial surface. Therefore, due to the few side effects of the compounds, mitochondria containing the compounds according to the present invention can be effectively used to treat cancer. Attached Figure Description
[0016] Figure 1 A schematic diagram of an expression vector for expressing a single-chain variable region fragment of an anti-HER2 antibody in fused mitochondrial form is shown.
[0017] Figure 2The results show the expression of the anti-HER2 antibody single-chain variable region fragment in the human fetal kidney cell line (HEK293), as confirmed by Western blot.
[0018] Figure 3 The results, confirmed by confocal microscopy, show the intracellular location of the single-chain variable region fragment of the anti-HER2 antibody expressed in the human fetal kidney cell line (HEK293). Scale bar represents 10 μm.
[0019] Figure 4 The results, confirmed by Western blot, show that the single-chain variable region fragment of the anti-HER2 antibody expressed in the human fetal kidney cell line (HEK293) is located in the same intracellular location as mitochondria.
[0020] Figure 5 The image shows mitochondria (MTs) isolated from a human fetal kidney cell line (HEK293) expressing a single-chain variable region fragment of an anti-HER2 antibody. α-HER2scFv The graph shows the ATP measurement results. In this case, the control group consisted of mitochondria isolated from HEK293 cells that did not express the anti-HER2 antibody single-chain variable region fragment.
[0021] Figure 6 The image shows mitochondria (MTs) isolated from a human fetal kidney cell line (HEK293) expressing a single-chain variable region fragment of an anti-HER2 antibody. α-HER2scFv The graph shows the results of membrane potential measurements. In this case, the control group consisted of mitochondria isolated from HEK293 cells that did not express the anti-HER2 antibody single-chain variable region fragment.
[0022] Figure 7 The image shows mitochondria (MTs) isolated from a human fetal kidney cell line (HEK293) expressing a single-chain variable region fragment of an anti-HER2 antibody. α-HER2scFv The graph shows the results of reactive oxygen species (ROS) measurements in HEK293 cells. In this case, the control group consisted of mitochondria isolated from HEK293 cells that did not express the single-chain variable region fragment of the anti-HER2 antibody.
[0023] Figure 8 The results show the expression of HER2 in human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), lung fibroblast cell line (WI-38), and human gastric cancer cell lines (NCI-N87 and MKN-74), as confirmed by Western blot.
[0024] Figure 9The results show the expression of HER2 in human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), human lung fibroblast cell line (WI-38), and human gastric cancer cell lines (NCI-N87 and MKN-74), as confirmed by immunocytochemical staining.
[0025] Figure 10 The results show the expression of HER2 in human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), and human gastric cancer cell lines (NCI-N87 and MKN-74), as confirmed by flow cytometry.
[0026] Figure 11 The image shows mitochondria (MTs) isolated from the human fetal kidney cell line (HEK293) expressing a single-chain variable region fragment of an anti-HER2 antibody. α-HER2scFv Experimental methods for HER2 targeting ability.
[0027] Figure 12 Showing HER2 + Cells (human breast cancer cell line SK-BR-3) and HER2 - Cells (human lung cancer cell line NCI-H1975) were co-cultured and then used MT α-HER2scFv The results of intracellular expression of HER2 and the anti-HER2 antibody single-chain variable region fragment, confirmed by immunocytochemical staining, after treatment of the culture medium. In this case, MT was a mitochondrial isolated from HEK293 cells that did not have the anti-HER2 antibody single-chain variable region fragment fused to it.
[0028] Figure 13 Showing HER2 + Cells (human breast cancer cell line BT-474) and HER2 - Cells (human lung cancer cell line NCI-H1975) were co-cultured and then used MT α-HER2scFv Following cell treatment, intracellular expression of HER2 and the anti-HER2 antibody single-chain variable region fragment was confirmed by immunocytochemical staining. In this case, MT was a mitochondrial isolated from HEK293 cells that did not have the anti-HER2 antibody single-chain variable region fragment fused to it.
[0029] Figure 14 Showing HER2 + Cells (human gastric cancer cell line NCI-N87) and HER2 - Cells (human gastric cancer cell line MKN-74) were co-cultured and then used MT α-HER2scFvFollowing cell treatment, intracellular expression of HER2 and the anti-HER2 antibody single-chain variable region fragment was confirmed by immunocytochemical staining. In this case, MT was a mitochondrial isolated from HEK293 cells that did not have the anti-HER2 antibody single-chain variable region fragment fused to it.
[0030] Figure 15 Showing HER2 + Cells (human breast cancer cell line SK-BR-3) and HER2 - Cells (human breast cancer cell line MDA-MB-231) were co-cultured and then used MT α-HER2scFv Following cell treatment, intracellular expression of HER2 and the anti-HER2 antibody single-chain variable region fragment was confirmed by immunocytochemical staining. In this case, MT was a mitochondrial isolated from HEK293 cells that did not have the anti-HER2 antibody single-chain variable region fragment fused to it.
[0031] Figure 16 Showing HER2 + Cells (human breast cancer cell line BT-474) and HER2 - Cells (human breast cancer cell line MDA-MB-231) were co-cultured and then used MT α-HER2scFv Following cell treatment, intracellular expression of HER2 and the anti-HER2 antibody single-chain variable region fragment was confirmed by immunocytochemical staining. In this case, MT was a mitochondrial isolated from HEK293 cells that did not have the anti-HER2 antibody single-chain variable region fragment fused to it.
[0032] Figure 17 The preparation of DOX_MT was shown. α-HER2scFv The method in which MT α-HER2scFv It was stained with MitoTracker Green and bound to the compound payload doxorubicin.
[0033] Figure 18 The images show human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231) and human lung cancer cell line (NCI-H1975) as observed by confocal microscopy using DOX_MT. α-HER2scFv The result after processing.
[0034] Figure 19 The images show human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) as observed by confocal microscopy using DOX_MT. α-HER2scFv The morphological changes and death process of cancer cells over time after treatment.
[0035] Figure 20 The table shows the standard curve obtained by measuring the absorbance of doxorubicin at each concentration.
[0036] Figure 21 The measurement was displayed using DOX or DOX_MT. α-HER2scFv A graph showing the results of cytotoxicity treatments on human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), and human gastric cancer cell lines (NCI-N87 and MKN-74). In this case, MT refers to MT without DOX loading. α-HER2scFv .
[0037] Figure 22 The measurement was displayed using DOX or DOX_MT. α-HER2scFv A graph showing the results of cytotoxicity treatment of human lung fibroblast cell lines (WI-38 and CCD-8Lu). In this case, MT is MT without DOX loading. α-HER2scFv .
[0038] Figure 23 This shows confirmation of DOX or DOX_MT. α-HER2scFv IC50 was observed in human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), human gastric cancer cell lines (NCI-N87 and MKN-74), and human lung fibroblast cell lines (WI-38 and CCD-8Lu). 50 The result of the value.
[0039] Figure 24 The measurement was performed using 0.5 μM DOX or DOX_MT. α-HER2scFv Charts showing the results of cytotoxicity treatments on human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), human gastric cancer cell line (NCI-N87 and MKN-74), and human lung fibroblast cell line (WI-38 and CCD-8Lu). In this case, MT refers to MT without DOX loading. α-HER2scFv .
[0040] Figure 25 The results show that human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were confirmed by TUNEL assay using MT. α-HER2scFv or DOX_MT α-HER2scFv The result of cell apoptosis after treatment.
[0041] Figure 26 The results showed confirmation by Western blot analysis using MT. α-HER2scFv or DOX_MTα-HER2scFv Results of apoptosis induced by treatment of human breast cancer cell lines (SK-BR-3 and BT-474).
[0042] Figure 27 The results show that human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were confirmed by flow cytometry using MT. α-HER2scFv or DOX_MT α-HER2scFv The result of cell apoptosis after treatment. In this case, MT is MT without DOX loading. α-HER2scFv .
[0043] Figure 28 This shows confirmation of DOX_MT α-HER2scFv Experimental method for selective killing of cancer cells expressing HER2.
[0044] Figure 29 The results showed that the human breast cancer cell line BT-474 (HER2) was confirmed to be effective by TUNEL assay. + (white arrow) and human lung fibroblast cell line WI-38 (HER2) - Co-culture, then using DOX_MT α-HER2scFv Results of cell apoptosis treatment.
[0045] Figure 30 The synthesis process of triphenylphosphine (TPP)-doxorubicin (TPP-DOX) is shown.
[0046] Figure 31 The results of the TPP-DOX MRI analysis are shown.
[0047] Figure 32 The preparation of TPP-DOX_MT was shown. α-HER2scFv The method in which MT α-HER2scFv It was stained with MitoTracker Green and bound to the compound's payload TPP-DOX.
[0048] Figure 33 The images show human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231) and lung cancer cell line (NCI-H1975) as observed by confocal microscopy using TPP-DOX_MT. α-HER2scFv The result after processing.
[0049] Figure 34 The human breast cancer cell lines (SK-BR-3 and BT-474) and the human gastric cancer cell line (NCI-N87) observed by confocal microscopy are shown using TPP-DOX_MT. α-HER2scFv The morphological changes and death process of cancer cells after treatment.
[0050] Figure 35 The measurement was shown using TPP-DOX and TPP-DOX_MT. α-HER2scFv Results of cytotoxicity treatment of human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), and human gastric cancer cell lines (NCI-N87 and MKN-74). In this case, MT refers to MT without DOX loading. α-HER2scFv .
[0051] Figure 36 It displays the measurement using TPP-DOX and TPP-DOX_MT. α-HER2scFv Results of cytotoxicity treatment of human lung fibroblast cell lines (WI-38 and CCD-8Lu). In this case, MT is MT without DOX loading. α-HER2scFv .
[0052] Figure 37 The confirmed TPP-DOX and TPP-DOX_MT were displayed. α-HER2scFv IC50 was observed in human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), human gastric cancer cell lines (NCI-N87 and MKN-74), and human lung fibroblast cell lines (WI-38 and CCD-8Lu). 50 The result of the value.
[0053] Figure 38 The measurement was performed using 0.5 μM TPP-DOX or TPP-DOX_MT. α-HER2scFv Results of cytotoxicity treatment of human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), human gastric cancer cell line (NCI-N87 and MKN-74), and human lung fibroblast cell line (WI-38 and CCD-8Lu).
[0054] Figure 39 The results show that human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231) and gastric cancer cell line (NCI-N87) were confirmed by TUNEL assay using MT. α-HER2scFv Or TPP-DOX_MT α-HER2scFv The result of cell apoptosis after treatment.
[0055] Figure 40 The results showed confirmation by Western blot analysis using MT. α-HER2scFv Or TPP-DOX_MT α-HER2scFvResults of apoptosis induced by treatment of human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87).
[0056] Figure 41 This demonstrates the effect of flow cytometry on MT. α-HER2scFv Or TPP-DOX_MT α-HER2scFv Results of apoptosis induced by treatment of human breast cancer cell lines (SK-BR-3 and BT-474) and gastric cancer cell line (NCI-N87).
[0057] Figure 42 This confirms TPP-DOX_MT α-HER2scFv Experimental method for selective killing of cells expressing HER2.
[0058] Figure 43 The results showed that the human breast cancer cell line SK-BR-3 (HER2) was confirmed to be effective by TUNEL assay. + (white arrow) and human lung fibroblast cell line CCD-8Lu (HER2) - Co-culture, then using TTP-DOX_MT α-HER2scFv The result of cell apoptosis after cell treatment.
[0059] Figure 44 A schematic diagram of an expression vector for expressing a single-chain variable region fragment of an anti-PDL1 antibody in fused mitochondrial form is shown.
[0060] Figure 45 The results show the results of Western blot confirmation of the single-chain variable region fragment of the anti-PDL1 antibody expressed in the human fetal kidney cell line (HEK293).
[0061] Figure 46 The results show the expression of PD-L1 in human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484) as confirmed by Western blot.
[0062] Figure 47 The following is a demonstration of the method used to verify PDL1. + Cells and PDL1 - Cell co-culture, followed by the use of mitochondria (MTs) isolated from a human fetal kidney cell line (HEK293) expressing a single-chain variable region fragment of an anti-PDL1 antibody. α-PDL1scFv After cell treatment, MT α-PDL1scFv Experimental methods for PDL1 targeting capability.
[0063] Figure 48This demonstrates the efficacy of immunocytochemical staining in the human gastric cancer cell line SNU-216 (PDL1). + (white arrow) and SNU-484 (PDL1) - Co-culture, or co-culturing the human pancreatic cancer cell line BXPC-3 (PDL1) + (white arrow) and human pancreatic cancer cell line CFPAC-1 (PDL1) - Co-culture, then using MT α-PDL1scFv The result of intracellular expression of the single-chain variable region fragment of the anti-PDL1 antibody after cell treatment. In this case, MT is a mitochondrial isolated from HEK293 cells that does not have the single-chain variable region fragment of the anti-PDL1 antibody fused to it.
[0064] Figure 49 The preparation of DOX_MT was shown. α-PDL1scFv The method in which MT α-PDL1scFv It was stained with MitoTracker Green and bound to the compound payload doxorubicin (DOX).
[0065] Figure 50 The measurement was shown using MT. α-PDL1scFv or DOX_MT α-PDL1scFv Chart showing the results of cytotoxicity treatment of human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484).
[0066] Figure 51 The results show that human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484), confirmed by Western blot, were used with MT. α-PDL1scFv or DOX_MT α-PDL1scFv The results of apoptosis in the treated cells.
[0067] Figure 52 A schematic diagram of an expression vector for expressing a single-chain variable region fragment of an anti-mesothelin (MSLN) antibody in fused mitochondrial form is shown.
[0068] Figure 53 The results show the expression of the single-chain variable region fragment of the anti-MSLN antibody in the human fetal kidney cell line (HEK293) as confirmed by Western blot.
[0069] Figure 54 The preparation of PBA_MT was shown. α-MSLNscFv The method in which MT α-MSLNscFv It was stained with MitoTracker Green and bound to the compound payload pheophytic acid A (PBA).
[0070] Figure 55 The measurement was shown using MT. α-MSLNscFv or PBA_MT α-MSLNscFv A graph showing the results of cytotoxicity treatment of the human pancreatic cancer cell line (AsPC-1). MT α-MSLNscFv For PBA_MT α-MSLNscFv The negative control.
[0071] Figure 56 The measurement was shown using MT. α-MSLNscFv or PBA_MT α-MSLNscFv A graph showing the results of cytotoxicity treatment of the human pancreatic cancer cell line (Capan-1). MT α-MSLNscFv For PBA_MT α-MSLNscFv The negative control.
[0072] Figure 57 The measurement was shown using MT. α-MSLNscFv or PBA_MT α-MSLNscFv A graph showing the results of cytotoxicity treatment of the human pancreatic cancer cell line (Capan-2). MT α-MSLNscFv For PBA_MT α-MSLNscFv The negative control.
[0073] Figure 58 The measurement was shown using MT. α-MSLNscFv or PBA_MT α-MSLNscFv A graph showing the results of cytotoxicity treatment of the human pancreatic cancer cell line (Mia PaCa-2). MT α-MSLNscFv For PBA_MT α-MSLNscFv The negative control.
[0074] Figure 59 The preparation of Gem_MT was shown. α-MSLNscFv The method in which MT α-MSLNscFv The compound was stained with MitoTracker Green and bound to the compound's payload, gemcitabine.
[0075] Figure 60 The measurement was shown using MT. α-MSLNscFv or Gem_MT α-MSLNscFv A graph showing the results of cytotoxicity treatment of human pancreatic cancer cell lines (AsPC-1, Capan-1, Capan-2, and Mia PaCa-2). MT α-MSLNscFv For Gem_MT α-MSLNscFv The negative control.
[0076] Figure 61 The preparation of VIBE_MT was shown. α-MSLNscFv The method in which MT α-MSLNscFvThe compound was stained with MitoTracker Green and bound to the compound's payload, vinorelbine.
[0077] Figure 62 The measurement was shown using MT. α-MSLNscFv or VIBE_MT α-MSLNscFv A graph showing the results of cytotoxicity treatment of human pancreatic cancer cell lines (AsPC-1, Capan-1, Capan-2, and Mia PaCa-2). MT α-MSLNscFv For VIBE_MT α-MSLNscFv The negative control.
[0078] Figure 63 The image shows the results used to validate the transplantation of human gastric cancer cell line NCI-N87 (HER2). + The xenograft mouse model formed by administering MT α-HER2scFv After that, MT α-HER2scFv Experimental methods for HER2 targeting ability.
[0079] Figure 64 The observed expression of transplanted human gastric cancer cell line NCI-N87 (HER2) was shown. + The xenograft mouse model formed by administering MT α-HER2scFv After that, MT α-HER2scFv Results located within a tumor.
[0080] Figure 65 Displays the information used to verify TPP-DOX or TPP-DOX_MT α-HER2scFv In transplantation of human gastric cancer cell line NCI-N87 (HER2) + Experimental methods for assessing the anticancer efficacy in xenograft mouse models.
[0081] Figure 66 This demonstrates the transplantation of human gastric cancer cell line NCI-N87 (HER2). + The xenograft mouse model was established by administering TPP-DOX or TPP-DOX_MT. α-HER2scFv The results of tumor size (tumor volume) were then measured according to the date.
[0082] Figure 67 To confirm the effectiveness of TPP-DOX or TPP-DOX_MT from the start of administration α-HER2scFv 25 days later, the transplanted human gastric cancer cell line NCI-N87 (HER2) was successfully treated. + A schematic diagram of the size of the tumor extracted from the xenograft mouse model formed.
[0083] Figure 68 This shows the process from the start of applying TPP-DOX or TPP-DOX_MT. α-HER2scFv25 days later, measurements were taken on the transplanted human gastric cancer cell line NCI-N87 (HER2). + A chart showing the results of tumor weight extracted from a xenograft mouse model.
[0084] Figure 69 This demonstrates that in an allogeneic mouse model formed by transplanting the mouse melanoma cell line B16F10 overexpressing human HER2, MT was confirmed to be effective. α-HER2scFv TPP-DOX or TPP-DOX_MT α-HER2scFv Experimental methods for assessing the anti-cancer effects.
[0085] Figure 70 This demonstrates the application of MT to an allogeneic mouse model formed by transplanting a mouse melanoma cell line B16F10 that overexpresses human HER2. α-HER2scFv TPP-DOX or TPP-DOX_MT α-HER2scFv The results of tumor size (tumor volume) were then measured according to the date.
[0086] Figure 71 To confirm the effectiveness of MT administration from the start α-HER2scFv TPP-DOX or TPP-DOX_MT α-HER2scFv A schematic diagram of the tumor size extracted from an allogeneic mouse model formed by transplanting mouse melanoma cell line B16F10 that expresses human HER2 21 days later.
[0087] Figure 72 Showing the process from the start of MT application α-HER2scFv TPP-DOX or TPP-DOX_MT α-HER2scFv The results of measuring tumor weight extracted from an allogeneic mouse model formed by transplanting human HER2-overexpressing mouse melanoma cell line B16F10 21 days later are shown in the chart.
[0088] Figure 73 This demonstrates the efficacy of MT in a xenograft mouse model formed by transplanting a mouse melanoma cell line B16F10 that overexpresses human HER2. α-HER2scFv DOX or DOX_MT α-HER2scFv Experimental methods for assessing the anticancer effects.
[0089] Figure 74 This demonstrates the administration of MT to an allogeneic mouse model formed by transplanting a mouse melanoma cell line B16F10 that overexpresses human HER2. α-HER2scFv DOX or DOX_MT α-HER2scFv A chart showing the results of tumor size measurements by date.
[0090] Figure 75 To confirm the effectiveness of MT administration from the start α-HER2scFvTPP-DOX or TPP-DOX_MT α-HER2scFv The size of the tumor extracted from an allogeneic mouse model formed by transplanting mouse melanoma cell line B16F10 that expresses human HER2 21 days later.
[0091] Figure 76 Showing the process from the start of MT application α-HER2scFv DOX or DOX_MT α-HER2scFv The results of measuring tumor weight extracted from an allogeneic mouse model formed by transplanting human HER2-overexpressing mouse melanoma cell line B16F10 21 days later are shown in the chart. Detailed Implementation
[0092] Mitochondria containing anticancer agents
[0093] In one aspect of the invention, mitochondria comprising an anticancer agent are provided. Furthermore, in another aspect of the invention, a pharmaceutical composition for the prevention or treatment of cancer is provided, comprising mitochondria containing an anticancer agent as an active ingredient.
[0094] As used in this article, the term "mitochondria" refers to organelles in eukaryotic cells that participate in the synthesis and regulation of adenosine triphosphate (ATP), the intracellular energy source. Mitochondria are involved in various metabolic pathways in the body, such as cell signaling, cell differentiation, cell death, and the control of the cell cycle and cell growth. Therefore, it has been reported that downregulation or dysregulation of mitochondrial function due to genetic, environmental, or unknown causes is associated with the occurrence of mitochondrial-related genetic diseases, such as inflammatory diseases like rheumatoid arthritis, ischemic diseases, infectious diseases, heart disease, muscle diseases, degenerative diseases such as Parkinson's disease or Alzheimer's disease, and the development of various diseases, such as carcinogenesis and cancer metastasis.
[0095] Mitochondria can be obtained from eukaryotes, mammals, or humans. Specifically, mitochondria can be isolated from cells or tissues. For example, mitochondria can be obtained from somatic cells, germ cells, or stem cells, and can be isolated from blood cells or platelets. Furthermore, mitochondria can be isolated by lysing tissues or cells through concentration, or by lysing tissue or cell samples after cryopreservation and thawing.
[0096] Specifically, somatic cells can be muscle cells, liver cells, nerve cells, fibroblasts, epithelial cells, fat cells, bone cells, white blood cells, lymphocytes, platelets, or mucosal cells.
[0097] Furthermore, stem cells are undifferentiated cells capable of differentiating into various types of tissue cells, and can be any, but not limited to, selected from the group consisting of mesenchymal stem cells, adult stem cells, induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, neural stem cells, limb stem cells, and tissue-derived stem cells. In this case, mesenchymal stem cells can be obtained from any of the group consisting of umbilical cord, umbilical cord blood, bone marrow, adipose tissue, muscle, nerve, skin, synovial fluid, testes, amnion, and placenta.
[0098] In addition, mitochondria can be isolated from cells or tissues cultured in vitro, or from samples that have been frozen and thawed.
[0099] Furthermore, mitochondria can be obtained from autologous, allogenic, or xenogenic subjects. Specifically, autologous mitochondria refer to mitochondria obtained from the tissues or cells of the same subject. Allogeneic mitochondria refer to mitochondria obtained from another subject belonging to the same species but with a different allele. Xenogenic mitochondria refer to mitochondria obtained from another subject belonging to a different species.
[0100] Furthermore, mitochondria can be mitochondria isolated from cells. Additionally, mitochondria can be intact and possess mitochondrial activity.
[0101] On the other hand, when mitochondria are isolated from a specific cell, they can be isolated using a variety of improved methods, including various known methods, such as using specific buffer solutions or using potential differences and magnetic fields.
[0102] To preserve mitochondrial activity, mitochondria can be isolated by lysing cells and centrifuging.
[0103] In this scenario, the anticancer agent may be present in the outer membrane of the mitochondria. Specifically, the anticancer agent can be located between the outer and inner membranes. Furthermore, the anticancer agent can be located in the cristae. It can also be present in the matrix inside the inner membrane.
[0104] Furthermore, the mitochondria can be modified mitochondria. In this case, the modified mitochondria can be mitochondria on the cell surface that have antibodies or fragments thereof that specifically bind to tumor-associated antigens (TAAs).
[0105] In this context, tumor-associated antigens can be selected from any one of the following groups, but are not limited to: CD19, CD20, melanoma antigen E (MAGE), NY-ESO-1, carcinoembryonic antigen (CEA), mucin 1 cell surface-associated antigen (MUC-1), prostate acid phosphatase (PAP), prostate-specific antigen (PSA), survivin, tyrosine-associated protein 1 (tyrp1), tyrosine-associated protein 2 (tyrp2), brachyyury, mesothelin, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), ERBB2, Wilms tumor protein (WT1), FAP, EpCAM, PD-L1, ACPP, CPT1A, IFNG, CD274, FOLR1, EPCAM, ICAM2, NCAM1, LRRC4, UNC5H2, LILRB2, CEACAM, MSLN, conjugative 3, and combinations thereof.
[0106] As used herein, the term "cancer" is classified as a disease in which normal tissue cells proliferate indefinitely for various reasons, disregarding the vital signs of the living organism or the condition of surrounding tissues. In this invention, cancer can be any cancer selected from the group consisting of various human cancers, such as breast cancer, lung cancer, pancreatic cancer, glioblastoma, gastric cancer, liver cancer, colorectal cancer, prostate cancer, ovarian cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, and lymphoma, but is not limited to the types mentioned above.
[0107] As used herein, the term "anticancer agent" is a drug used to inhibit the proliferation of cancer cells. In this invention, the anticancer agent may be selected from, but is not limited to, the group consisting of chemical anticancer agents, targeted anticancer agents, and anthelmintics.
[0108] Specifically, "chemoanticancer agents" can be any one of the group consisting of alkylating agents, microtuble inhibitors, antimetbolites, and topoisomerase inhibitors, but are not limited to this group.
[0109] The alkylating agent may be selected from, but is not limited to, the group consisting of mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, ibusulfan, streptozocin, carmustine, iomustine, dacarbazine, cisplatin, carboplatin, and oxaliplatin. The microtubule inhibitor may be selected from, but is not limited to, docetaxel, vinblastine, oncovin, and vinorelbine. Antimetabolites may be selected from, but are not limited to, any one of the following groups: fluorouracil, capecitabine, cytarabine, gemcitabine, fludarabine, methotrexate, pemetrexed, and mecaptopurine. Topoisomerase inhibitors may be selected from, but are not limited to, any one of the following groups: doxorubincin, hycamtin, camptosar, etoposide, taxol, bleomycin, adriamycin, and cerubidine.
[0110] Furthermore, a “targeted anticancer agent” can be a compound that regulates a specific target biomarker. For example, a targeted anticancer agent can be any of the following groups of compounds that target BTK, Bcr-abl, EGFR, the PDGFR / VEGFR / FGFR family, MEK / RAF, HER2 / Neu, CDK, ubiquitin, JAK, MAP2K, ALK, PARP, TGFβRI, proteasome, Bcl-2, Braf, C-Met, VR1, VR2, VR3, c-kit, AXL, and RET, but is not limited thereto.
[0111] One embodiment of a compound in a targeted anticancer agent could be ibrutinib, which targets BTK. Alternatively, it could be dasatinib, nilotinib, imatinib, or bosutinib, which target Bcr-abl. Furthermore, it could be osimertinib, erlotinib, or gefitinib, which target EGFR, but is not limited to these. In addition, it can be nintedanib, sunitinib, sorafenib, cabozantinib, lenvatinib, regorafenib, masitinib, semaxanib, tivozanib, vandetanib, axitinib, or pazapanib, targeting the PDGFR / VEGFR / FGFR family, but is not limited to these. Furthermore, it can be trametinib / dabrafenib, targeting MEK / RAF, but is not limited to these.
[0112] In addition, it can be afatinib, lapatinib, or neratinib targeting HER2 / Neu, but is not limited to these. Additionally, it can be abemaciclib or palbociclib targeting CDK, but is not limited to these. Furthermore, it can be lenalidomide targeting ubiquitin, but is not limited to these. Furthermore, it can be ruxolitinib, lettaurtinib, or pacritinib targeting JAK, but is not limited to these. Furthermore, it can be cobimethinib, selumetinib, trametinib, or binimetinib targeting MAP2K, but is not limited to these. Furthermore, it can be alectinib or crizotinib targeting ALK, but is not limited to these. In addition, it can be olaparib, which targets PARP, but is not limited to it. Additionally, it can be galunisertib, which targets TGFβRI, but is not limited to it. Furthermore, it can be ixazomib, which targets the proteasome, but is not limited to it. Furthermore, it can be venetoclax, which targets Bcl-2, but is not limited to it. Furthermore, it can be vemurafenib, which targets Braf, but is not limited to it.
[0113] Furthermore, the term "anthelmintic" can be selected from any of the following groups: OXPHOS (oxidative phosphorylation) inhibitors, glycolysis inhibitors, glycolysis-related indirect inhibitors, PPP (pentose phosphate pathway) inhibitors, and autophagy inhibitors, but is not limited thereto. Specifically, the anthelmintic can be selected from any of the following groups: pyrvinium, niclosamide, nitrozanide, ivermectin, fenbendazole, nitrozanide, and albendazole, but is not limited thereto.
[0114] Modified mitochondria
[0115] Modified mitochondria refer to mitochondria on the outer mitochondrial membrane that bind to exogenous proteins. In this case, modified mitochondria may be disclosed in Korean Patent Application Publication No. 10-2019-0048279.
[0116] As used herein, the term "exogenous protein" refers to a protein containing a target protein capable of functioning both inside and outside the cell. In this context, the exogenous protein is a protein not present in mitochondria and may be a recombinant protein. Specifically, the exogenous protein may include a mitochondrial anchoring peptide and a target protein. Furthermore, the exogenous protein may be a recombinant fusion protein comprising a mitochondrial anchoring peptide and a target protein. In this case, the exogenous protein may include a mitochondrial anchoring peptide. Preferably, the mitochondrial anchoring peptide may be a peptide that can be located on the outer mitochondrial membrane. Therefore, the exogenous protein can bind to the outer mitochondrial membrane via the mitochondrial anchoring peptide. The mitochondrial anchoring peptide may be a polypeptide comprising an N-terminal or C-terminal region of a protein present in mitochondrial membrane proteins; the N-terminal or C-terminal region of the aforementioned protein present on the outer mitochondrial membrane may be located on the outer mitochondrial membrane. In this case, the anchoring peptide may further include a mitochondrial signaling sequence.
[0117] One embodiment of the protein present in mitochondrial membrane proteins may be any one selected from the group consisting of TOM20, TOM70, OM45, TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x, and VAMP1B. In particular, when the mitochondrial anchoring peptide is derived from any one selected from the group consisting of TOM20, TOM70, and OM45, it may include the N-terminal region of TOM20, TOM70, or OM45. One embodiment of the mitochondrial anchoring peptide may be TOM70 derived from yeast as shown in SEQ ID NO: 75, or TOM70 derived from humans as shown in SEQ ID NO: 76. Another embodiment may be TOM20 derived from yeast as shown in SEQ ID NO: 77, or TOM20 derived from humans as shown in SEQ ID NO: 78. Another embodiment may be OM45 derived from yeast as shown in SEQ ID NO: 79.
[0118] Furthermore, when the mitochondrial anchoring peptide is derived from any one of the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x, and VAMP1B, it may include a C-terminal region selected from any one of the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x, and VAMP1B. One embodiment of the mitochondrial anchoring peptide may be TOM5 derived from yeast as shown in SEQ ID NO: 80 or TOM5 derived from humans as shown in SEQ ID NO: 81. Another embodiment may be TOM7 derived from yeast as shown in SEQ ID NO: 82 or TOM7 derived from humans as shown in SEQ ID NO: 83. Another embodiment may be TOM22 derived from yeast as shown in SEQ ID NO: 84 or TOM22 derived from humans as shown in SEQ ID NO: 85. Another embodiment may be Fis1 derived from yeast as shown in SEQ ID NO: 86, or Fis1 derived from human as shown in SEQ ID NO: 87. Another embodiment may be Bcl-2 alpha derived from human as shown in SEQ ID NO: 88. Another embodiment may be VAMP1 derived from yeast as shown in SEQ ID NO: 89, or VAMP1 derived from human as shown in SEQ ID NO: 90.
[0119] In this context, the target protein included in the exogenous protein that can function inside and outside the cell can be any of the following groups: active proteins that exhibit activity in the cell, proteins present in the cell, and proteins that have the ability to bind to ligands or receptors present in the cell membrane.
[0120] One embodiment of the active protein or a protein present in the cell may be selected from any one of the following groups: p53, granzyme B, Bax, Bak, PDCD5, E2F, AP-1 (Jun / Fos), EGR-1, retinoblastoma (RB), homologous phosphatase-tensin (PTEN), E-cadherin, neurofibromatosis protein-2 (NF-2), poly[ADP-ribose] synthase 1 (PARP-1), BRCA-1, BRCA-2, adenomatous colonic polyps (APC), tumor necrosis factor receptor-associated factor (TRAF), RAF kinase inhibitor protein (RKIP), p16, KLF-10, LKB1, LHX6, C-RASSF, DKK-3PD1, Oct3 / 4, Sox2, Klf4, and c-Myc. When the target protein is selected from the above groups, the target protein may bind to an anchoring peptide including the N-terminal region of TOM20, TOM70, or OM45.
[0121] This fusion protein can bind in the following order:
[0122] N-terminus - including the N-terminal region of TOM20, TOM70, or OM45, anchoring peptide - target protein - C-terminus.
[0123] Furthermore, the foreign protein may further include an amino acid sequence between the mitochondrial anchoring peptide and the target protein that is recognized by eukaryotic proteases, ubiquitin, or fragments thereof. Eukaryotic proteases are enzymes that degrade proteins present in eukaryotic cells. In this case, because the foreign protein includes an amino acid sequence recognized by the enzymes that degrade the protein, the foreign protein bound to the outer mitochondrial membrane can be separated into the anchoring peptide and the target protein within the cell.
[0124] In this embodiment, the ubiquitin fragment may include the C-terminal Gly-Gly amino acid sequence as shown in SEQ ID NO: 71, and may include 3-75 consecutive amino acids from the C-terminus. Furthermore, the exogenous protein may further include a linker between the target protein and the ubiquitin or a fragment thereof. In this embodiment, the linker may consist of 1-150 amino acids, or 10-100 amino acids, or 20-50 amino acids, but is not limited thereto. The linker may consist of amino acids suitably selected from 20 amino acids, preferably glycine and / or serine. One embodiment of the linker may consist of 5-50 amino acids composed of glycine and serine. One embodiment of the linker may be (G4S)n, where n is an integer from 1 to 10, and n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0125] In addition, proteins that have the ability to bind to ligands or receptors present in the cell membrane can be ligands or receptors present on the surface of tumor cells. In this context, the ligands or receptors present on the surface of tumor cells can be, but are not limited to, any one of the following groups: CD19, CD20, melanoma antigen E (MAGE), NY-ESO-1, carcinoembryonic antigen (CEA), mucin 1 cell surface associated (MUC-1), prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), survivin, tyrosine-associated protein 1 (tyrp1), tyrosine-associated protein 2 (tyrp2), brachyyury, mesothelin, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), ERBB2, Wilms tumor protein (WT1), FAP, EpCAM, PD-L1, ACPP, CPT1A, IFNG, CD274, FOLR1, EPCAM, ICAM2, NCAM1, LRRC4, UNC5H2LILRB2, CEACAM, conjugin 3, and combinations thereof.
[0126] Furthermore, proteins capable of binding to ligands or receptors present in the cell membrane can be antibodies or fragments thereof selected from any of the above groups. In particular, antibody fragments refer to fragments having the same complementarity-determining region (CDR) as the antibody. Specifically, it can be Fab, scFv, F(ab')2, or combinations thereof.
[0127] In this context, the target protein can bind to the anchoring peptide in the C-terminal region of any of the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x, and VAMP1B, and the exogenous protein can bind in the following order:
[0128] N-terminal target protein - including the C-terminal region of the anchored peptide selected from any one of the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x and VAMP1B.
[0129] Furthermore, the exogenous protein may further include a linker between the target protein and a C-terminal region selected from any one of the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x, and VAMP1B. In this case, the linker is as described above. In this case, the target protein, active protein, protein present in the cell, and protein having the ability to bind to ligands or receptors present in the cell membrane, etc., are as described above.
[0130] In one embodiment of the target protein, the antibody or fragment thereof targeting a specific cell may be in the form of an anchoring peptide binding to the C-terminal region of any one of the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-x, and VAMP1B. Modified mitochondria that bind to the target protein can be readily introduced to the specific target site, thereby enabling efficient entry of mitochondria into the specific cell.
[0131] One implementation of the modified mitochondria can be in the form of binding to one or more target proteins. Specifically, it can be in the form of binding to target proteins including p53 and target proteins including anti-HER-2 antibodies or fragments thereof. Such modified mitochondria can efficiently deliver mitochondria to cancer cells expressing HER-2. Furthermore, cancer cells can be effectively killed by p53 bound to the modified mitochondria.
[0132] Depending on the intended use of the modified mitochondria, target proteins comprising one or more active proteins can be constructed and made to bind to the mitochondria. Furthermore, depending on the target cell, target proteins targeting specific cells can be constructed in various ways.
[0133] Fusion proteins that include both mitochondrial outer membrane targeting proteins and target proteins can be termed fusion proteins that improve mitochondrial activity. Such fusion proteins can have any of the following structures:
[0134] <Structure 1>
[0135] N-terminus - Mitochondrial outer membrane anchoring peptide - target protein - C-terminus
[0136] <Structure 2>
[0137] N-terminus - Mitochondrial outer membrane anchoring peptide - ubiquitin or fragments thereof - target protein - C-terminus
[0138] <Structure 3>
[0139] N-terminus - Mitochondrial outer membrane targeting peptide - Linker 1 - Ubiquitin or fragment thereof - Target protein - C-terminus
[0140] <Structure 4>
[0141] N-terminus - Mitochondrial outer membrane anchoring peptide - ubiquitin or fragment thereof - linker 2 - target protein - C-terminus
[0142] <Structure 5>
[0143] N-terminus - Mitochondrial outer membrane targeting peptide - Linker 1 - Ubiquitin or fragment thereof - Linker 2 - Target protein - C-terminus
[0144] In the above structural formulas 1-5, the outer membrane anchoring peptide can be the terminal sequence of a protein selected from the group consisting of TOM20, TOM70, and OM45, and the target protein can be any one selected from the group consisting of p53, granzyme B, Bax, Bak, PDCD5, E2F, AP-1 (Jun / Fos), EGR-1, retinoblastoma (RB), homologous phosphatase-tensin (PTEN), cadherin (E-cadherin), neurofibromatosis protein-2 (NF-2), poly[ADP-ribose] synthase 1 (PARP-1), BRCA-1, BRCA-2, adenomatous colonic polyp (APC), tumor necrosis factor receptor-associated factor (TRAF), RAF kinase inhibitor protein (RKIP), p16, KLF-10, LKB1, LHX6, C-RASSF, and DKK-3PD1.
[0145] In this case, linker 1 or 2 can be a polypeptide composed of 1-100, 1-80, 1-50, or 1-30 amino acids, respectively, and is preferably a polypeptide composed of 1-30 amino acids composed of serine, glycine, or threonine alone or in combination. Alternatively, linker 1 or 2 can be a polypeptide composed of 5-15 amino acids, and is preferably a polypeptide composed of 5-15 amino acids composed of serine, glycine, or threonine alone or in combination. One embodiment of the linker can be (GGGGS)3 (SEQ ID NO: 70).
[0146] <Structure 6>
[0147] N-terminus - target protein - mitochondrial outer membrane anchoring peptide - C-terminus
[0148] <Structure 7>
[0149] N-terminus - target protein - ubiquitin or its fragment - mitochondrial outer membrane anchoring peptide - C-terminus
[0150] <Structure 8>
[0151] N-terminus - target protein - linker 1 - ubiquitin or fragment thereof - mitochondrial outer membrane anchoring peptide - C-terminus
[0152] <Structure 9>
[0153] N-terminus - target protein - ubiquitin or fragment thereof - linker 2 - mitochondrial outer membrane anchoring peptide - C-terminus
[0154] <Structure 10>
[0155] N-terminus - target protein - linker 1 - ubiquitin or fragment thereof - linker 2 - mitochondrial outer membrane targeting peptide - C-terminus
[0156] In the above structural formulas 6-10, the outer membrane anchoring peptide can be the terminal sequence of a protein selected from the group consisting of TOM5, TOM6, TOM7, TOM22, Fis1, Bcl-2, Bcl-X, and VAMP1B, and the target protein can be selected from p53, granzyme B, etc. B) Any one of the following groups: Bax, Bak, PDCD5, E2F, AP-1 (Jun / Fos), EGR-1, retinoblastoma (RB), homologous phosphatase-tensin (PTEN), cadherin (E-cadherin), neurofibromatosis protein-2 (NF-2), poly[ADP-ribose] synthase 1 (PARP-1), BRCA-1, BRCA-2, adenomatous colonic polyp (APC), tumor necrosis factor receptor-associated factor (TRAF), RAF kinase inhibitor protein (RKIP), p16, KLF-10, LKB1, LHX6, C-RASSF, DKK-3PD1, Oct3 / 4, Sox2, Klf4, and c-Myc. In this case, linker 1 or 2 is as described above.
[0157] For pharmaceutical compositions, mitochondria may be included, but are not limited to, at concentrations of about 0.1 µg / mL to about 500 µg / mL, about 0.2 µg / mL to about 450 µg / mL, or about 0.5 µg / mL to about 400 µg / mL. The inclusion of mitochondria within these ranges can help adjust the mitochondrial dosage during administration and may improve the degree of improvement in the patient's disease symptoms. In this case, the mitochondrial dosage can be determined by quantifying the membrane proteins of the isolated mitochondria. Specifically, the isolated mitochondria can be quantified using the Bradford protein assay.
[0158] Furthermore, the pharmaceutical composition may, but is not limited to, contain mitochondrial-binding anticancer agents at concentrations of 0.1 µg / mL to 500 µg / mL, 0.2 µg / mL to 450 µg / mL, or 0.5 µg / mL to 400 µg / mL. Anticancer agents contained within the above ranges can help adjust the dosage of the anticancer agent during administration and can improve the degree of improvement in the patient's disease symptoms.
[0159] The mitochondrial-binding anticancer agent may be contained in amounts of about 0.01 µg to 1 µg, about 0.05 µg to 0.5 µg, or about 0.1 µg to 0.3 µg per µg of mitochondria. Preferably, it may be contained in an amount of about 0.2 µg.
[0160] The anticancer agent and mitochondria can be mixed in an appropriate ratio so that the anticancer agent can be contained in the mitochondria. For example, the mixing ratio of the anticancer agent and mitochondria based on weight ratio can be from about 1:10 to about 10:1, from about 1:9 to about 9:1, from about 1:8 to about 8:1, from about 1:7 to about 7:1, from about 1:6 to about 6:1, from about 1:5 to about 5:1, from about 1:4 to about 4:1, from about 1:3 to about 3:1, from about 1:2 to about 2:1, or a weight ratio of about 1:1. Preferably, it can be about 1:5.
[0161] In particular, anticancer agents can be those combined with triphenylphosphine (TPP).
[0162] As used herein, the term "triphenylphosphine (TPP)" refers to a lipophilic cationic compound that can easily penetrate cell and mitochondrial membranes and is directly absorbed into the mitochondria under the influence of a negative voltage (-150 to -170 mV) present within the mitochondrial membrane. Due to these properties, TPP is used as a target for cancer cells, cancer stem cells, and fibroblasts, as it accumulates more abundantly in the mitochondria of cancer cells or cardiomyocytes, which exhibit significantly different mitochondrial membrane potentials compared to normal cells.
[0163] In this case, the anticancer agent binding to TPP may be contained in the mitochondria in amounts of about 0.01 µg to 1 µg, about 0.05 µg to 0.5 µg, or about 0.1 µg to 0.3 µg per µg of mitochondria. Preferably, it may be contained in an amount of about 0.25 µg.
[0164] Furthermore, the anticancer agent bound to TPP and the mitochondria can be mixed in an appropriate ratio so that the anticancer agent can be contained in the mitochondria. For example, the mixing ratio of the anticancer agent and the TPP-bound mitochondria based on weight ratio can be about 1:10 to about 10:1, about 1:9 to about 9:1, about 1:8 to about 8:1, about 1:7 to about 7:1, about 1:6 to about 6:1, about 1:5 to about 5:1, about 1:4 to about 4:1, about 1:3 to about 3:1, about 1:2 to about 2:1, or about 1:1. Preferably, it can be about 1:4.
[0165] In one embodiment of this specification, a mitochondrial cell (TPP-DOX_MT) fused with an anti-HER2 antibody fragment including TPP-DOX was constructed. α-HER2scFv ), in which TPP is combined with Doxorubicin (DOX) ( Figure 30-32 ), and confirmed its effectiveness in cancer cells ( Figure 33-43 ) and tumor mouse models ( Figures 65-68 It exhibits excellent anti-cancer activity.
[0166] Furthermore, TPP may include TPP derivatives. TPP derivatives can be, but are not limited to, 2-butene-1,4-di-TPP, 2-chlorobenzyl-TPP, 3-tolylmethyl-TPP, 2,4-p-dichlorobenzyl-TPP, 1-naphthylmethyl-TPP, and p-xylenebis-TPP. Moreover, TPP derivatives may further include their derivatives. For example, it can be a derivative of 2-butene-1,4-di-TPP, a derivative of 2-chlorobenzyl-TPP, a derivative of 3-tolylmethyl-TPP, a derivative of 2,4-p-dichlorobenzyl-TPP, a derivative of 1-naphthylmethyl-TPP, a derivative of p-xylenebis-TPP, etc., but is not limited to these.
[0167] This invention includes pharmaceutical compositions comprising mitochondria containing anticancer agents that can be used to prevent or treat cancer, and / or increase therapeutic effects (efficacy). In this case, the mitochondria and the anticancer agent are as described above.
[0168] Cancer can be any of, but is not limited to, the group consisting of breast cancer, lung cancer, pancreatic cancer, glioblastoma, stomach cancer, liver cancer, colorectal cancer, prostate cancer, ovarian cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, and lymphoma.
[0169] As used herein, the term "prevention" refers to any action that inhibits or delays the occurrence of cancer by administering a pharmaceutical composition. Furthermore, "treatment" refers to any action that improves or beneficially alters the symptoms of cancer by administering a pharmaceutical composition.
[0170] As used herein, the term "efficacy" may be determined by one or more parameters, such as survival rate or disease-free survival over a period of time such as 1 year, 5 years, or 10 years. Additionally, parameters may include inhibition of at least one tumor size in the subject's body.
[0171] Pharmacokinetic parameters such as bioavailability and baseline parameters such as clearance can also affect efficacy. Therefore, “enhanced efficacy” (e.g., improved efficacy) may be attributed to enhanced pharmacokinetic parameters and enhanced efficacy, which can be measured by comparing clearance and tumor growth in test animals or human subjects, or by comparing parameters such as survival rate, recurrence rate, or disease-free survival.
[0172] The preferred dosage of a pharmaceutical composition may vary depending on the patient's condition and weight, the severity of the disease, the dosage form of the drug, the route of administration, and the timing of administration, but those skilled in the art can make appropriate selections. In the pharmaceutical compositions of this invention for the prevention or treatment of cancer, the active ingredient may be contained in any amount (effective amount) depending on the use, formulation, combined purpose, etc., as long as it has anticancer activity. Here, "effective amount" refers to the amount of active ingredient capable of inducing an anticancer effect. This effective amount can be determined experimentally within the ordinary capabilities of those skilled in the art.
[0173] The pharmaceutical compositions of the present invention may further include a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be any carrier, as long as it is a non-toxic material suitable for delivery to a patient. Distilled water, alcohol, fats, waxes, and inert solids can all be included as carriers. Furthermore, pharmaceutically acceptable excipients (buffers, dispersants) may be included in the pharmaceutical composition.
[0174] Specifically, the pharmaceutical composition may be prepared as a parenteral formulation according to conventional methods known in the art, depending on the route of administration, and may contain a pharmaceutically acceptable carrier in addition to the active ingredient. Here, "pharmaceutically acceptable" means that it does not inhibit the activity of the active ingredient and does not have toxicity beyond what is appropriate for the intended use.
[0175] When the pharmaceutical composition of the present invention is prepared as a parenteral formulation, it can be formulated with a suitable carrier into the form of an injection, a transdermal formulation, and a nasal inhaler, according to methods known in the art. When formulated as an injection, sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof can be used as suitable carriers. Ringer's solution, PBS (phosphate-buffered saline) containing triethanolamine, or sterile water for injection, such as an isotonic solution of 5% glucose, are preferred carriers.
[0176] The pharmaceutical composition of the present invention can be an injectable formulation. Therefore, the pharmaceutical composition according to the present invention can be formulated into a physically or chemically very stable injectable by adjusting the pH value using a buffer solution such as an acidic aqueous solution or phosphate, which can be used as an injectable to ensure product stability according to the prescribed injection dosage.
[0177] Specifically, the pharmaceutical compositions of the present invention may include water for injection. Water for injection refers to distilled water prepared for dissolving solid injections or diluting water-soluble injections. It may be glucose injection, xylitol injection, D-mannitol injection, fructose injection, physiological saline, dextran 40 injection, dextran 70 injection, amino acid injection, Ringer's solution, lactate-Ringer's solution, or a phosphate buffer solution or sodium dihydrogen phosphate-citric acid buffer solution with a pH of approximately 3.5-7.5.
[0178] On the other hand, the pharmaceutical compositions of the present invention are administered in pharmaceutically effective amounts. The terms "therapeuticly effective amount" or "pharmaceutically effective amount" refer to an amount of compound or composition effective in preventing or treating a target disease, sufficient to treat the disease with a reasonable benefit / risk ratio suitable for medical treatment, and without causing side effects. The level of an effective amount can be determined based on factors including the patient's health status, the type and severity of the disease, the activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, factors of drugs to be used in combination or concurrently, and other factors well known in the medical field. In one embodiment, a therapeutically effective amount refers to a drug amount effective in treating cancer.
[0179] As used herein, the terms “administration” or “application” refer to the introduction of a predetermined substance into a subject by an appropriate method. The route of administration of the composition may be any general route, as long as it can reach the target tissue. It may be intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, local, intranasal, or rectal administration, but is not limited thereto.
[0180] The preferred dosage of the pharmaceutical composition of the present invention can be, but is not limited thereto, a single administration of the mitochondria at an amount of 0.01 mg / kg to 5 mg / kg, 0.1 mg / kg to 4 mg / kg, or 0.25 mg / kg to 2.5 mg / kg, depending on the weight of the recipient. That is, in terms of cellular activity, it is most preferred to administer the pharmaceutical composition comprising modified mitochondria containing an amount of anticancer agent as described above, based on the weight of the subject with cancerous tissue. Furthermore, the pharmaceutical composition can be administered 1-10 times, 3-8 times, or 5-6 times, preferably 5 times. In this case, the dosing interval can be 1-7 days or 2-5 days, preferably 3 days. This dosage should not be construed as limiting the scope of the invention in any way.
[0181] The term "subject" refers to a subject to whom the (prescription) composition of the present invention can be applied, and may be a subject suffering from cancer. Furthermore, the subject may be a mammal such as a rat, mouse, or livestock, including humans, preferably humans. In addition to mitochondria containing anticancer agents, the compositions of the present invention may further comprise any known and proven compounds or natural extracts with anticancer activity and safety to enhance and strengthen the anticancer activity. In this case, the pharmaceutical composition and the compound or natural extract with anticancer activity may be administered simultaneously or sequentially.
[0182] In another aspect of the invention, a method for preparing mitochondria containing an anticancer agent is provided, comprising mixing an anticancer agent and isolated mitochondria. In this case, the anticancer agent and mitochondria are as described above.
[0183] The anticancer agent and mitochondria can be mixed in an appropriate ratio so that the anticancer agent can be contained in the mitochondria. For example, the mixing ratio of the anticancer agent and mitochondria based on weight ratio can be about 1:10 to about 10:1, about 1:9 to about 9:1, about 1:8 to about 8:1, about 1:7 to about 7:1, about 1:6 to about 6:1, about 1:5 to about 5:1, about 1:4 to about 4:1, about 1:3 to about 3:1, about 1:2 to about 2:1, or about 1:1. Preferably, it can be about 1:5.
[0184] In another aspect of the invention, a modified anticancer agent chemically combined with TPP is provided. In this case, TPP and the anticancer agent are as described above.
[0185] In another aspect of the invention, the use of a pharmaceutical composition comprising mitochondria containing an anticancer agent is provided for the prevention or enhancement of cancer treatment efficacy. In this case, the anticancer agent and mitochondria are as described above.
[0186] In another aspect of the invention, a method for treating cancer and / or a method for improving therapeutic efficacy is provided, comprising administering to a subject a pharmaceutical composition comprising mitochondria containing an anticancer agent. In this case, the anticancer agent, mitochondria, and administration are all as described above. The subject may be a subject suffering from cancer. Furthermore, the subject may be a mammal, preferably a human.
[0187] Example
[0188] The present invention will now be described in more detail through the following examples. However, the following embodiments are for illustrative purposes only, and the scope of the invention is not limited thereto.
[0189] I. Confirming the targeting ability of mitochondria that bind to the target protein.
[0190] Preparation Example 1. Preparation of HEK293 cell line containing mitochondria fused with anti-HER2scFv antibody
[0191] To specifically introduce mitochondria into HER2-expressing tumor cells, an anti-HER2scFv antibody (SEQ ID NO: 98) that specifically binds to HER2 was constructed and fused to the outer mitochondrial membrane. Figure 1 and 2 The specific construction method is described in Korean Patent Application Publication No. 10-2019-0124656.
[0192] Example 1. Demonstrating the characteristics of mitochondria fused with anti-HER2scFv antibody.
[0193] Example 1.1. Analysis of anti-HER2scFv antibody expression
[0194] To confirm the effectiveness of anti-HER2scFv in the mitochondrial (MT) cells containing anti-HER2scFv antibody constructed in the above preparation example 1, α-HER2scFv The expression level of ) in HEK293 cells was determined by immunocytochemical staining, and the cells were stained and images were observed using confocal microscopy.
[0195] Specifically, HEK293 cells were used at a rate of 3 × 10⁻⁶. 4 Cells were seeded per well in 24-well plates and cultured for 24 hours. After 24 hours of culture, cells were stained with MitoTracker Red for approximately 30 minutes, washed with PBS, and then fixed with 3.7% formaldehyde. After removing the formaldehyde, the primary antibody (anti-myc antibody, Roche, 11667149001) was diluted 1:1,000 with PBS containing 1% goat serum, and the cells were treated with this diluted solution and reacted for 18 hours. After the reaction, the primary antibody was removed by washing with PBS, and then the secondary antibody (anti-mouse IgG antibody, labeled with Alexa Fluor® 488, Invitrogen, 11001) was diluted 1:500 with PBS containing 0.1% BSA, and the cells were treated with this diluted solution and reacted for approximately 1 hour. After the reaction, the cells were washed with PBS, mounted, and observed using a confocal microscope. At this point, the cell nuclei were observed using DAPI staining.
[0196] The results confirmed that the location of the red fluorescence labeled with mitochondria was consistent with the location of the green fluorescence labeled with anti-HER2scFv antibody. Figure 3 ).
[0197] Example 1.2. Confirmation of the expression location of anti-HER2scFv antibody
[0198] Western blot was performed to confirm whether the anti-HER2scFv antibody, constructed in the same manner as in Preparation Example 1 above, was expressed in the mitochondria of HEK293 cells.
[0199] Specifically, after lysis of cells expressing anti-HER2scFv, the cell extract was separated into mitochondrial and cytoplasmic fractions by centrifugation. Each fraction was subjected to electrophoresis and Western blot. To identify anti-HER2scFv, mitochondrial markers, and cytoplasmic marker proteins, anti-myc antibody (Roche, 11667149001), anti-COX4 antibody (abcam, 33985), and anti-β-tubulin antibody (Thermo, MA5-16308) were used as primary antibodies, respectively. Anti-mouse IgG HRP or anti-rabbit IgG HRP were used as secondary antibodies.
[0200] The results confirmed that the anti-HER2scFv antibody was present in the mitochondrial region along with COX4, a positive marker for mitochondria, but not in the cytoplasmic region where the positive marker β-tubulin was present. Figure 4 The results of immunocytochemical staining and Western blot analysis in the above examples confirmed the expression of anti-HER2scFv antibody in the mitochondria of HEK293 cells.
[0201] Example 1.3. Measurement of the ability of mitochondria fused with anti-HER2scFv antibody to produce ATP.
[0202] To compare the functional differences between mitochondria fused with the anti-HER2scFv antibody constructed in the same manner as in Example 1 above and normal mitochondria, samples from HEK293 cells (MT) were compared. α-HER2scFv (This cell line expresses mitochondria fused with anti-HER2scFv antibody) and the ability of mitochondria isolated from HEK293 cells to produce ATP, which is one of the main functions of mitochondria.
[0203] Specifically, isolated mitochondria (5 μg / 100 μL) were treated with 25 μM ADP and 100 μL luciferin, and the ATP produced in the mitochondria and the luminescence intensity (RLU) produced by the luciferin reaction were measured to confirm their ATP production capacity. The results showed that MT and MT... α-HER2scFv There is no difference in the ability to produce ATP. Figure 5 ).
[0204] Example 1.4. Measurement of membrane potential of mitochondria fused with anti-HER2scFv antibody
[0205] To compare the functional differences between mitochondria fused with the anti-HER2scFv antibody constructed in the same manner as in Preparation Example 1 above and normal mitochondria, HEK293 cells (MT) including mitochondria fused with the anti-HER2scFv antibody were compared. α-HER2scFv The membrane potential of untreated HEK293 cells (MT) and untreated HEK293 cells (MT) is one of the main characteristics of mitochondria.
[0206] Specifically, cells were packed at 3 × 10 4Cells were seeded per well in 96-well plates and cultured for 24 hours. After 24 hours, cells were treated with DCFDA (Invitrogen, C6827) dye and reacted for 1 hour. Subsequently, cells were washed with PBS and stained with Hoechst 33242 for 10 minutes. The fluorescence values of DCFDA and Hoechst 33242 were measured, and the membrane potential was determined by calculating their ratio (DCFDA fluorescence value / Hoechst 33242 fluorescence value). The results showed that MT and MT... α-HER2scFv The membrane potentials were not different. Figure 6 ).
[0207] Example 1.5. Measurement of reactive oxygen species in mitochondria fused with anti-HER2scFv antibody
[0208] To compare the reactive oxygen species (ROS) production levels between mitochondria fused with the anti-HER2scFv antibody constructed in the same manner as in Preparation Example 1 above and normal mitochondria, HEK293 cells (MT cells) including mitochondria fused with the anti-HER2scFv antibody were measured. α-HER2scFv ) and reactive oxygen species in the mitochondria of untreated HEK293 cells (MT).
[0209] Specifically, cells were packed at 3 × 10 4 Cells were seeded per well into 96-well plates and cultured for 24 hours. After 24 hours, cells were treated with TMRE (Invitrogen, T669) dye and reacted for 1 hour. Cells were washed with PBS and then stained with Hoechst 33242 for 10 minutes. The fluorescence values of TMRE and Hoechst 33242 were measured, and the production of reactive oxygen species was determined by calculating their ratio (fluorescence value of TMRE / fluorescence value of Hoechst 33242). The results showed that MT and MT2 were isolated from the cells. α-HER2scFv There was no difference in the production of reactive oxygen species. Figure 7 ).
[0210] Example 2. Analysis of HER2 expression in human cancer cell lines and normal cell lines.
[0211] Example 2.1. Western blot analysis confirmed the expression of HER2 in human cancer cell lines and normal cell lines.
[0212] The expression levels of HER2 in human breast cancer, lung cancer, gastric cancer cell lines, and lung fibroblast cell lines were confirmed by Western blot.
[0213] Specifically, human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human lung cancer cell line (NCI-H1975), human gastric cancer cell line (MKN-74 and NCI-N87), and human lung fibroblast cell line (WI-38) were used at approximately 1×10⁻⁶. 6 Cells / well were seeded into 6-well plates and cultured for 24 hours. SK-BR-3, BT-474, and NCI-N87 cells were prepared by culturing in RPMI-1640 medium containing 10% FBS, while MDA-MB-231, NCI-H1975, MKN-74, and WI-38 cells were prepared by culturing in DMEM medium containing 10% FBS.
[0214] After 24 hours, the culture medium was removed, and the cells were washed twice with PBS. Then, 100 μL of RIPA buffer containing protease inhibitors was added directly to the cells. After 10 minutes, the cells were scraped and transferred to microtubes, then centrifuged at approximately 12,000 xg for 10 minutes. The separated supernatant was transferred to a new microtube, and protein quantification was performed using BCA analysis. The same number of proteins for each sample were subjected to electrophoresis followed by Western blot. Anti-HER2 antibody (Cell signaling, 29D8) and anti-β-actin antibody (Sigma, A2208) were used as primary antibodies, and anti-mouse IgG HRP and anti-rabbit IgG HRP were used as secondary antibodies.
[0215] The results confirmed that SK-BR-3, BT-474, and NCI-N87 cells are HER2-expressing cells. + On the other hand, MDA-MB-231, NCI-H1975, MKN-74, and WI-38 cells showed almost no HER2 expression, indicating that they are HER2-positive cells. - cell( Figure 8 ).
[0216] Example 2.2. Immunocytochemical staining confirmed the expression of HER2 in human cancer cell lines and normal cell lines.
[0217] To confirm the expression level of HER2 in human breast cancer, lung cancer, gastric cancer cell lines and human lung fibroblast cell lines, immunocytochemical staining was performed using anti-HER2 antibody.
[0218] Specifically, the cells were divided into groups of 3 × 10⁻⁶. 4Cells were seeded per well in 24-well plates and cultured for 24 hours. After 24 hours, cells were fixed with 3.7% formaldehyde. Formaldehyde was removed, and the primary antibody (anti-HER2 antibody, Cell Signaling Technology, 2165) was diluted 1:1,000 with PBS containing 1% goat serum. Cells were treated with this diluted solution and reacted for 18 hours. The primary antibody was washed away with PBS, and then the secondary antibody (anti-rabbit IgG antibody, labeled with Alexa Fluor® 488, Invitrogen, 11008) was diluted 1:500 with PBS containing 0.1% BSA. Cells were treated with this diluted solution and reacted for 1 hour. After the reaction, cells were washed with PBS, mounted, and observed using a confocal microscope. DAPI staining was used to observe the cell nuclei.
[0219] The results showed that for SK-BR-3, BT-474, and NCI-N87 cells, i.e. HER2 + In cells, HER2 is expressed on the cell surface and observed to have green fluorescence, while in MDA-MB-231, NCI-H1975, MKN74, and CCD-8Lu cells, HER2 is expressed... - Cells, no green fluorescence was observed ( Figure 9 ).
[0220] Example 2.3. Flow cytometry confirmed the expression of HER2 in human cancer cell lines.
[0221] To confirm the expression level of HER2 in human breast cancer, lung cancer, and gastric cancer cell lines, flow cytometry was performed using an anti-HER2 antibody.
[0222] Specifically, human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231), human gastric cancer cell lines (NCI-N87 and MKN-74), and human lung cancer cell line (NCI-H1975) were respectively fed with approximately 1×10 6Cells were seeded per well into 6-well plates and cultured for 24 hours. After 24 hours, the culture medium was removed, cells were treated with 0.05% trypsin-EDTA and collected, then fixed with 3.7% formaldehyde. The primary antibody (anti-HER2 antibody, CellSignaling Technology, 2165) was diluted 1:1,000 in PBS containing 1% goat serum, and the cells were treated with this dilution for 18 hours. The primary antibody was washed away with PBS, and then the secondary antibody (anti-rabbit IgG antibody, Alexa Fluor® 555, Invitrogen, 21428) was diluted 1:500 in PBS containing 0.1% BSA, and the cells were treated with this dilution for 1 hour. After the reaction, the cells were washed with PBS, and HER2 expression was confirmed by flow cytometry.
[0223] The results showed that for SK-BR-3, BT-474, and NCI-N87 cells, i.e. HER2 + In these cells, HER2 is expressed on the cell surface, and the observed fluorescence value (PE-A) is high. However, for MDA-MB-231, NCI-H1975, and MKN-74 cells, HER2... - Cells that showed fluorescence values higher than HER2 + Low cell count ( Figure 10 ).
[0224] The results of Western blot analysis, immunocytochemical staining, and flow cytometry confirm that SK-BR-3, BT-474, and NCI-N87 cells express HER2. + Cells, while MDA-MB-231, NCI-H1975, MKN-74, WI-38 cells and CCD-8Lu cells are HER2 cells. - cell.
[0225] Example 3. Validating the HER2 targeting of mitochondria fused with anti-HER2scFv antibody
[0226] To verify the HER2-targeting ability of mitochondria fused with the anti-HER2scFv antibody, constructed in the same manner as in Preparation Example 1 above, mitochondria fused with the anti-HER2scFv antibody (MT) were... α-HER2scFv ) and HER2 + Cells and HER2 - Cells were co-cultured and then subjected to immunocytochemical staining.
[0227] Specifically, HER2 + Cells and HER2 - Cells together at 1.5 × 10 4Cells were seeded into 24-well plates and co-cultured in DMEM medium containing 10% FBS for 24 hours. At this time, HER2... + Cells SK-BR-3, BT-474, and NCI-N87 were prepared by culturing in RPMI-1640 medium containing 10% FBS, HER2 - Cells MDA-MB-231, NCI-H1975, and MKN-74 were prepared by culturing in DMEM medium containing 10% FBS. Untreated HEK293 cells (MT) and HEK293 cells (MTB) including mitochondria fused with anti-HER2scFv antibody were treated with MitoTracker Red, respectively. α-HER2scFv Mitochondria were prepared and stained. After co-culturing for 24 hours, each isolated mitochondrial was treated with the co-cultured cells and reacted for 12 hours. Figure 11 ).
[0228] Example 3.1. Confirmation of the location of mitochondria fused with anti-HER2scFv antibody in HER2-positive and negative cell lines.
[0229] Cells treated in the same manner as in Example 3 above were washed once with PBS and fixed with 3.7% formaldehyde at room temperature for 30 minutes, followed by immunocytochemical staining. Anti-HER2 antibody (Cell signaling, 29D8) was used as the primary antibody, and Alexa Fluor® 488-labeled anti-rabbit IgG antibody (Invitrogen, 11008) was used as the secondary antibody. DAPI staining was used to observe the cell nuclei.
[0230] The results are as follows Figure 12 As shown, when co-cultured SK-BR-3 (HER2) cells were treated with mitochondria (MT) derived from untreated HEK293 cells, + ) and NCI-H1975 (HER2) - When SK-BR-3 (HER2) cells are present, + ) cells and NCI-H1975 (HER2) - Mitotracker Red (red fluorescence) staining was also observed in mitochondria in cells. On the other hand, when mitochondria derived from HEK293 cells, including mitochondria fused with anti-HER2scFv antibody, were used... α-HER2scFv When treating cells, in HER2 + Mitotracker Red stained mitochondria were specifically observed in SK-BR-3 cells.
[0231] In co-cultured BT-474 (HER2)+ ) and NCI-H1975 (HER2) - In BT-474 (HER2) cells, in the MT-treated group, + ) cells and NCI-H1975 (HER2) - Mitotracker Red stained mitochondria were similarly observed in MT cells, while in MT cells... α-HER2scFv In the processing group, only in HER2 + Mitotracker Red staining of mitochondria was specifically observed in BT-474 cells. Figure 13 ).
[0232] In co-cultured NCI-N87 (HER2) + ) and MKN-74 (HER2) - In ) cells, in the MT-treated group, in NCI-N87 (HER2) cells + ) cells and MKN-74 (HER2) - Mitotracker Red stained mitochondria were similarly observed in MT cells, while in MT cells... α-HER2scFv In the processing group, only in HER2 + Mitotracker Red staining of mitochondria was specifically observed in NCI-N87 cells. Figure 14 ).
[0233] In co-cultured SK-BR-3 (HER2) + ) and MDA-MB-231 (HER2 - In SK-BR-3 (HER2) cells, in the MT-treated group, + ) cells and MDA-MB-231 (HER2) - Mitotracker Red stained mitochondria were similarly observed in MT cells, while in MT cells... α-HER2scFv In the processing group, only in HER2 + Mitotracker Red staining of mitochondria was specifically observed in SK-BR-3 cells. Figure 15 ).
[0234] In co-cultured BT-474 (HER2) + ) and MDA-MB-231 (HER2 - In BT-474 (HER2) cells, in the MT-treated group, + ) cells and MDA-MB-231 (HER2) - Mitotracker Red stained mitochondria were similarly observed in MT cells, while in MT cells...α-HER2scFv In the processing group, only in HER2 + Mitotracker Red staining of mitochondria was specifically observed in BT-474 cells. Figure 16 ).
[0235] The above results confirm that mitochondria (MTs) fused with the anti-HER2scFv antibody are involved. α-HER2scFv It can specifically target HER2 cells that express the HER2 antigen. + cell.
[0236] II. Preparation and confirmation of the activity of mitochondria containing anticancer agents and binding target proteins.
[0237] Preparation Example 2. Preparation of mitochondrial complex fused with anti-HER2scFv antibody and doxorubicin
[0238] HEK293 cells containing mitochondria fused with anti-HER2scFv antibody were treated with MitoTracker Green to stain the mitochondria (green fluorescence), and then the mitochondria were isolated (MT). α-HER2scFv 30 µg of isolated mitochondria were reacted with 100 µM doxorubicin (DOX) at 4 °C for 10 min, followed by centrifugation at approximately 12,000 xg for 10 min to remove unreacted doxorubicin. Subsequently, the mitochondria were washed twice with 500 μL SHE buffer (250 mM sucrose, 20 mM HEPES (pH 7.4), 2 mM EGTA) to obtain mitochondria containing doxorubicin (DOX_MT). α-HER2scFv () Figure 17 ).
[0239] Example 4. Evaluation of DOX_MT α-HER2scFv Anticancer activity against cancer cells
[0240] Example 4.1. Confirmation of DOX_MT α-HER2scFv Delivery characteristics into cancer cells
[0241] DOX_MT were obtained using the same method as in Preparation Example 2 described above. α-HER2scFv Human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231) and human lung cancer cell line (NCI-H1975) were processed and then observed using a confocal microscope. The cell nuclei were then observed using DAPI staining.
[0242] The results showed that MitoTracker Green stained mitochondria (MTs) were observed in the cytoplasm. α-HER2scFvDoxorubicin (DOX), which exhibits green fluorescence, was observed to show red fluorescence in the cell nucleus. Figure 18 The above results indicate that DOX_MT transported into cells... α-HER2scFv Doxorubicin moves to the cell nucleus and resides in the DNA within the nucleus.
[0243] Example 4.2. Confirmation using DOX_MT α-HER2scFv Morphological changes of treated cancer cells
[0244] DOX_MT were obtained using the same method as in Preparation Example 2 described above. α-HER2scFv Human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were treated, and then the morphological changes of cancer cells over time were observed using confocal microscopy. DAPI staining was used to observe the cell nuclei.
[0245] The results showed that using DOX_MT α-HER2scFv After 6 hours of treatment with (yellow fluorescence), most of the doxorubicin (DOX, red fluorescence) was present in the mitochondria along with it (green fluorescence). However, over time, doxorubicin was observed in the nucleus, as indicated by DOX_MT. α-HER2scFv Significant changes in cell morphology were observed after 72 hours of treatment. Figure 19 ).
[0246] Example 4.3. Measurement and MT α-HER2scFv Combined doxorubicin concentration
[0247] To quantify the DOX_MT obtained using the same method as in Preparation Example 2 described above, α-HER2scFv The concentrations of doxorubicin were combined, and a standard curve was prepared by measuring the absorbance of doxorubicin at each concentration. Then, the results were calculated using DOX_MT. α-HER2scFv The concentration of doxorubicin combined.
[0248] Specifically, 100 μL of doxorubicin solutions at concentrations of 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, and 0 μM were mixed with DOX_MT diluted 1 / 20 in PBS. α-HER2scFv Aliquots were dispensed into 96-well plates. Absorbance (emission wavelength 590 nm) was then measured using a microplate reader (BioTek, Synerge HTX). A standard curve was prepared based on the absorbance values according to the doxorubicin concentration, and then the standard curve was obtained by replacing DOX_MT. α-HER2scFv The absorbance value of the diluted solution is used to determine the relationship with DOX_MT. α-HER2scFv The concentration of bound doxorubicin ( Figure 20 ).
[0249] Example 4.4. DOX_MT at various concentrations α-HER2scFv Treating cancer cells to demonstrate their ability to inhibit proliferation
[0250] To verify the DOX_MT obtained in the same manner as in Preparation Example 2 above. α-HER2scFv The anticancer activity was demonstrated using 200 μg MT. α-HER2scFv And 100 μM doxorubicin (DOX), and by using DOX_MT α-HER2scFv We evaluated the inhibitory effect on cell proliferation by treating human breast cancer, lung cancer, and gastric cancer cell lines.
[0251] Specifically, human breast cancer (SK-BR-3, BT-474, and MDA-MB-231), lung cancer (NCI-H1975), and gastric cancer (NCI-N87 and MKN-74) cell lines were respectively used at approximately 3 × 10⁻⁶. 3 Cells were seeded per well into 96-well plates and cultured for 24 hours. SK-BR-3, BT-474, and NCI-N87 cells were cultured in RPMI-1640 medium containing 10% FBS, while MDA-MB-231, NCI-H1975, and MKN-74 cells were cultured in DMEM medium containing 10% FBS. After 24 hours of culture, cells were treated with doxorubicin (DOX) or DOX_MT at concentrations of 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.1 μM, 0.05 μM, 0.025 μM, and 0.01 μM. α-HER2scFv Each cell was processed. After 144 hours of sample processing, cell proliferation was measured using the WST-1 assay.
[0252] The results are as follows Figure 21 As shown, no cell proliferation inhibition was observed in the untreated group (NC) and the mitochondrial-only treated group (MT). On the other hand, no inhibition was observed in the DOX-treated group and the DOX_MT group. α-HER2scFv In the treatment group, cancer cell proliferation was inhibited in a concentration-dependent manner. Specifically, it was confirmed that compared to the untreated group, cancer cell proliferation was significantly reduced when treated with 1 μM DOX_MT. α-HER2scFv During treatment, depending on the cancer cell line, cell growth was inhibited by approximately 60% to 90% ( Figure 21 ).
[0253] Example 4.5. DOX_MT at various concentrations α-HER2scFv Treatment of normal cells to demonstrate proliferation inhibition ability
[0254] 200 μg of MT α-HER2scFvThe reaction was carried out with 100 μM doxorubicin (DOX) in the same manner as in Preparation Example 2 above. To confirm the obtained DOX_MT... α-HER2scFv The effect on cell proliferation of normal cells was evaluated using DOX_MT. α-HER2scFv Inhibitory effect on cell proliferation of human lung fibroblasts.
[0255] Specifically, human lung fibroblast cell lines WI-38 and CCD-8Lu were used at approximately 3 × 10⁻⁶ ppm. 3 Cells / well were seeded into 96-well plates and cultured for 24 hours. WI-38 and CCD-8Lu were cultured in DMEM medium containing 10% FBS. After 24 hours of culture, cells were injected with doxorubicin (DOX) or DOX_MT at concentrations of 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.1 μM, 0.05 μM, 0.025 μM, and 0.01 μM. α-HER2scFv Each cell was processed. After 144 hours of sample processing, cell proliferation was measured using the WST-1 assay.
[0256] The results are as follows Figure 22 As shown, no inhibitory effect on cell proliferation was observed in the untreated group (NC) and the mitochondrial-only treated group (MT). Furthermore, this was confirmed in the DOX-treated group and the DOX_MT group. α-HER2scFv In the treatment group, the cell proliferation inhibition ability was weaker than that of cancer cells.
[0257] Example 4.6. Analysis using DOX_MT α-HER2scFv IC that treats cancer cells and normal cells 50 value
[0258] According to the DOX_MT concentrations in Examples 4.4 and 4.5 α-HER2scFv Cell proliferation inhibition results, analysis of IC50 in each cell type 50 Value and shown in Figure 23 .
[0259] Example 4.7. Comparison using DOX_MT α-HER2scFv The ability to inhibit the proliferation of cancer cells and normal cells
[0260] 200 μg of MT α-HER2scFv The reaction was carried out with 100 μM doxorubicin (DOX) in the same manner as in Preparation Example 2 above. To compare the obtained DOX_MT... α-HER2scFv Effects on cell proliferation of cancer cells and normal cells, using the same concentration of DOX_MT α-HER2scFv After treating human breast cancer, lung cancer, gastric cancer cell lines and lung fibroblast cell lines, the cell proliferation inhibition capacity was measured.
[0261] Specifically, human breast cancer (SK-BR-3, BT-474, and MDA-MB-231), lung cancer (NCI-H1975), gastric cancer (MKN-74 and NCI-N87) cell lines and lung fibroblast cell lines (CCD-8Lu and WI-38) were respectively loaded with approximately 3 × 10 3 Cells were seeded per well into 96-well plates and cultured for 24 hours. SK-BR-3, BT-474, and NCI-N87 cells were cultured in RPMI-1640 medium containing 10% FBS. MDA-MB-231, NCI-H1975, MKN-74, CCD-8Lu, and WI-38 cells were cultured in DMEM medium containing 10% FBS. After 24 hours of culture, cells were injected with 0.5 μM doxorubicin (DOX) or DOX_MT, respectively. α-HER2scFv Cells were treated, and after 144 hours, the cell proliferation inhibition ability was evaluated using WST-1 assay. At this point, only the mitochondrial treatment group (MT) showed significant inhibition. α-HER2scFv ) as DOX_MT α-HER2scFv The negative control was used. Statistical analysis was performed using Graphpad 5.0 software, and p-values were measured using one-way ANOVA (Turkey's test) (*p<0.05, **p<0.01, and ***p<0.001).
[0262] The results are as follows Figure 24 As shown, for the untreated group (NC) of cancer cells and normal cells, compared with the mitochondrial-only treated group (MT) α-HER2scFv No cell proliferation inhibition was observed in the DOX-treated group and the DOX_MT group. α-HER2scFv In the treatment group, compared with the untreated group, the cell proliferation inhibition effect on cancer cells was approximately 50% to 80% or higher, while the cell proliferation inhibition effect on normal cells was approximately 25% or lower.
[0263] Example 4.8. Verification using DOX_MT via TUNEL testing. α-HER2scFv Treatment of cancer cell apoptosis
[0264] To verify the DOX_MT obtained in the same manner as in Preparation Example 2 above... α-HER2scFv Apoptosis-inducing activity in cancer cells, using DOX_MT α-HER2scFv After processing human breast cancer and gastric cancer cell lines, TUNEL assays were performed.
[0265] Specifically, human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were used at approximately 3 × 10⁻⁶. 410 cells / well were seeded into 24-well plates and cultured for 24 hours. After 24 hours of culture, cells were seeded with MT. α-HER2scFv Or 1 μMDOX_MT α-HER2scFv Cells were treated, and after 48 hours, TUNEL assays were performed to confirm apoptosis. At this point, the mitochondrial-only treatment group (MT) was... α-HER2scFv ) as DOX_MT α-HER2scFv The control group was used. DAPI staining was used to observe the cell nuclei.
[0266] The results showed that in the mitochondrial-only treatment group (MT) α-HER2scFv Almost no apoptosis was observed in DOX_MT (green fluorescence). However, in DOX_MT... α-HER2scFv Increased apoptosis was observed in the nuclei of cells in the treated group. These results confirm that DOX_MT... α-HER2scFv Treatment to induce apoptosis ( Figure 25 ).
[0267] Example 4.9. Western blot analysis confirmed the effectiveness of DOX_MT. α-HER2scFv Treatment of cancer cell apoptosis
[0268] To verify the DOX_MT obtained in the same manner as in Preparation Example 2 above... α-HER2scFv Apoptosis in cancer cells, using DOX_MT α-HER2scFv After processing human breast cancer cell lines, Western blot was performed using antibodies targeting apoptosis markers.
[0269] Specifically, human breast cancer cell lines (SK-BR-3 and BT-474) were respectively used at approximately 5 × 10⁻⁶. 6 Cells were seeded per well into 6-well plates and cultured for 24 hours. After 24 hours of culture, cells were seeded separately using MT... α-HER2scFv or DOX_MT α-HER2scFv Cells were treated, and after 96 hours, they were lysed, proteins were extracted, and Western blots were performed. Anti-PARP lysis antibody (Cell Signaling, 9541S), anti-cysteine lysis antibody (Cell Signaling, 9664S), anti-phospho-p53 antibody (ABclonal, AP0762), and anti-β-actin antibody (Sigma, A2228) were used as primary antibodies. Anti-mouse IgG HRP or anti-rabbit IgG HRP were used as secondary antibodies. Protein levels were corrected for by β-actin expression levels. At this point, only the mitochondrial treatment group (MT) was included. α-HER2scFv ) as DOX_MT α-HER2scFv The negative control.
[0270] The results showed that in the mitochondrial-only treatment group (MT)α-HER2scFv In the DOX_MT group, similar to the untreated group, no cleavage forms of PARP and caspase 3 were observed during apoptosis, nor was phosphorylated p53 observed. On the other hand, in the DOX_MT group... α-HER2scFv In the treatment group, phosphorylated p53, as well as the expression of cleaved forms of PARP and caspase 3, were observed. Figure 26 The above results confirm that DOX_MT α-HER2scFv Treatment induces apoptosis.
[0271] Example 4.10. Flow cytometry confirmed the presence of DOX_MT. α-HER2scFv Treatment of cancer cell apoptosis
[0272] To verify the DOX_MT obtained in the same manner as in Preparation Example 2 above... α-HER2scFv Apoptosis in cancer cells, using DOX_MT α-HER2scFv After processing human breast cancer and gastric cancer cell lines, flow cytometry measurements were performed using annexin V / PI staining.
[0273] Specifically, human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were respectively fed with approximately 5 × 10⁻⁶ cells per cell line. 6 10 cells / well were seeded into 6-well plates and cultured for 24 hours. After 24 hours of culture, cells were seeded using MT... α-HER2scFv Or 1 μMDOX_MT α-HER2scFv Cell processing. After 96 hours of treatment, cells were washed twice with PBS and treated with 0.05% trypsin-EDTA to obtain cells. The obtained cells were centrifuged and then washed with PBS to remove 0.05% trypsin-EDTA. Subsequently, cells were stained for 10 minutes using an annexin V / PI staining kit (Roche, 11988549001), and the stained cells were analyzed using a FACS device (Beckman-Coulter, CytoFLEX). At this point, only the mitochondrial treatment group (MT) was analyzed. α-HER2scFv ) as DOX_MT α-HER2scFv The negative control.
[0274] The results showed that, for the untreated group (NC), compared with the mitochondrial-only treated group (MT), α-HER2scFv No changes in annexin V / PI values were observed in DOX_MT. On the other hand, annexin V / PI values were observed in DOX_MT. α-HER2scFv There has been an increase in the processing group ( Figure 27 The above results confirm that DOX_MT α-HER2scFv Treatment induces apoptosis.
[0275] Example 4.11. Evaluation of DOX_MT α-HER2scFv Selective apoptosis-inducing activity in HER2-expressing cells
[0276] To verify the DOX_MT obtained in the same manner as in Preparation Example 2 above... α-HER2scFv HER2-selective apoptosis induction, using DOX_MT α-HER2scFv Processing co-cultured HER2 + Cancer cells and HER2 - Normal cells were then subjected to TUNEL assay and immunocytochemical staining.
[0277] Specifically, the human breast cancer cell line BT-474 (HER2) + ) and human lung fibroblast cell line WI-38 (HER2) - Together with 3×10 4 Cells / well were seeded into 24-well plates and co-cultured in DMEM medium containing 10% FBS for 24 hours. BT-474 cells were prepared by culturing in RPMI-1640 medium containing 10% FBS, while WI-38 cells were prepared by culturing in DMEM medium containing 10% FBS. After 24 hours of culture, cells were seeded with 1 μM DOX_MT. α-HER2scFv The co-cultured cells were treated and cultured for another 48 hours. Apoptosis was assessed by TUNEL assay and immunocytochemical staining. Figure 28 ).
[0278] Example 4.12. Verification of DOX_MT by TUNEL detection α-HER2scFv Selective apoptosis-inducing activity in HER2-expressing cells
[0279] Cells treated in the same manner as in Example 4.11 above were washed twice with PBS and then fixed with 3.7% formaldehyde at room temperature for 30 minutes. Subsequently, anti-HER2 antibody (Cell Signaling Technology, 2165) was used as the primary antibody, and Alexa Fluor® 555-labeled anti-rabbit IgG antibody (Invitrogen, 21428) was used as the secondary antibody. + Cells were labeled with red fluorescence. Subsequently, cells were stained with TUNEL solution for 30 minutes. Cells that underwent apoptosis were labeled with green fluorescence and mounted for observation using a confocal microscope. At this point, DAPI staining was used to observe the cell nuclei.
[0280] The results showed that strong green fluorescence was selectively observed only in BT-474 cells (white arrows), which are HER2 cells. + cancer cell( Figure 29 The above results confirm that DOX_MT α-HER2scFv Apoptosis can be selectively induced based on the presence or absence of HER2 expression.
[0281] Preparation Example 3. Preparation of compounds bound to triphenylphosphine-doxorubicin
[0282] To effectively deliver the anticancer drug doxorubicin (DOX) into isolated mitochondria, compounds capable of targeting mitochondria are fused with doxorubicin. The most representative mitochondrial-targeting compound is triphenylphosphine (TPP), and anticancer agents bound to TPP include... Figure 30 The reaction was carried out as shown, and TPP-doxorubicin (TPP-DOX) was prepared using the method known in "Mitochondrial Delivery of Doxorubicin via Triphenylphosphine Modification for Overcoming Drug Resistance in MDA-MB-435 / DOX Cells" (Molecular Pharmaceutics, 11(8), 2640-2649). The compound was confirmed to be TPP-doxorubicin by MRI analysis. Figure 31 ).
[0283] Preparation Example 4. Preparation of the mitochondrial-TPP and doxorubicin complex
[0284] HEK293 cells expressing anti-HER2scFv antibody were treated with MitoTracker Green to stain mitochondria, and then mitochondrial MTs were isolated. α-HER2scFv Subsequently, 30 µg of mitochondria (MT) fused with anti-HER2scFv antibody were... α-HER2scFv The mixture was reacted with 100 µM TPP-doxorubicin at 4 °C for 10 min, followed by centrifugation at approximately 12,000 x g for 10 min to remove unreacted TPP-doxorubicin. The reaction product was washed twice with 500 µL SHE buffer (250 mM sucrose, 20 mM HEPES (pH 7.4), 2 mM EGTA) to obtain mitochondria containing TPP-doxorubicin (TPP-DOX_MT). α-HER2scFv () Figure 32 ).
[0285] Example 5. Evaluation of TPP-DOX_MT α-HER2scFv Anticancer activity against cancer cells
[0286] Example 5.1. Confirmation of TPP-DOX_MT α-HER2scFvDelivery characteristics into cancer cells
[0287] TPP-DOX_MT were obtained using the same method as in Preparation Example 4 described above. α-HER2scFv Human breast cancer cell lines (SK-BR-3, BT-474, and MDA-MB-231) and human lung cancer cell line (NCI-H1975) were processed and then observed using a confocal microscope. The cell nuclei were then observed using DAPI staining.
[0288] The results showed that MitoTracker Green (MT) was observed in the same location in the cytoplasm. α-HER2scFv Mitochondria stained with stained mitochondria and doxorubicin (TPP-DOX) showing red fluorescence (TPP-DOX) Figure 33 The above results confirm that TPP-DOX and MT... α-HER2scFv The TPP-DOX_MT that was transferred α-HER2scFv They are all located in the cytoplasm.
[0289] Example 5.2. Confirmation of the use of TPP-DOX_MT α-HER2scFv Morphological changes of treated cancer cells
[0290] TPP-DOX_MT were obtained using the same method as in Preparation Example 4 described above. α-HER2scFv Human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were treated, and then the morphological changes of cancer cells over time were observed using confocal microscopy. DAPI staining was used to observe the cell nuclei.
[0291] The results showed that using TPP-DOX_MT α-HER2scFv After 12 hours of treatment with (yellow fluorescence), most of TPP-DOX (red fluorescence) was present in the mitochondria along with it (green fluorescence). However, over time, TPP-DOX was observed in the nucleus, as indicated by TPP-DOX_MT. α-HER2scFv Significant changes in cell morphology were observed after 72 hours of treatment. Figure 34 ).
[0292] Example 5.3. Using TPP-DOX_MT at various concentrations α-HER2scFv Treating cancer cells to demonstrate their ability to inhibit proliferation
[0293] To verify the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above... α-HER2scFv The anticancer activity was demonstrated by using TPP-DOX_MT α-HER2scFv The inhibitory effect on cell proliferation was evaluated by treating human breast cancer, lung cancer, and gastric cancer cell lines.
[0294] Specifically, human breast cancer (SK-BR-3, BT-474, and MDA-MB-231), lung cancer (NCI-H1975), and gastric cancer (NCI-N87 and MKN-74) cell lines were respectively used at approximately 3 × 10⁻⁶. 3 Cells / well were seeded into 96-well plates and cultured for 24 hours. Human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were cultured in RPMI-1640 medium containing 10% FBS, while human breast cancer cell line MDA-MB-231, human lung cancer cell line NCI-H1975, and human gastric cancer cell line MKN-74 were cultured in DMEM medium containing 10% FBS. After 24 hours of culture, cells were seeded with TPP-DOX or TPP-DOX_MT at concentrations of 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.1 μM, 0.05 μM, 0.025 μM, and 0.01 μM. α-HER2scFv Each cell was treated. Cell proliferation was measured using the WST-1 assay 144 hours after sample treatment. At this time, only the mitochondrial treatment group (MT, MT...) was considered. α-HER2scFv (as TPP-DOX_MT) α-HER2scFv The negative control.
[0295] The results are as follows Figure 35 As shown, no cell proliferation inhibition was observed in the untreated group (NC) and the mitochondrial-only treated group (MT). On the other hand, no inhibition was observed in the TPP-DOX treated group and the TPP-DOX_MT group. α-HER2scFv In the treatment group, cancer cell proliferation was inhibited in a concentration-dependent manner. Specifically, it was confirmed that compared to the untreated group, cancer cell proliferation was significantly reduced when treated with 1 μM TPP-DOX_MT. α-HER2scFv During treatment, cell growth was inhibited by approximately 60% to 70%, depending on the cancer cell line.
[0296] Example 5.4. Using TPP-DOX_MT at various concentrations α-HER2scFv Treatment of normal cells to demonstrate proliferation inhibition ability
[0297] To verify the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above... α-HER2scFv The effect on normal cell proliferation was evaluated using TPP-DOX_MT. α-HER2scFv Inhibition of cell proliferation after treatment of human lung fibroblasts.
[0298] Specifically, human lung fibroblast cell lines WI-38 and CCD-8Lu were used at approximately 3 × 10⁻⁶ ppm. 3Cells / well were seeded into 96-well plates and cultured for 24 hours. During this time, WI-38 and CCD-8Lu were cultured in DMEM medium containing 10% FBS. After 24 hours of culture, cells were seeded into wells of TPP-DOX or TPP-DOX_MT at concentrations of 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.1 μM, 0.05 μM, 0.025 μM, and 0.01 μM. α-HER2scFv Each cell was treated. Cell proliferation was measured using the WST-1 assay 144 hours after sample treatment. At this time, only the mitochondrial treatment group (MT, MT...) was considered. α-HER2scFv (as TPP-DOX_MT) α-HER2scFv The negative control.
[0299] The results are as follows Figure 36 As shown, no cell proliferation inhibition was observed in the untreated group (NC) and the mitochondrial-only treated group (MT). Furthermore, this was confirmed in the TPP-DOX treated group and the TPP-DOX_MT group. α-HER2scFv In the treatment group, the cell proliferation inhibition ability was weaker than that of cancer cells.
[0300] Example 5.5. Analysis using TPP-DOX_MT α-HER2scFv IC that treats cancer cells and normal cells 50 value
[0301] According to the TPP-DOX_MT concentrations in Examples 5.3 and 5.4 α-HER2scFv Cell proliferation inhibition results, analysis of IC50 in each cell type 50 Value and shown in Figure 37 .
[0302] Example 5.6. Comparison using TPP-DOX_MT α-HER2scFv The ability to inhibit the proliferation of cancer cells and normal cells
[0303] To compare the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above, α-HER2scFv Effects on the proliferation of cancer cells and normal cells, using the same concentration of TPP-DOX_MT α-HER2scFv After treating human breast cancer, lung cancer, gastric cancer cell lines and lung fibroblast cell lines, the cell proliferation inhibition capacity was measured.
[0304] Specifically, human breast cancer (SK-BR-3, BT-474, and MDA-MB-231), lung cancer (NCI-H1975), gastric cancer (MKN-74 and NCI-N87) cell lines and lung fibroblast cell lines (CCD-8Lu and WI-38) were respectively loaded with approximately 3 × 10 3Cells were seeded per well into 96-well plates and cultured for 24 hours. SK-BR-3, BT-474, and NCI-N87 cells were cultured in RPMI-1640 medium containing 10% FBS, while MDA-MB-231, NCI-H1975, MKN-74, CCD-8Lu, and WI-38 cells were cultured in DMEM medium containing 10% FBS. After 24 hours of culture, cells were seeded with 0.5 μM TPP-DOX or TPP-DOX_MT, respectively. α-HER2scFv Cells were treated, and after 144 hours, the cell proliferation inhibition ability was evaluated using WST-1 assay. At this point, only the mitochondrial treatment group (MT) showed significant inhibition. α-HER2scFv (as TPP-DOX_MT) α-HER2scFv The negative control was used. Statistical analysis was performed using Graphpad 5.0 software, and the p-values were measured using a one-way ANOVA (Turkey's) test (*p<0.05, **p<0.01 and ***p<0.001).
[0305] The results are as follows Figure 38 As shown, for the untreated group (NC) of cancer cells and normal cells, compared with the mitochondrial-only treated group (MT) α-HER2scFv No cell proliferation inhibition was observed in the TPP-DOX-only treatment group and the TPP-DOX_MT group. α-HER2scFv In the treated group, the inhibitory effect on cancer cell proliferation was approximately 60% to 75% or higher compared to the untreated group. However, it has been confirmed that, unlike cancer cells, the inhibitory effect on the proliferation of normal cells was weak.
[0306] Example 5.7. TUNEL testing confirms TPP-DOX_MT α-HER2scFv Treatment of cancer cell apoptosis
[0307] To verify the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above... α-HER2scFv Apoptosis-inducing activity in cancer cells was measured using TPP-DOX_MT. α-HER2scFv After processing human breast cancer and gastric cancer cell lines, TUNEL assays were performed.
[0308] Specifically, human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were respectively fed with approximately 3 × 10⁻⁶ cells per cell line. 4 10 cells / well were seeded into a 24-well plate and cultured for 24 hours. After 24 hours of culture, cells were seeded using MT... α-HER2scFv Or 1 μMTPP-DOX_MT α-HER2scFv After treating the cells, TUNEL assays were performed 48 hours later to confirm apoptosis. At this point, the mitochondrial-only treatment group (MT) was... α-HER2scFv(as TPP-DOX_MT) α-HER2scFv The control group was used. DAPI staining was used to observe the cell nuclei.
[0309] The results showed that in the mitochondrial-only treatment group (MT) α-HER2scFv Almost no apoptosis was observed in TPP-DOX_MT (green fluorescence). However, in TPP-DOX_MT... α-HER2scFv Increased apoptosis was observed in the nuclei of cells in the treated group. These results confirm that TPP-DOX_MT... α-HER2scFv Treatment to induce apoptosis ( Figure 39 ).
[0310] Example 5.8. Western blot analysis confirmed the effectiveness of TPP-DOX_MT. α-HER2scFv Treatment of cancer cell apoptosis
[0311] To verify the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above... α-HER2scFv The effect of TPP-DOX_MT on apoptosis in cancer cells. α-HER2scFv After treating human breast cancer and gastric cancer cell lines, Western blots were performed using antibodies targeting apoptosis markers.
[0312] Specifically, human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were respectively fed with approximately 5 × 10⁻⁶ cells per cell line. 6 Cells / well were seeded into 6-well plates and cultured for 24 hours. After 24 hours of culture, cells were seeded separately using MT. α-HER2scFv Or 1μM TPP-DOX_MT α-HER2scFv Cells were treated, and after 96 hours, they were lysed, proteins were extracted, and Western blot analysis was performed. Anti-PARP lysis antibody (Cell Signaling, 9541S), anti-cysteine lysis antibody (Cell Signaling, 9664S), anti-phospho-p53 antibody (ABclonal, AP0762), and anti-β-actin antibody (Sigma, A2228) were used as primary antibodies. Anti-mouse IgG HRP or anti-rabbit IgG HRP were used as secondary antibodies. Protein levels were corrected for by β-actin expression levels. At this point, only the mitochondrial treatment group (MT) was analyzed. α-HER2scFv (as TPP-DOX_MT) α-HER2scFv The control group.
[0313] The results showed that in the mitochondrial-only treatment group (MT) α-HER2scFvIn the TPP-DOX_MT group, similar to the untreated group, no cleavage forms of PARP and caspase 3 were observed during apoptosis, nor was the phosphorylated form of p53 observed. On the other hand, in the TPP-DOX_MT group... α-HER2scFv In the treatment group, expression of phosphorylated p53 and PARP, as well as the cleaved form of caspase 3, was observed. Figure 40 The above results confirm that TPP-DOX_MT α-HER2scFv Treatment induces apoptosis.
[0314] Example 5.9. Flow cytometry confirmed the effectiveness of TPP-DOX_MT. α-HER2scFv apoptosis of treated cancer cells
[0315] To verify the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above... α-HER2scFv The effect of TPP-DOX_MT on apoptosis in cancer cells. α-HER2scFv After processing human breast cancer and gastric cancer cell lines, flow cytometry was performed using annexin V / PI staining.
[0316] Specifically, human breast cancer cell lines (SK-BR-3 and BT-474) and human gastric cancer cell line (NCI-N87) were respectively fed with approximately 5 × 10⁻⁶ cells per cell line. 6 10 cells / well were seeded into 6-well plates and cultured for 24 hours. After 24 hours of culture, cells were seeded using MT... α-HER2scFv Or 1 μMTPP-DOX_MT α-HER2scFv Cell processing. After 96 hours, cells were washed twice with PBS and treated with 0.05% trypsin-EDTA to obtain cells. The obtained cells were centrifuged and then washed with PBS to remove 0.05% trypsin-EDTA. Subsequently, cells were stained for 10 minutes using an annexin V / PI staining kit (Roche, 11988549001), and the stained cells were analyzed using a FACS device (Beckman-Coulter, CytoFLEX). At this point, only the mitochondrial treatment group (MT) was analyzed. α-HER2scFv (as TPP-DOX_MT) α-HER2scFv The negative control.
[0317] The results showed that, for the untreated group (NC), compared with the mitochondrial-only treated group (MT), α-HER2scFv No changes in the annexin V / PI value were observed in TPP-DOX_MT. On the other hand, no changes were observed in the TPP-DOX_MT. α-HER2scFv In the treatment group, the annexin V / PI ratio increased ( Figure 41 The above results confirm that TPP-DOX_MT α-HER2scFv Treatment induces apoptosis.
[0318] Example 5.10. Evaluation of TPP-DOX_MT α-HER2scFv Selective apoptosis-inducing activity in HER2-expressing cells
[0319] To verify the TPP-DOX_MT obtained in the same manner as in Preparation Example 4 above... α-HER2scFv HER2-selective apoptosis induction was demonstrated using TPP-DOX_MT. α-HER2scFv Processing co-cultured HER2 + Cancer cells and HER2 - Normal cells were then subjected to TUNEL assay and immunocytochemical staining.
[0320] Specifically, the human breast cancer cell line SK-BR-3 (HER2) + ) and human lung fibroblast cell line CCD-8Lu (HER2) - ) with 3×10 4 Cells were seeded at 10% per well into 24-well plates and co-cultured in DMEM medium containing 10% FBS for 24 hours. SK-BR-3 cells were prepared by culturing in RPMI-1640 medium containing 10% FBS, and WI-38 cells were prepared by culturing in DMEM medium containing 10% FBS. After 24 hours of culture, cells were seeded with 1 μM TPP-DOX_MT... α-HER2scFv The co-cultured cells were treated and cultured for another 48 hours. Apoptosis was evaluated by TUNEL assay and immunocytochemical staining. Figure 42 ).
[0321] Example 5.11. Confirmation of TPP-DOX_MT by TUNEL testing α-HER2scFv HER2-expressing cells selectively induce apoptosis
[0322] Cells treated in the same manner as in Example 5.10 above were washed twice with PBS and then fixed with 3.7% formaldehyde at room temperature for 30 minutes. Subsequently, anti-HER2 antibody (Cell signaling, 29D8) was used as the primary antibody, and Alexa Fluor® 555 (Invitrogen, 21428) as the secondary antibody. + Cells were labeled with red fluorescence. Afterward, they were stained with TUNEL solution for 30 minutes. Cells that underwent apoptosis were labeled with green fluorescence and mounted for observation using a confocal microscope. At this point, DAPI staining was used to observe the cell nuclei.
[0323] The results showed that strong green fluorescence was selectively observed only in SK-BR-3 cells (white arrows), which are HER2 cells.+ cell( Figure 43 The above results confirm that TPP-DOX_MT α-HER2scFv Apoptosis can be selectively induced based on the presence or absence of HER2 expression.
[0324] Preparation Example 5. Preparation of HEK293 cell line including mitochondria fused with anti-PDL1scFv antibody.
[0325] To specifically introduce mitochondria into tumor cells expressing PDL1, an anti-PDL1 scFv antibody (SEQ ID NO: 94) that specifically binds to PDL1 was constructed and fused to the outer mitochondrial membrane. Figure 44 and 45 The specific construction method is described in Korean Patent Application Publication No. 10-2019-0124656.
[0326] Example 6. Analysis of PDL1 expression in human cancer cell lines by Western blot
[0327] Western blot analysis was performed to confirm the expression levels of PDL1 in human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484).
[0328] Specifically, human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484) were used at approximately 1×10⁻⁶. 6 Cells were seeded per well into 6-well plates and cultured in DMEM medium containing 10% FBS for 24 hours. After 24 hours, the culture medium was removed, cells were washed twice with PBS, and then 100 μL of RIPA buffer containing protease inhibitors was added directly to the cells. After 10 minutes, the cells were scraped and transferred to microtubes, then centrifuged at approximately 12,000 xg for 10 minutes. The separated supernatant was transferred to a new microtube and protein quantification was performed using BCA analysis. The same number of proteins for each sample were electrophoresed and then Western blotted. Anti-PDL1 antibody (Cell signaling, 13684) and anti-β-tubulin antibody (Thermo Fisher, MA5-16308) were used as primary antibodies, and anti-mouse IgG HRP antibody or anti-rabbit IgG HRP antibody were used as secondary antibodies.
[0329] The results are as follows Figure 46 As shown, this confirms that BXPC-3 and SNU-216 cells are PDL1-expressing cells. +On the other hand, it was confirmed that CFPAC-1 and SNU-484 cells expressed almost no PDL1, indicating that they are PDL1-dependent cells. - cell.
[0330] Example 7. Validation of PDL1 targeting in mitochondria fused with anti-PDL1scFv antibody
[0331] To verify the PDL1 targeting ability of mitochondria fused with the anti-PDL1scFv antibody constructed in Preparation Example 5 above, co-cultured PDL1 + Cells and PDL1 - Cells fused with anti-PDL1scFv antibody mitochondria (MT) α-PDL1scFv The cells were treated and then subjected to immunocytochemical staining.
[0332] Specifically, BXPC-3 (PDL1) + ) and CFPAC-1 (PDL1 - ), or SNU-216 (PDL1) + ) and SNU-484 (PDL1) - Together at 1.5×10 4 Cells / wells were seeded into 24-well plates and co-cultured in DMEM medium containing 10% FBS for 24 hours. The results were obtained by treating untreated HEK293 cells (MT) with MitoTracker Red and HEK293 cells (MT) containing mitochondria fused with anti-PDL1scFv antibody. α-PDL1scFv Mitochondria were stained to prepare mitochondria for use as samples, and then the mitochondria were isolated. After co-culturing for 24 hours, the co-cultured cells were treated with each isolated mitochondria and reacted for 24 hours. Figure 47 ).
[0333] Example 7.1. Confirmation of the location of mitochondria fused with anti-PDL1scFv antibody in PDL1-positive and negative cell lines.
[0334] Cells treated in the same manner as in Example 4 above were washed once with PBS and fixed with 3.7% formaldehyde at room temperature for 30 minutes, followed by immunocytochemical staining. Anti-PDL1 antibody (Cell signaling, 86744) was used as the primary antibody, and Alexa Fluor 488 goat anti-rabbit IgG (H+L) was used as the secondary antibody. DAPI staining was used to observe the cell nuclei.
[0335] The results are as follows Figure 48 As shown, when co-cultured BXPC-3 (PDL1) cells were treated with mitochondria (MT) derived from untreated HEK293 cells... +) and CFPAC-1 (PDL1 - When cells are in BXPC-3 (PDL1) + ) and CFPAC-1 (PDL1 - Mitotracker Red (red fluorescence) staining was also observed in mitochondria in cells. On the other hand, when mitochondria derived from HEK293 cells, including mitochondria fused with anti-PDL1scFv antibody, were used... α-PDL1scFv When cells were treated, mitochondria stained with Mitotracker Red were specifically observed in PDL1+ cells (BXPC-3 cells).
[0336] Furthermore, similarly, in co-cultured SNU-216 (PDL1) + ) and SNU-484 (PDL1) - In cells, in the MT-treated group, in PDL1 + (SNU-216) and SNU-484 (PDL1 - Mitotracker Red stained mitochondria were similarly observed in MT cells, while in MT cells... α-PDL1scFv In the processing group, only in PDL1 + This was specifically observed in SNU-216 cells. The results indicate that mitochondria fused with the anti-PDL1scFv antibody specifically target cells expressing the PDL1 antigen.
[0337] Preparation Example 6. Preparation of mitochondrial complexes fused with anti-PDL1scFv antibody and doxorubicin
[0338] 30 µg of mitochondria (MT) isolated from HEK293 cells, including mitochondria fused with anti-PDL1scFv antibody, were used to prepare the mitochondria. α-PDL1scFv The mitochondria were reacted with 100 μM doxorubicin (DOX) at 4 °C for 10 min, followed by centrifugation at approximately 12,000 xg for 10 min to remove unreacted doxorubicin. Subsequently, the mitochondria were washed twice with 500 μL SHE buffer (250 mM sucrose, 20 mM HEPES (pH 7.4), 2 mM MEGTA) to obtain the doxorubicin-containing mitochondria (DOX_MT). α-PDL1scFv () Figure 49 ).
[0339] Example 8. Evaluation of DOX_MT α-PDL1scFv Anticancer activity against cancer cells
[0340] Example 8.1. DOX_MT at various concentrations α-PDL1scFv Treatment to confirm cell proliferation inhibition ability
[0341] To verify the DOX_MT obtained in the same manner as in Preparation Example 6 above α-PDL1scFv The anticancer activity was measured using DOX_MT. α-PDL1scFv The inhibitory effect on cell proliferation was evaluated after treating human pancreatic cancer and gastric cancer cell lines.
[0342] Specifically, human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484) were used at approximately 5 × 10⁻⁶ cells per day. 3 Cells / well were seeded into 96-well plates and cultured for 24 hours. After 24 hours of culture, DOX_MT was administered at concentrations of 0.01 μM, 0.025 μM, 0.05 μM, 0.1 μM, 0.25 μM, 0.5 μM, and 1 μM. α-PDL1scFv Each cell was treated. Cell proliferation was measured every 24 hours using the WST-1 assay until 168 hours after sample treatment. At this point, only the mitochondrial treatment group (MT) was considered. α-PDL1scFv ) as DOX_MT α-PDL1scFv The negative control.
[0343] The results showed that, for the untreated group (NC), compared with the mitochondrial-only treated group (MT), α-PDL1scFv No cell proliferation inhibition was observed in DOX_MT. On the other hand, no inhibition of cell proliferation was observed in DOX_MT. α-PDL1scFv In the treatment group, cancer cell proliferation was inhibited over time in a concentration-dependent manner. Figure 50 ).
[0344] Example 8.2. Western blot analysis confirms DOX_MT α-PDL1scFv Treatment of cancer cell apoptosis
[0345] To confirm DOX_MT α-PDL1scFv Apoptosis in cancer cells, using DOX_MT α-PDL1scFv After treating human pancreatic cancer and gastric cancer cell lines, Western blots were performed using antibodies targeting apoptosis markers.
[0346] Specifically, human pancreatic cancer cell lines (BXPC-3 and CFPAC-1) and human gastric cancer cell lines (SNU-216 and SNU-484) were respectively injected at approximately 5 × 10⁻⁶. 6 Seed cells per well and cultured for 24 hours.
[0347] After 24 hours of incubation, MT was used respectively α-PDL1scFv or DOX_MT α-PDL1scFvCells were treated, and after 96 hours, they were lysed, proteins were extracted, and Western blots were performed. Anti-PARP lysis antibody (Cell Signaling, 9541S), anti-caspase 3 lysis antibody (Cell Signaling, 9664), anti-phospho-p53 antibody (ABclonal, AP0762), and anti-β-actin antibody (Sigma, A2228) were used as primary antibodies, and anti-mouse IgG HRP or anti-rabbit IgG HRP were used as secondary antibodies. Protein levels were corrected for by β-actin expression levels. At this point, only the mitochondrial treatment group (MT) was included. α-PDL1scFv ) as DOX_MT α-PDL1scFv The negative control.
[0348] The results showed that in the mitochondrial-only treatment group (MT) α-PDL1scFv In the DOX_MT group, similar to the untreated group, no cleaved forms of PARP and caspase 3 observed during apoptosis were observed, nor was phosphorylated p53 observed. On the other hand, in the DOX_MT group... α-PDL1scFv In the treatment group, phosphorylated p53, as well as the expression of cleaved forms of PARP and caspase 3, were observed. Figure 51 The above results confirm that DOX_MT α-PDL1scFv Treatment induces apoptosis.
[0349] Preparation Example 7. Preparation of HEK293 cell line including mitochondria fused with anti-MSLN scFv antibody.
[0350] To specifically introduce mitochondria into tumor cells expressing mesothelin (MSLN), an anti-MSLNscFv antibody (SEQ ID NO: 102) that specifically binds to MSLN was constructed and fused to the outer mitochondrial membrane. Figure 52 and 53 The specific construction method is described in Korean Patent Application Publication No. 10-2019-0124656.
[0351] Preparation Example 8. Preparation of mitochondrial complexes fused with anti-MSLNscFv antibody and pheophytic chlorophyll A
[0352] 100 μg of mitochondria (MT) isolated from HEK293 cells, including mitochondria fused with anti-MSLNscFv antibody. α-MSLNscFvThe mitochondria were reacted with 100 μM pheophorbyl chlorophyll A (PBA) at 4 °C for 10 min, followed by centrifugation at approximately 12,000 x g for 10 min to remove unreacted PBA. Subsequently, the mitochondria were washed twice with 500 μL SHE buffer (250 mM sucrose, 20 mM HEPES (pH 7.4), 2 mM EGTA) to obtain PBA_MT. α-MSLNscFv () Figure 54 ).
[0353] Example 9. Confirmation of PBA_MT α-MSLNscFv Treatment of cell proliferation inhibition ability
[0354] To verify the PBA_MT obtained in the same manner as in Preparation Example 8 above. α-MSLNscFv The anticancer activity of PBA_MT α-MSLNscFv The inhibitory effect on cell proliferation was evaluated after treating human pancreatic cancer cell lines.
[0355] Specifically, human pancreatic cancer cell lines AsPC-1, Capan-1, Capan-2, and Mia PaCa-2 were administered at a dose of 5 × 10⁻⁶. 3 10 cells / well were seeded into 96-well plates and cultured for 24 hours. Afterwards, MT was used... α-MSLNscFv Or 1 µg PBA-MT α-MSLNscFv Cells were treated, cultured for another 72 hours, and then cell proliferation was evaluated using WST-1 assay. At this point, only the mitochondrial treatment group (MT) was observed. α-MSLNscFv ) as PBA_MT α-MSLNscFv The negative control.
[0356] The results showed that, for the untreated group (CTR), compared with the mitochondrial-only treated group (MT), α-MSLNscFv No inhibitory effect on cell proliferation was observed. On the other hand, it was confirmed that in PBA_MT... α-MSLNscFv In the treated group, cell growth was inhibited by approximately 80% to 95% compared to the untreated group. Figures 55 to 58 (Bottom).
[0357] In addition, MT in each pancreatic cancer cell line was observed using an inverted microscope. α-MSLNscFv and PBA_MT α-MSLNscFv Morphological changes were treated. In MT α-MSLNscFv In the treatment group, almost no morphological changes were observed compared to the untreated group, while in PBA_MT α-MSLNscFv In the treatment group, it was confirmed that the cell morphology of all cancer cell lines changed. Figures 55 to 58 (at the top).
[0358] Preparation Example 9. Preparation of mitochondrial complex fused with anti-MSLNscFv antibody and gemcitabine
[0359] 100 μg of mitochondria isolated from HEK293 cells containing mitochondria fused with anti-MSLNscFv antibody were reacted with 100 μM gemcitabine (Gem) at 4°C for 10 min, followed by centrifugation at approximately 12,000 xg for 10 min to remove unreacted gemcitabine. Subsequently, the cells were washed twice with 500 μL SHE buffer (250 mM sucrose, 20 mM HEPES (pH 7.4), 2 mM EGTA) to obtain the gemcitabine-containing mitochondria (Gem_MT). α-MSLNscFv () Figure 59 ).
[0360] Example 10. Confirmation using Gem_MT α-MSLNscFv Treatment of cell proliferation inhibition ability
[0361] To verify the Gem_MT obtained in the same manner as in Preparation Example 9 above. α-MSLNscFv The anticancer activity of Gem_MT α-MSLNscFv After treating human pancreatic cancer cell lines, the inhibitory effect on cell proliferation was evaluated.
[0362] Specifically, human pancreatic cancer cell lines AsPC-1, Capan-1, Capan-2, and Mia PaCa-2 were administered at approximately 5 × 10⁻⁶ mg / L. 3 10 cells / well were seeded into 96-well plates and cultured for 24 hours. After 24 hours of culture, cells were seeded using MT... α-MSLNscFv Or 2 µg Gem_MT α-MSLNscFv Each cell was treated and cultured for 72 hours, after which cell proliferation was measured using WST-1 assay. At this point, only the mitochondrial treatment group (MT) was included. α-MSLNscFv ) as Gem_MT α-MSLNscFv The negative control.
[0363] The results showed that, for the untreated group (CTR), compared with the mitochondrial-only treated group (MT), α-MSLNscFv No cell proliferation inhibition was observed in Gem_MT. On the other hand, it was confirmed that compared to the untreated group, Gem_MT... α-MSLNscFv The treatment group showed approximately 20% to 30% cell growth inhibition, depending on the cancer cell line. Figure 60 ).
[0364] Preparation Example 10. Preparation of mitochondrial complexes fused with anti-MSLNscFv antibody and vinorelbine
[0365] 100 μg of mitochondria (MT) isolated from HEK293 cells, including mitochondria fused with anti-MSLNscFv antibody. α-MSLNscFv The mitochondria were reacted with 100 μM vinorelbine (VIBE) at 4°C for 10 min, followed by centrifugation at approximately 12,000 xg for 10 min to remove unreacted vinorelbine. Subsequently, the mitochondria were washed twice with 500 μL SHE buffer (250 mM sucrose, 20 mM HEPES (pH 7.4), 2 mM MEGTA) to obtain vinorelbine-containing mitochondria (VIBE_MT). α-MSLNscFv () Figure 61 ).
[0366] Example 11. Confirmation of VIBE_MT α-MSLNscFv Treatment of cell proliferation inhibition ability
[0367] To verify the VIBE_MT obtained in the same manner as in Preparation Example 10 above α-MSLNscFv The anticancer activity of VIBE_MT α-MSLNscFv The inhibitory effect on cell proliferation was evaluated after treating human pancreatic cancer cell lines.
[0368] Specifically, human pancreatic cancer cell lines AsPC-1, Capan-1, Capan-2, and MIA PaCa-2 were administered at approximately 5 × 10⁻⁶ mg / L. 3 10 cells / well were seeded into a 96-well plate and cultured for 24 hours. After 24 hours of culture, cells were seeded using MT... α-MSLNscFv Or 2 µg VIBE_MT α-MSLNscFv Each cell was treated and cultured for 72 hours, after which cell proliferation was measured using the WST-1 assay. At this point, only the mitochondrial treatment group (MT) was observed. α-MSLNscFv ) as VIBE_MT α-MSLNscFv The negative control.
[0369] The results showed that, for the untreated group (CTR), compared with the mitochondrial-only treated group (MT), α-MSLNscFv No cell proliferation inhibition was observed. On the other hand, it was confirmed that VIBE_MT showed better cell proliferation inhibition compared to the untreated group. α-MSLNscFv The treatment group showed approximately 50% inhibition of cell growth based on the cancer cell line. Figure 62 ).
[0370] Example 12. Verification of MT α-HER2scFv Tumor cell targeting in xenograft tumor mouse models
[0371] Five-week-old male BALB / c nude mice (initial weight 18-20g) (Nara Biotech) were acclimatized for one week, and then HER2 +Human gastric cancer cell line NCI-N87 at 1×10 7 Cells / mouse cells were subcutaneously transplanted to the flank of the mouse to construct a xenograft tumor model. The tumor was established when its average volume reached 50 mm². 3 For 20 μg or more, administer MT intravenously. α-HER2scFv Twenty-four hours later, mouse tissues were extracted. Immunohistochemical staining analysis was performed on each extracted tissue using anti-myc antibody to confirm MT. α-HER2scFv Distribution in mouse tissues ( Figure 63 ).
[0372] Example 12.1. Confirmation of MT α-HER2scFv Tumor cell targeting in xenograft tumor mouse models
[0373] Immunohistochemical staining was performed on mouse tissues treated in the same manner as in Example 12 above. Mitochondrial MT-labeled tissues were used. α-HER2scFv The anti-myc antibody (Roche, 11667149001) was used as the primary antibody, and the anti-mouse IgG antibody (Invitrogen, 11001) labeled with Alexa Fluor®488 was used as the secondary antibody. At this time, the cell nuclei were observed by DAPI staining.
[0374] The results showed that MT was not observed in kidney and liver tissues. α-HER2scFv However, MT was observed in tumor tissue. α-HER2scFv ( Figure 64 The above results confirm that MT injected into the mouse vein... α-HER2scFv It specifically targeted NCI-N87 (HER2) cells subcutaneously transplanted into the flank of mice. + Tumor cells.
[0375] Example 13. Evaluation of TPP-DOX_MT α-HER2scFv Anticancer activity in xenograft tumor mouse models
[0376] Five-week-old male BALB / c nude mice (initial weight 18-20 grams) (Nara Biotech) underwent acclimatization training for one week, followed by HER2... + Human gastric cancer cell line NCI-N87 was used at 1×10 7 Cells / mouse cells were subcutaneously transplanted to the flank of the mouse to construct a xenograft tumor model. The tumors were selected when their average volume reached 50–100 mm². 3 Mice were divided into 3 groups of 7 each and intravenously injected with 4 μg of TPP-DOX or TPP-DOX_MT. α-HER2scFv Once a week for a total of 7 times. Tumor size is measured every 2-4 days. Tumor tissue is extracted 25 days after the start of administration to measure its size and weight. Figure 65 ).
[0377] Example 13.1. Confirmation of TPP-DOX_MT α-HER2scFv Tumor cell growth inhibition ability in xenograft tumor mouse models
[0378] The results of experiments conducted using the method described in Example 13 above indicate that, in the TPP-DOX administration group, tumor size remained similar to that of the control group (CTR) until day 30. On the other hand, compared to the control group, TPP-DOX_MT... α-HER2scFv The tumor size in the treatment group was significantly reduced ( Figure 66 In addition, the size of the tumor extracted after the experiment ( ). Figure 67 ) and weight ( Figure 68 In TPP-DOX_MT α-HER2scFv The effect was also significantly reduced in the treatment group. Statistical analysis was performed using Graphpad 5.0 software, and the p-value was measured using a one-way ANOVA (Turkey's) test (*p<0.05).
[0379] Example 14. Evaluation of TPP-DOX_MT α-HER2scFv Anticancer activity in xenograft tumor mouse models
[0380] Seven-week-old female C57BL / 6 mice (Samtako Bio Korea) were acclimatized for one week, and then the mouse melanoma cell line B16F10 was used at approximately 5 × 10⁻⁶. 5 One cell / mouse was subcutaneously transplanted into the flank of mice to construct xenograft tumor mice. At this time, B16F10 cells overexpressing the human HER2 gene were used as B16F10 cells. When the average tumor volume reached 100–200 mm... 3 At that time, the mice were divided into 4 groups of 3 mice each, and MT was administered. α-HER2scFv (20 µg), TPP-DOX (5 µg) or TPP-DOX_MT α-HER2scFv (TPP-DOX / MT: 5 µg / 20 µg) Intravenous injection, 3 times a week for 3 weeks. Tumor size was measured 3 times a week. At the end of the experiment (3 weeks after the start of administration), tumor tissue was extracted from mice and its size and weight were measured. Figure 69 ).
[0381] Example 14.1. Confirmation of TPP-DOX_MT α-HER2scFv Tumor cell growth inhibition ability in animal models of allogeneic cancer cell transplantation
[0382] The experimental results obtained using the method described in Example 14 above show that, in MT α-HER2scFvIn the TPP-DOX administration group, tumor size was similar to that in the control group (CTR). On the other hand, compared to the control group, the TPP-DOX_MT... α-HER2scFv The tumor size in the treatment group was significantly reduced ( Figure 70 In addition, TPP-DOX_MT α-HER2scFv The size of the tumors extracted from the treatment group after the experiment ( Figure 71 ) and weight ( Figure 72 All of them have decreased.
[0383] Example 15. Evaluation of DOX_MT α-HER2scFv Anticancer activity in allogeneic tumor animal models
[0384] Seven-week-old female C57BL / 6 mice (Samtako Bio Korea) were acclimatized for one week, and then the mouse melanoma cell line B16F10 was used at approximately 5 × 10⁻⁶. 5 One cell / mouse was subcutaneously transplanted into the flank of mice to construct xenograft tumor mice. B16F10 cells overexpressing the human HER2 gene were used as B16F10 cells. The tumor volume was increased to an average of 100–200 mm². 3 Mice were divided into 4 groups of 3 mice each, and were intravenously injected with MT 3 times a week. α-HER2scFv (20 µg), DOX (4 µg) or DOX_MT α-HER2scFv (TPP-DOX / MT: 4 µg / 20 µg), continued for 3 weeks. Tumor size was measured 3 times per week. At the end of the experiment (3 weeks after the start of administration), tumor tissue was extracted from mice and its size and weight were measured. Figure 73 ).
[0385] Example 15.1. Confirmation of DOX_MT α-HER2scFv Tumor cell growth inhibition ability in xenograft tumor animal models
[0386] The experimental results obtained using the method described in Example 14 above show that, in MT α-HER2scFv In the treatment group, tumor size was similar to that in the control group (CTR). On the other hand, compared with the control group, the DOX treatment group and the DOX_MT group... α-HER2scFv Tumor size was significantly reduced in the treatment group. Furthermore, it was confirmed that DOX_MT significantly reduced tumor size compared to the DOX-treated group. α-HER2scFv The tumor size in the treatment group decreased further ( Figure 74 Furthermore, compared to the control group, DOX_MT α-HER2scFv The size of the tumor extracted from the drug-treated group after the experiment ( Figure 75 ) and weight ( Figure 76 All of them have decreased.
[0387] [Free text of sequence lists]
[0388] SEQ ID NO: 1: T2p53 primer
[0389] SEQ ID NO: 2: Xp53 primer
[0390] SEQ ID NO: 3: Nucleotide sequence encoding p53
[0391] SEQ ID NO: 4: NdeUB primers
[0392] SEQ ID NO: 5: T2UB primer
[0393] SEQ ID NO: 6: Nucleotide sequence encoding UB-p53
[0394] SEQ ID NO: 7: NdeTOM70 primers
[0395] SEQ ID NO: 8: TOM70-AS primers
[0396] SEQ ID NO: 9: TOM70UB-S primer
[0397] SEQ ID NO: 10: T2UB-AS primers
[0398] SEQ ID NO: 11: Nucleotide sequence encoding TOM70-UB-p53
[0399] SEQ ID NO: 12: TOM70 (G)3-AS primers
[0400] SEQ ID NO: 13: (G)3UB-S primer
[0401] SEQ ID NO: 14: Xp53 (noT) primers
[0402] SEQ ID NO: 15: Nucleotide sequence encoding TOM70-(GGGGS)3-UB-p53
[0403] SEQ ID NO: 16:B(G)3p53
[0404] SEQ ID NO: 17: Nucleotide sequence encoding TOM70-(GGGGS)3-p53
[0405] SEQ ID NO: 18: Xp53 (noT) primer
[0406] SEQ ID NO: 19: XTOM7 primer
[0407] SEQ ID NO: 20: LTOM7 primer
[0408] SEQ ID NO: 21: Nucleotide sequence encoding UB-p53-TOM7
[0409] SEQ ID NO: 22: Rp53 primer
[0410] SEQ ID NO: 23: Nucleotide sequence encoding p53-myc / His
[0411] SEQ ID NO: 24: T2GZMB primers
[0412] SEQ ID NO: 25: XGZMB (noT) primer
[0413] SEQ ID NO: 26: Nucleotide sequence encoding granzyme B
[0414] SEQ ID NO: 27: Nucleotide sequence encoding TOM70-(GGGGS)3-UB-granulase B
[0415] SEQ ID NO: 28: Nucleotide sequence encoding UB-granulase B-TOM7
[0416] SEQ ID NO: 29: T2RKIP primers
[0417] SEQ ID NO: 30: XRKIP (noT) primers
[0418] SEQ ID NO: 31: Nucleotide sequence encoding RKIP
[0419] SEQ ID NO: 32: Nucleotide sequence encoding TOM70-(GGGGS)3-UB-RKIP
[0420] SEQ ID NO: 33: T2PTEN primers
[0421] SEQ ID NO: 34: XPTEN (noT) primers
[0422] SEQ ID NO: 35: Nucleotide sequence encoding PTEN
[0423] SEQ ID NO: 36: Nucleotide sequence encoding TOM70-(GGGGS)3-UB-PTEN
[0424] SEQ ID NO: 37: Nucleotide sequence encoding scFvHER2
[0425] SEQ ID NO: 38: Nucleotide sequence encoding UB-scFvHER2-TOM7
[0426] SEQ ID NO: 39: RscFvHER2 primer
[0427] SEQ ID NO: 40: XTOM7 (noT) primer
[0428] SEQ ID NO: 41: Nucleotide sequence encoding scFvHER2-TOM7-myc / His
[0429] SEQ ID NO: 42: Nucleotide sequence encoding scFvMEL
[0430] SEQ ID NO: 43: Nucleotide sequence encoding UB-scFvMEL-TOM7
[0431] SEQ ID NO: 44: RscFvMEL primers
[0432] SEQ ID NO: 45: Nucleotide sequence encoding scFvMEL-TOM7-myc / His
[0433] SEQ ID NO: 46: Nucleotide sequence encoding scFvPD-L1
[0434] SEQ ID NO: 47: Nucleotide sequence encoding scFvPD-L1-TOM7-myc / His
[0435] SEQ ID NO: 48: Amino acid sequence of p53
[0436] SEQ ID NO: 49: Amino acid sequence of UB-p53
[0437] SEQ ID NO: 50: Amino acid sequence of TOM70-UB-p53
[0438] SEQ ID NO: 51: Amino acid sequence of TOM70-(GGGGS)3-UB-p53
[0439] SEQ ID NO: 52: Amino acid sequence of TOM70-(GGGGS)3-p53
[0440] SEQ ID NO: 53: Amino acid sequence of UB-p53-TOM7
[0441] SEQ ID NO: 54: Amino acid sequence of p53-myc / His
[0442] SEQ ID NO: 55: Amino acid sequence of granzyme B
[0443] SEQ ID NO: 56: Amino acid sequence of TOM70-(GGGGS)3-UB-granzyme B
[0444] SEQ ID NO: 57: Amino acid sequence of UB-granzyme B-TOM7
[0445] SEQ ID NO: 58: Amino acid sequence of RKIP
[0446] SEQ ID NO: 59: Amino acid sequence of TOM70-(GGGGS)3-UB-RKIP
[0447] SEQ ID NO: 60: Amino acid sequence of PTEN
[0448] SEQ ID NO: 61: Amino acid sequence of TOM70-(GGGGS)3-UB-PTEN
[0449] SEQ ID NO: 62: Amino acid sequence of scFvHER2
[0450] SEQ ID NO: 63: Amino acid sequence of UB-scFvHER2-TOM7
[0451] Amino acid sequence of SEQ ID NO: 64: scFvHER2-TOM7-myc / His
[0452] SEQ ID NO: 65: Amino acid sequence of scFvMEL
[0453] SEQ ID NO: 66: Amino acid sequence of UB-scFvMEL-TOM7
[0454] The amino acid sequence of SEQ ID NO: 67: scFvMEL-TOM7-myc / His
[0455] SEQ ID NO: 68: Amino acid sequence of scFvPD-L1
[0456] SEQ ID NO: 69: Amino acid sequence of scFvPD-L1-TOM7-myc / His
[0457] SEQ ID NO: 70: Connector
[0458] SEQ ID NO: 71: Amino acid sequence of ubiquitin
[0459] SEQ ID NO: 72: Nucleotide sequence encoding ubiquitin
[0460] SEQ ID NO: 73: Amino acid sequence of p53
[0461] SEQ ID NO: 74: Nucleotide sequence encoding p53
[0462] SEQ ID NO: 75: TOM70 of Saccharomyces cerevisiae
[0463] SEQ ID NO: 76: TOM70 of humans
[0464] SEQ ID NO: 77: TOM20 of Saccharomyces cerevisiae
[0465] SEQ ID NO: 78: TOM20 for humans
[0466] SEQ ID NO: 79: OM45 of Saccharomyces cerevisiae
[0467] SEQ ID NO: 80: TOM5 of Saccharomyces cerevisiae
[0468] SEQ ID NO: 81: Human TOM5
[0469] SEQ ID NO: 82: TOM7 of Saccharomyces cerevisiae
[0470] SEQ ID NO: 83: TOM7 of Man
[0471] SEQ ID NO: 84: TOM22 of Saccharomyces cerevisiae
[0472] SEQ ID NO: 85: TOM22 of Man
[0473] SEQ ID NO: 86: Fis1 of Saccharomyces cerevisiae
[0474] SEQ ID NO: 87: Human Fis1
[0475] SEQ ID NO: 88: Human Bcl-2α
[0476] SEQ ID NO: 89: VAMP1 of Saccharomyces cerevisiae
[0477] SEQ ID NO: 90: Human VAMP1
[0478] SEQ ID NO: 91: P53-promoter-S
[0479] SEQ ID NO: 92: P53-promoter-AS
[0480] SEQ ID NO: 93: Nucleotide sequence encoding scFvPDL1-myc-TOM7
[0481] SEQ ID NO: 94: Amino acid sequence of scFvPDL1-myc-TOM7
[0482] SEQ ID NO: 95: Nucleotide sequence encoding scFvHER2
[0483] SEQ ID NO: 96: Amino acid sequence of scFvHER2
[0484] SEQ ID NO: 97: Nucleotide sequence encoding scFvHER2-myc-TOM7
[0485] SEQ ID NO: 98: Amino acid sequence of scFvHER2-myc-TOM7
[0486] SEQ ID NO: 99: Nucleotide sequence encoding scFvMSLN
[0487] SEQ ID NO: 100: Amino acid sequence of scFvMSLN
[0488] SEQ ID NO: 101: Nucleotide sequence encoding scFvMSLN-myc-TOM7
[0489] The amino acid sequence of SEQ ID NO: 102: scFvMSLN-myc-TOM7. <110> Baiyan Biotechnology Company <120> Mitochondria containing anticancer drugs and their applications <130> P23111530WP <150> KR 10-2020-0137779 <151> 2020-10-22 <160> 102 <170> KoPatentIn 3.0 <210> 1 <211> 39 <212> DNA <213> Artificial sequence <220> <223> T2p53 primers <400> 1 aaaaaaccgc ggtggtgagg agccgcagtc agatcctag 39 <210> 2 <211> 35 <212> DNA <213> Artificial sequence <220> <223> Xp53 primer <400> 2 aaaaaactcg agtgagtctg agtcaggccc ttctg 35 <210> 3 <211> 1186 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding p53 <400> 3 ccgcggtggt gaggagccgc agtcagatcc tagcgtcgag ccccctctga gtcaggaaac 60 attttcagac ctgtggaaac tacttcctga aaacaacgtt ctgtccccct tgccgtccca 120 agcaatggat gatttgatgc tgtccccgga cgatattgaa caatggttca ctgaagaccc 180 aggtccagat gaagctccca gaatgccaga ggctgctccc cgcgtggccc ctgcaccagc 240 agctcctaca ccggcggccc ctgcaccagc cccctcctgg cccctgtcat cttctgtccc 300 ttcccagaaa acctaccagg gcagctacgg tttccgtctg ggcttcttgc attctgggac 360 agccaagtct gtgacttgca cgtactcccc tgccctcaac aagatgtttt gccaactggc 420 caagacctgc cctgtgcagc tgtgggttga ttccacaccc ccgcccggca cccgcgtccg 480 cgccatggcc atctacaagc agtcacagca catgacggag gttgtgaggc gctgccccca 540 ccatgagcgc tgctcagata gcgatggtct ggcccctcct cagcatctta tccgagtgga 600 aggaaatttg cgtgtggagt atttggatga cagaaacact tttcgacata gtgtggtggt 660 gccctatgag ccgcctgagg ttggctctga ctgtaccacc atccactaca actacatgtg 720 taacagttcc tgcatgggcg gcatgaaccg gaggcccatc ctcaccatca tcacactgga 780 agactccagt ggtaatctac tgggacggaa cagctttgag gtgcgtgttt gtgcctgtcc 840 tgggagagac cggcgcacag aggaagagaa tctccgcaag aaaggggagc ctcaccacga 900 gctgccccca gggagcacta agcgagcact gcccaacaac accagctcct ctccccagcc 960 aaagaagaaa ccactggatg gagaatattt cacccttcag atccgtgggc gtgagcgctt 1020 cgagatgttc cgagagctga atgaggcctt ggaactcaag gatgcccagg ctgggaagga 1080 gccagggggg agcagggctc actccagcca cctgaagtcc aaaaagggtc agtctacctc 1140 ccgccataaa aaactcatgt tcaagacaga agggcctgac tcagac 1186 <210> 4 <211> 35 <212> DNA <213> Artificial sequence <220> <223> NdeUB primers <400> 4 ggattccata tgcaactttt cgtcaaaact ctaac 35 <210> 5 <211> 27 <212> DNA <213> Artificial sequence <220> <223> T2UB primers <400> 5 atgaccaccg cggagtctca acaccaa 27 <210> 6 <211> 1460 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding UB-p53 <400> 6 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atgcaaatct tcgtcaaaac tctaacaggg aagactataa ccctagaggt tgaaccatcc 120 gacactattg aaaacgtcaa agctaaaatt caagataaag aaggtatccc tccggatcag 180 cagagattga tttttgctgg taagcaacta gaagatggta gaaccttgtc tgactacaac 240 atccaaaagg aatctactct tcacttggtg ttgagactcc gcggtggtga ggagccgcag 300 tcagatccta gcgtcgagcc ccctctgagt caggaaacat tttcagacct gtggaaacta 360 cttcctgaaa acaacgttct gtcccccttg ccgtcccaag caatggatga tttgatgctg 420 tccccggacg atattgaaca atggttcact gaagacccag gtccagatga agctcccaga 480 atgccagagg ctgctccccg cgtggcccct gcaccagcag ctcctacacc ggcggcccct 540 gcaccagccc cctcctggcc cctgtcatct tctgtccctt cccagaaaac ctaccagggc 600 agctacggtt tccgtctggg cttcttgcat tctgggacag ccaagtctgt gacttgcacg 660 tactcccctg ccctcaacaa gatgttttgc caactggcca agacctgccc tgtgcagctg 720 tgggttgatt ccacaccccc gcccggcacc cgcgtccgcg ccatggccat ctacaagcag 780 tcacagcaca tgacggaggt tgtgaggcgc tgcccccacc atgagcgctg ctcagatagc 840 gatggtctgg cccctcctca gcatcttatc cgagtggaag gaaatttgcg tgtggagtat 900 ttggatgaca gaaacacttt tcgacatagt gtggtggtgc cctatgagcc gcctgaggtt 960 ggctctgact gtaccaccat ccactacaac tacatgtgta acagttcctg catgggcggc 1020 atgaaccgga ggcccatcct caccatcatc acactggaag actccagtgg taatctactg 1080 ggacggaaca gctttgaggt gcgtgtttgt gcctgtcctg ggagagaccg gcgcacagag 1140 gaagagaatc tccgcaagaa aggggagcct caccacgagc tgcccccagg gagcactaag 1200 cgagcactgc ccaacaacac cagctcctct ccccagccaa agaagaaacc actggatgga 1260 gaatatttca cccttcagat ccgtgggcgt gagcgcttcg agatgttccg agagctgaat 1320 gaggccttgg aactcaagga tgcccaggct gggaaggagc caggggggag cagggctcac 1380 tccagccacc tgaagtccaa aaagggtcag tctacctccc gccataaaaa actcatgttc 1440 aagacagaag ggcctgatag 1460 <210> 7 <211> 59 <212> DNA <213> Artificial sequence <220> <223> NdeTOM70 primer <400> 7 gaattccata tgaaaagttt tataactcgg aataaaactg caattttcgc aactgttgc 59 <210> 8 <211> 38 <212> DNA <213> Artificial sequence <220> <223> TOM70-AS primers <400> 8 ggtgcatact actattatca aacttttcgt caaaactc 38 <210> 9 <211> 36 <212> DNA <213> Artificial sequence <220> <223> TOM70UB-S primers <400> 9 ggctacgtatttatttccaa cttttcgtca aaactc 36 <210> 10 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> T2UB-AS primers <400> 10 ggcaccaccg cggagtctca acac 24 <210> 11 <211> 1515 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding TOM70-UB-p53 <400> 11 atgaaaagtt ttataactcg gaataaaact gcaattttcg caactgttgc tgctacggga 60 accgctattg gtgcatacta ctattatcaa atcttcgtca aaactctaac agggaagaact 120 ataaccctag aggttgaacc atccgacact attgaaaacg tcaaagctaa aattcaagat 180 240 ggtagaacct tgtctgacta caacatccaa aaaggaatcta ctcttcactt ggtgttgaga 300 ctccgcggtg gtgaggagcc gcagtcagat cctagcgtcg agccccctct gagtcaggaa 360 aacttttcag acctgtggaa actacttcct gaaaaacg ttctgtcccc cttgccgtcc 420 caagcaatgg atgatttgat gctgtccccg gacgatattg aacaatggtt cactgaagac 480 ccaggtccag atgaagctcc cagaatgcca gaggctgctc cccgcgtggc ccctgcacca 540 gcagctccta caccggcggc ccctgcacca gccccctcct ggcccctgtc atcttctgtc 600 ccttcccaga aaacctacca gggcagctac ggtttccgtc tgggcttctt gcattctggg 660 acagccaagt ctgtgacttg cacgtactcc cctgccctca acaagatgtt ttgccaactg 720 gccaagacct gccctgtgca gctgtgggtt gattccacac ccccgcccgg cacccgcgtc 780 cgcgccatgg ccatctacaa gcagtcacag cacatgacgg aggttgtgag gcgctgcccc 840 caccatgagc gctgctcaga tagcgatgt ctggccccctc ctcagcatct tatccgagtg 900 gaaggaaatt tgcgtgtgga gtatttggat gatagaaca ctttcgaca tagtgtggtg 960 gtgcctag agccgcctga ggttggctct gactgtacca ccatccacta caactacatg 1020 tgtacagtt cctgcatggg cggcatgaac cggaggccca tcccaccat catcacactg 1080 gaagactcca gtgtaatct actgggacgg aacagctttg aggtgcgtgt tgtgctgt 1140 cctgggagag accggcgcac agaggagag aatctccgca agaagggga gcctcaccac 1200 gagctgcccc cagggagcac taagcgagca ctgcccaca acaccagctc ctctccccag 1260 ccaaagaga aaccactgga tggaatat ttcaccctc agatccgtgg gcgtgagcgc 1320 ttcgagatgt tccgagagct gatgaggcc ttggactca aggatgccca ggctgggaag 1380 gagccagggg gagcaggggc tcatchcagc cacctgaagt ccaaaaggg tcagtctacc 1440 tcccgccata aaaaactcat gttcagaca gaagggcctg actcagacct cgagcaccac 1500 caccaccacc actag 1515 <210> 12 <211> 59 <212> DNA <213> Artificial sequence <220> <223> TOM70(G)3-AS primers <400> 12 gcccccggat cctccacccc cgcttccgcc acctccataa tagtagtatg caccaatag 59 <210> 13 <211> 32 <212> DNA <213> Artificial sequence <220> <223> (G)3UB-S primers <400> 13 ggtggaggat ccgggggcgc ggaagccaaaa tc 32 <210> 14 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Xp53(noT) primers <400> 14 aaaaaactcg aggtctgagt caggcccttc tg 32 <210> 15 <211> 1560 <212> DNA <213> Artificial sequence <220> <223> The nucleotide sequence encoding TOM70-(GGGGS)3-UB-p53 <400> 15 atgaaaagtt ttataactcg gaataaaact gcaattttcg caactgttgc tgctacggga 60 accgctattg gtgcatacta ctattatgga ggtggcggaa gcgggggtgg aggatccggg 120 ggcggcggaa gccaaatctt cgtcaaaact ctaacaggga agactataac cctagaggtt 180 gaaccatccg acactattga aaacgtcaaa gctaaaaattc aagataaaga aggtatccct 240 ccggatcagc agagattgat ttttgctggt aagcaactag aagatggtag aaccttgtct 300 gactacaaca tccaaaagga atctactctt cacttggtgt tgagactccg cggtggtgag 360 gagccgcagt cagatcctag cgtcgagccc cctctgagtc aggaaacatt ttcagacctg 420 tggaaactac ttcctgaaaa caacgttctg tcccccttgc cgtcccaagc aatggatgat 480 ttgatgctgt ccccggacga tattgaacaa tggttcactg aagacccagg tccagatgaa 540 gctcccagaa tgccagaggc tgctccccgc gtggcccctg caccagcagc tcctacaccg 600 gcggcccctg caccagcccc ctcctggccc ctgtcatctt ctgtcccttc ccagaaaacc 660 taccagggca gctacggttt ccgtctgggc ttcttgcatt ctgggacagc caagtctgtg 720 acttgcacgt actcccctgc cctcaacaag atgttttgcc aactggccaa gacctgccct 780 gtgcagctgt gggttgattc cacacccccg cccggcaccc gcgtccgcgc catggccatc 840 tacaagcagt cacagcacat gacggaggtt ggaggcgct gcccccacca tgagcgctgc 900 tcagatagcg atggtctggc ccctcctcag catcttatcc gagtggaagg aaatttgcgt 960 gtggagtatt tggatgacag aaacactttt cgacatagtg tggtggtgcc ctatgagccg 1020 cctgaggttg gctctgactg taccaccatc cactacaact acatgtgtaa cagttcctgc 1080 atgggcggca tgaaccggag gcccatcctc accatcatca cactggaaga ctccagtggt 1140 aatctactgg gacggaacag ctttgaggtg cgtgtttgtg cctgtcctgg gagagaccgg 1200 cgcacagagg aagagaatct ccgcaagaaa ggggagcctc accacgagct gcccccaggg 1260 agcactaagc gagcactgcc caacaacacc agctcctctc cccagccaaa gaagaaacca 1320 ctggatggag aatatttcac ccttcagatc cgtgggcgtg agcgcttcga gatgttccga 1380 gagctgaatg aggccttgga actcaaggat gcccaggctg ggaaggagcc aggggggagc 1440 agggctcact ccagccacct gaagtccaaa aagggtcagt ctacctcccg ccataaaaaa 1500 ctcatgttca agacagaagg gcctgactca gacctcgagc accaccacca ccaccactag 1560 1560 <210> 16 <211> 51 <212> DNA <213> Artificial sequence <220> <223> B(G)3p53 <400> 16 ggtggaggat ccgggggcgg cggaagcgag gagccgcagt cagatcctag c 51 <210> 17 <211> 1335 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding TOM70-(GGGGS)3-p53 <400> 17 atgaaaagtt ttataactcg gaataaaact gcaattttcg caactgttgc tgctacggga 60 accgctattg gtgcatacta ctattatgga ggtggcggaa gcgggggtgg aggatccggg 120 ggcggcggaa gcgaggagcc gcagtcagat cctagcgtcg agccccctct gagtcaggaa 180 acattttcag acctgtggaa actacttcct gaaaacaacg ttctgtcccc cttgccgtcc 240 caagcaatgg atgatttgat gctgtccccg gacgatattg aacaatggtt cactgaagac 300 ccaggtccag atgaagctcc cagaatgcca gaggctgctc cccgcgtggc ccctgcacca 360 gcagctccta caccggcggc ccctgcacca gccccctcct ggcccctgtc atcttctgtc 420 ccttcccaga aaacctacca gggcagctac ggtttccgtc tgggcttctt gcattctggg 480 acagccaagt ctgtgacttg cacgtactcc cctgccctca acaagatgtt ttgccaactg 540 gccaagacct gccctgtgca gctgtgggtt gattccacac ccccgcccgg cacccgcgtc 600 cgcgccatgg ccatctacaa gcagtcacag cacatgacgg aggttgtgag gcgctgcccc 660 caccatgagc gctgctcaga tagcgatggt ctggcccctc ctcagcatct tatccgagtg 720 gaaggaaatt tgcgtgtgga gtatttggat gacagaaaca cttttcgaca tagtgtggtg 780 gtgccctatg agccgcctga ggttggctct gactgtacca ccatccacta caactacatg 840 tgtaacagtt cctgcatggg cggcatgaac cggaggccca tcctcaccat catcacactg 900 gaagactcca gtggtaatct actgggacgg aacagctttg aggtgcgtgt ttgtgcctgt 960 cctgggagag accggcgcac agaggaagag aatctccgca agaaagggga gcctcaccac 1020 gagctgcccc cagggagcac taagcgagca ctgcccaaca acaccagctc ctctccccag 1080 ccaaagaaga aaccactgga tggagaatat ttcacccttc agatccgtgg gcgtgagcgc ttcgagatgt tccgagagct gaatgaggcc ttggaactca aggatgccca ggctgggaag 1260. gagccagggg ggagcagggc tcactccagc cacctgaagt ccaaaaaggg tcagtctacc tcccgccata aaaaactcat gttcaagaca gaagggcctg actcagacct cgagcaccac caccaccacc actag <210> 18 <211> 32 <212> DNA <213> The snowstorm <220> <223> Xp53(noT) indicator <400> 18 aaaaaactcg aggtctgagt caggcccttc tg <210> 19 <211> 36 <212> DNA <213> The snowstorm <220> <223> XTOM7 Building <400> 19 aaaaaactcg agtttgccat tcgctggggc tttatc <210> 20 <211> 38 <212> DNA <213> The snowstorm <220> <223> LTOM7 HOUSE <400> 20 38. aaaaaagtcg acttatcccc aaagtaggct caaaacag <210> 21 <211> 1578 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding UB-p53-TOM7 <400> 21 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atgcaaatct tcgtcaaaac tctaacaggg aagactataa ccctagaggt tgaaccatcc 120 gacactattg aaaacgtcaa agctaaaatt caagataaag aaggtatccc tccggatcag 180 cagagattga tttttgctgg taagcaacta gaagatggta gaaccttgtc tgactacaac 240 atccaaaagg aatctactct tcacttggtg ttgagactcc gcggtggtga ggagccgcag 300 tcagatccta gcgtcgagcc ccctctgagt caggaaacat tttcagacct atggaaacta 360 cttcctgaaa acaacgttct gtcccccttg ccgtcccaag caatggatga tttgatgctg 420 tccccggacg atattgaaca atggttcact gaagacccag gtccagatga agctcccaga 480 atgccagagg ctgctccccg cgtggcccct gcaccagcag ctcctacacc ggcggcccct 540 gcaccagccc cctcctggcc cctgtcatct tctgtccctt cccagaaaac ctaccagggc 600 agctacggtt tccgtctggg cttcttgcat tctgggacag ccaagtctgt gacttgcacg 660 tactcccctg ccctcaacaa gatgttttgc caactggcca agacctgccc tgtgcagctg 720 tgggttgatt ccacaccccc gcccggcacc cgcgtccgcg ccatggccat ctacaagcag 780 tcacagcaca tgacggaggt tgtgaggcgc tgcccccacc atgagcgctg ctcagatagc 840 gatggtctgg cccctcctca gcatcttatc cgagtggaag gaaatttgcg tgtggagtat 900 ttggatgaca gaaacacttt tcgacatagt gtggtggtgc cctatgagcc gcctgaggtt 960 ggctctgact gtaccaccat ccactacaac tacatgtgta acagttcctg catgggcggc 1020 atgaaccgga ggcccatcct caccatcatc acactggaag actccagtgg taatctactg 1080 ggacggaaca gctttgaggt gcatgtttgt gcctgtcctg ggagagaccg gcgcacagag 1140 gaagagaatc tccgcaagaa aggggagcct caccacgagc tgcccccagg gagcactaag 1200 cgagcactgt ccaacaacac cagctcctct ccccagccaa agaagaaacc actggatgga 1260 gaatatttca cccttcagat ccgtgggcgt gagcgcttcg agatgttccg agagctgaat 1320 gaggccttgg aactcaagga tgcccaggct gggaaggagc caggggggag cagggctcac 1380 tccagccacc tgaagtccaa aaagggtcag tctacctccc gccataaaaa actcatgttc 1440 aagacagaag ggcctgactc agacctcgag tttgccattc gctggggctt tatccctctt 1500 gtgatttacc tgggatttaa gaggggtgca gatcccggaa tgcctgaacc aactgttttg 1560 agcctacttt ggggatag 1578 <210> 22 <211> 35 <212> DNA <213]] Artificial sequence <220> <223> Rp53 primer <400> 22 aaaaaagaat tcatggtctg agtcaggccc ttctg 35 <210> 23 <211> 1266 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding p53-myc / His <400> 23 atggaggagc cgcagtcaga tcctagcgtc gagccccctc tgagtcagga aacattttca 60 gacctgtgga aactacttcc tgaaaacaac gttctgtccc ccttgccgtc ccaagcaatg 120 gatgatttga tgctgtcccc ggacgatatt gaacaatggt tcactgaaga cccaggtcca 180 gatgaagctc ccagaatgcc agaggctgct ccccgcgtgg cccctgcacc agcagctcct 240 acaccggcgg cccctgcacc agccccctcc tggcccctgt catcttctgt cccttcccag 300 aaaacctacc agggcagcta cggtttccgt ctgggcttct tgcattctgg gacagccaag 360 tctgtgactt gcacgtactc ccctgccctc aacaagatgt tttgccaact ggccaagacc 420 tgccctgtgc agctgtgggt tgattccaca cccccgcccg gcacccgcgt ccgcgccatg 480 gccatctaca agcagtcaca gcacatgacg gaggttgtga ggcgctgccc ccaccatgag 540 cgctgctcag atagcgatgg tctggcccct cctcagcatc ttatccgagt ggaaggaaat 600 ttgcgtgtgg agtatttgga tgacagaaac acttttcgac atagtgtggt ggtgccctat 660 gagccgcctg aggttggctc tgactgtacc accatccact acaactacat gtgtaacagt 720 tcctgcatgg gcggcatgaa ccggaggccc atcctcacca tcatcacact ggaagactcc 780 agtggtaatc tactgggacg gaacagcttt gaggtgcgtg tttgtgcctg tcctgggaga 840 gaccggcgca cagaggaaga gaatctccgc aagaaagggg agcctcacca cgagctgccc 900 ccagggagca ctaagcgagc actgcccaac aacaccagct cctctcccca gccaaagaag 960 aaaccactgg atggagaata tttcaccctt cagatccgtg ggcgtgagcg cttcgagatg 1020 ttccgagagc tgaatgaggc cttggaactc aaggatgccc aggctgggaa ggagccaggg 1080 gggagcaggg ctcactccag ccacctgaag tccaaaaagg gtcagtctac ctcccgccat 1140 aaaaaactca tgttcaagac agaagggcct gactcagacc tcgagtctag agggcccttc 1200 gaacaaaaac tcatctcaga agaggatctg aatatgcata ccggtcatca tcaccatcac 1260 cattga 1266 <210> 24 <211> 51 <212> DNA <213> Artificial sequence <220> <223> T2GZMB primer <400> 24 aaaaaaccgc ggtggtatca tcgggggaca tgaggcacat gaggccaagc c 51 <210> 25 <211> 38 <212> DNA <213> Artificial sequence <220> <223> XGZMB(noT) primer <400> 25 aaaaaactcg aggtagcgtt tcatggtttt ctttatcc 38 <210> 26 <211> 691 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding granzyme B <400> 26 ccgcggtggt atcatcgggg gacatgaggc caagccccac tcccgcccct acatggctta 60 tcttatgatc tgggatcaga agtctctgaa gaggtgcggt ggcttcctga tacaagacga 120 cttcgtgctg acagctgctc actgttgggg aagctccata aatgtcacct tgggggccca 180 caatatcaaa gaacaggagc cgacccagca gtttatccct gtgaaaagac ccatccccca 240 tccagcctat aatcctaaga acttctccaa cgacatcatg ctactgcagc tggagagaaa 300 ggccaagcgg accagagctg tgcagcccct caggctacct agcaacaagg cccaggtgaa 360 gccagggcag acatgcagtg tggccggctg ggggcagacg gcccccctgg gaaaacactc 420 acacacacta caagaggtga agatgacagt gcaggaagat cgaaagtgcg aatctgactt 480 acgccattat tacgacagta ccattgagtt gtgcgtgggg gacccagaga ttaaaaagac 540 ttcctttaag ggggactctg gaggccctct tgtgtgtaac aaggtggccc agggcattgt 600 ctcctatgga cgaaacaatg gcatgcctcc acgagcctgc accaaagtct caagctttgt 660 acactggata aagaaaacca tgaaacgcta c 691 <210> 27 <211> 1065 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding TOM70-(GGGGS)3-UB-Granzyme B <400> 27 atgaaaagtt ttataactcg gaataaaact gcaattttcg caactgttgc tgctacggga 60 accgctattg gtgcatacta ctattatgga ggtggcggaa gcgggggtgg aggatccggg 120 ggcggcggaa gccaaatctt cgtcaaaact ctaacaggga agactataac cctagaggtt 180 gaaccatccg acactattga aaacgtcaaa gctaaaattc aagataaaga aggtatccct 240 ccggatcagc agagattgat ttttgctggt aagcaactag aagatggtag aaccttgtct 300 gactacaaca tccaaaagga atctactctt cacttggtgt tgagactccg cggtggtatc 360 atcgggggac atgaggccaa gccccactcc cgcccctaca tggcttatct tatgatctgg 420 gatcagaagt ctctgaagag gtgcggtggc ttcctgatac gagacgactt cgtgctgaca 480 gctgctcact gttggggaag ctccataaat gtcaccttgg gggcccacaa tatcaaagaa 540 caggagccga cccagcagtt tatccctgtg aaaagaccca tcccccatcc agcctataat 600 cctaagaact tctccaacga catcatgcta ctgcagctgg agagaaaggc caagcggacc 660 agagctgtgc agcccctcag gctacctagc aacaaggccc aggtgaagcc agggcagaca 720 tgcagtgtgg ccggctgggg gcagacggcc cccctgggaa aacactcaca cacactacaa 780 gaggtgaaga tgacagtgca ggaagatcga aagtgcgaat ctgacttacg ccattattac 840 gacagtacca ttgagttgtg cgtgggggac ccagagatta aaaagacttc ctttaagggg 900 gactctggag gccctcttgt gtgtaacaag gtggcccagg gcattgtctc ctatggacga 960 aacaatggca tgcctccacg agcctgcacc aaagtctcaa gctttgtaca ctggataaag 1020 aaaaccatga aacgctacct cgagcaccac caccaccacc actag 1065 <210> 28 <211> 1083 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding UB-Granzyme B-TOM7 <400> 28 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atgcaaatct tcgtcaaaac tctaacaggg aagactataa ccctagaggt tgaaccatcc 120 gacactattg aaaacgtcaa agctaaaatt caagataaag aaggtatccc tccggatcag 180 cagagattga tttttgctgg taagcaacta gaagatggta gaaccttgtc tgactacaac 240 atccaaaagg aatctactct tcacttggtg ttgagactcc gcggtggtat catcggggga 300 catgaggcca agccccactc ccgcccctac atggcttatc ttatgatctg ggatcagaag 360 tctctgaaga ggtgcggtgg cttcctgata cgagacgact tcgtgctgac agctgctcac 420 tgttggggaa gctccataaa tgtcaccttg ggggcccaca atatcaaaga acaggagccg 480 acccagcagt ttatccctgt gaaaagaccc atcccccatc cagcctataa tcctaagaac 540 ttctccaacg acatcatgct actgcagctg gagagaaagg ccaagcggac cagagctgtg 600 cagcccctca ggctacctag caacaaggcc caggtgaagc cagggcagac atgcagtgtg 660 gccggctggg ggcagacggc ccccctggga aaacactcac acacactaca agaggtgaag 720 atgacagtgc aggaagatcg aaagtgcgaa tctgacttac gccattatta cgacagtacc 780 attgagttgt gcgtggggga cccagagatt aaaaagactt cctttaaggg ggactctgga 840 ggccctcttg tgtgtaacaa ggtggcccag ggcattgtct cctatggacg aaacaatggc 900 atgcctccac gagcctgcac caaagtctca agctttgtac actggataaa gaaaaccatg 960 aaacgctacc tcgagtttgc cattcgctgg ggctttatcc ctcttgtgat ttacctggga 1020 tttaagaggg gtgcagatcc cggaatgcct gaaccaactg ttttgagcct actttgggga 1080 tag 1083 <210> 29 <211> 39 <212> DNA <213> Artificial sequence <220> <223> T2RKIP primer <400> 29 aaaaaaccgc ggtggtccgg tggacctcag caagtggtc 39 <210> 30 <211> 41 <212> DNA <213> Artificial sequence <220> <223> XRKIP(noT) primer <400> 30 aaaaaactcg agcttcccag acagctgctc gtacagtttg g 41 <210> 31 <211> 568 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding RKIP <400> 31 ccgcggtggt ccggtggacc tcagcaagtg gtccgggccc ttgagcctgc aagaagtgga 60 cgagcagccg cagcacccac tgcatgtcac ctacgccggg gcggcggtgg acgagctggg 120 caaagtgctg acgcccaccc aggttaagaa tagacccacc agcatttcgt gggatggtct 180 tgattcaggg aagctctaca ccttggtcct gacagacccg gatgctccca gcaggaagga 240 tcccaaatac agagaatggc atcatttcct ggtggtcaac atgaagggca atgacatcag 300 cagtggcaca gtcctctccg attatgtggg ctcggggcct cccaagggca caggcctcca 360 ccgctatgtc tggctggttt acgagcagga caggccgcta aagtgtgacg agcccatcct 420 cagcaaccga tctggagacc accgtggcaa attcaaggtg gcgtccttcc gtaaaaagta 480 tgagctcagg gccccggtgg ctggcacgtg ttaccaggcc gagtgggatg actatgtgcc 540 caaactgtac gagcagctgt ctgggaag 568 <210> 32 <211> 942 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding TOM70-(GGGGS)3-UB-RKIP <400> 32 atgaaaagtt ttataactcg gaataaaact gcaattttcg caactgttgc tgctacggga 60 accgctattg gtgcatacta ctattatgga ggtggcggaa gcgggggtgg aggatccggg 120 ggcggcggaa gccaaatctt cgtcaaaact ctaacaggga agactataac cctagaggtt 180 gaaccatccg acactattga aaacgtcaaa gctaaaattc aagataaaga aggtatccct 240 ccggatcagc agagattgat ttttgctggt aagcaactag aagatggtag aaccttgtct 300 gactacaaca tccaaaagga atctactctt cacttggtgt tgagactccg cggtggtccg 360 gtggacctca gcaagtggtc cgggcccttg agcctgcaag aagtggacga gcagccgcag 420 cacccactgc atgtcaccta cgccggggcg gcggtggacg agctgggcaa agtgctgacg 480 cccacccagg ttaagaatag acccaccagc atttcgtggg atggtcttga ttcagggaag 540 ctctacacct tggtcctgac agacccggat gctcccagca ggaaggatcc caaatacaga 600 gaatggcatc atttcctggt ggtcaacatg aagggcaatg acatcagcag tggcacagtc 660 ctctccgatt atgtgggctc ggggcctccc aagggcacag gcctccaccg ctatgtctgg 720 ctggtttacg agcaggacag gccgctaaag tgtgacgagc ccatcctcag caaccgatct 780 ggagaccacc gtggcaaatt caaggtggcg tccttccgta aaaagtatga gctcagggcc 840 ccggtggctg gcacgtgtta ccaggccgag tgggatgact atgtgcccaa actgtacgag 900 cagctgtctg ggaagctcga gcaccacccac caccacccact ag 942 <210> 33 <211> 42 <212> DNA <213> Artificial sequence <220> <223> T2PTEN primers <400> 33 aaaaaaccgc ggtggtacag ccatcatcaa agagatcgtt ag 42 <210> 34 <211> 36 <212> DNA <213> Artificial sequence <220> <223> XPTEN(noT) primers <400> 34 aaaaaactcg aggacttttg taatttgtgt atgctg 36 <210> 35 <211> 1216 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding PTEN <400> 35 ccgcggtggt acagccatca tcaaagagat cgttagcaga aacaaaagga gatatcaaga 60 ggatggattc gacttagact tgacctatat ttatccaaac attattgcta tgggatttcc 120 tgcagaaaga cttgaaggcg tatacaggaa caatattgat gatgtagtaa ggtttttgga 180 ttcaaagcat aaaaaccatt acaagatata caatctttgt gctgaaagac attatgacac 240 cgccaaattt aattgcagag ttgcacaata tccttttgaa gaccataacc caccacagct 300 agaacttatc aaaccctttt gtgaagatct tgaccaatgg ctaagtgaag atgacaatca 360 tgttgcagca attcactgta aagctggaaa gggacgaact ggtgtaatga tatgtgcata 420 tttattacat cggggcaaat ttttaaaggc acaagaggcc ctagatttct atggggaagt 480 aaggaccaga gacaaaaagg gagtaactat tcccagtcag aggcgctatg tgtattatta 540 tagctacctg ttaaagaatc atctggatta tagaccagtg gcactgttgt ttcacaagat 600 gatgtttgaa actattccaa tgttcagtgg cggaacttgc aatcctcagt ttgtggtctg 660 ccagctaaag gtgaagatat attcctccaa ttcaggaccc acacgacggg aagacaagtt 720 catgtacttt gagttccctc agccgttacc tgtgtgtggt gatatcaaag tagagttctt 780 ccacaaacag aacaagatgc taaaaaagga caaaatgttt cacttttggg taaatacatt 840 cttcatacca ggaccagagg aaacctcaga aaaagtagaa aatggaagtc tatgtgatca 900 agaaatcgat agcatttgca gtatagagcg tgcagataat gacaaggaat atctagtact 960 tactttaaca aaaaatgatc ttgacaaagc aaataaagac aaagccaacc gatacttttc 1020 tccaaatttt aaggtgaagc tgtacttcac aaaaacagta gaggagccgt caaatccaga 1080 ggctagcagt tcaacttctg taacaccaga tgttagtgac aatgaacctg atcattatag 1140 atattctgac accactgact ctgatccaga gaatgaacct tttgatgaag atcagcatac 1200 acaaattaca aaagtc 1216 <210> 36 <211> 1590 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding TOM70-(GGGGS)3-UB-PTEN <400> 36 atgaaaagtt ttataactcg gaataaaact gcaattttcg caactgttgc tgctacggga 60 accgctattg gtgcatacta ctattatgga ggtggcggaa gcgggggtgg aggatccggg 120 ggcggcggaa gccaaatctt cgtcaaaact ctaacaggga agactataac cctagaggtt 180 gaaccatccg acactattga aaacgtcaaa gctaaaaattc aagataaaga aggtatccct 240 ccggatcagc agagattgat ttttgctggt aagcaactag aagatggtag aaccttgtct 300 gactacaaca tccaaaagga atctactctt cacttggtgt tgagactccg cggtggtaca 360 gccatcatca aagagatcgt tagcagaaac aaaaggagat atcaagagga tggattcgac 420 ttagacttga cctatatta tccaaacatt attgctatgg gatttcctgc agaaagactt 480 gaaggcgtat acaggaacaa tattgatgat gtagtaaggt ttttggattc aaagcataaa 540 aaccattaca agatatacaa tctttgtgct gaaagacatt atgacaccgc caaatttaat 600 tgcagagttg cacaatatcc ttttgaagac cataacccac cacagctaga acttatcaaa 660 cccttttgtg aagatcttga ccaatggcta agtgaagatg acaatcatgt tgcagcaatt 720 cactgtaaag ctggaaaggg acgaactggt gtaatgatat gtgcatattt attacatcgg 780 ggcaattttt taaaggcaca agaggcccta gatttctatg gggaagtaag gaccagagac 840 aaaaagggag taactattcc cagtcagagg cgctatgtgt attattag ctacctgtta 900 aagaatcatc tggattag accagtggca ctgttgttc acaagatgat gtttgaact 960 attccaatgt tcagtggcgg aacttgcaat cctcagttg tggtctgcca gctaaaggtg 1020 aagatatatt cctccaattc aggaccacca cgacgggaag acagttcat gtactttgag 1080 ttccctcagc cgttacctgt gtgtggtgat atcaagtag agttctcca caacagaac 1140 aagatgctaa aaaaggacaa atgttcac tttgggtaa atacattctt cataccagga 1200 ccagaggaaa cctcagaaaa agtagaaaat ggaagtctat gtgatcaaga atcgatagc 1260 atttgcagta tagagcgtgc agataatgac aaggaatatc tagtacttac tttaacaaaa 1320 aatgatcttg aaagcaaaaagacaaa gccaaccgat acttttctcc aaatttttaag 1380 gtgaagctgt acttcacaa aacagtagag gagccgtcaa atccagaggc tagcagttca 1440 acttctgtaa caccagatgt tagtgacaat gaacctgatc attatagata ttctgacacc 1500 actgactctg atccagagaa tgaacctttt gatgaagatc agcatacaca aattacaaaa 1560 gtcctcgagc accaccacca ccaccactag 1590 <210> 37 <211> 739 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvHER2 <400> 37 ccgcggtggt gaagtgcaac ttgttgagag tggcggagga ctggtccaac cgggcggttc 60 acttaggctc tcatgtgcag cttcagggtt cacgttcacg gactatacaa tggactgggt 120 gaggcaagcc cctggtaagg gactggagtg ggttgctgac gttaacccta attccggtgg 180 gtccatctac aaccagcgat tcaagggacg atttactctt tcagtcgaca gaagcaaaaa 240 caccctctac ctccagatga actccttgcg ggcagaggat acagcggtct actattgcgc 300 gagaaacttg ggaccaagct tctacttcga ctactggggg caaggaacgc ttgttacggt 360 ttcaagcgga ggtggaggaa gtggaggtgg cggttccggc ggtggcggtt cagatataca 420 gatgacccaa tcacccagtt ctcttagcgc gtctgtaggc gacagggtaa ccataacctg 480 caaggcgtcc caggacgtgt caattggagt tgcctggtat cagcaaaaac ctgggaaagc 540 tccgaagctc ctgatttaca gcgcatctta ccgatatact ggtgtccctt caaggttcag 600 tggcagtgga tctgggacag actttacgct tactatcagc agtctgcaac ctgaggattt 660 cgcgacctac tactgtcagc agtattacat ctatccgtac acgttcggtc aaggtacaaa 720 ggtagaaata aaacgcact 739 <210> 38 <211> 1125 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding UB-scFvHER2-TOM7 <400> 38 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 atgcaaatct tcgtcaaaac tctaacaggg aagactataa ccctagaggt tgaaccatcc 120 gacactattg aaaacgtcaa agctaaaatt caagataaag aaggtatccc tccggatcag 180 cagagattga tttttgctgg taagcaacta gaagatggta gaaccttgtc tgactacaac 240 atccaaaagg aatctactct tcacttggtg ttgagactcc gcggtggtga agtgcaactt 300 gttgagagtg gcggaggact ggtccaaccg ggcggttcac ttaggctctc atgtgcagct 360 tcagggttca cgttcacgga ctatacaatg gactgggtga ggcaagcccc tggtaaggga 420 ctggagtggg ttgctgacgt taaccctaat tccggtgggt ccatctacaa ccagcgattc 480 aagggacgat ttactctttc agtcgacaga agcaaaaaca ccctctacct ccagatgaac 540 tccttgcggg cagaggatac agcggtctac tattgcgcga gaaacttggg accaagcttc 600 tacttcgact actgggggca aggaacgctt gttacggttt caagcggagg tggaggaagt 660 ggaggtggcg gttccggcgg tggcggttca gatatacaga tgacccaatc acccagttct 720 cttagcgcgt ctgtaggcga cagggtaacc ataacctgca aggcgtccca ggacgtgtca 780 attggagttg cctggtatca gcaaaaacct gggaaagctc cgaagctcct gatttacagc 840 gcatcttacc gatatactgg tgtcccttca aggttcagtg gcagtggatc tgggacagac 900 tttacgctta ctatcagcag tctgcaacct gaggatttcg cgacctacta ctgtcagcag 960 tattacatct atccgtacac gttcggtcaa ggtacaaagg tagaaataaa acgcactttt 1020 gccattcgct ggggctttat ccctcttgtg atttacctgg gatttaagag gggtgcagat 1080 cccggaatgc ctgaaccaac tgttttgagc ctactttggg gatag 1125 <210> 39 <211> 38 <212> DNA <213> Artificial sequence <220> <223> RscFvHER2 primers <400> 39 aaaaaagaat tcatggaagt gcaacttgtt gagagtgg 38 <210> 40 <211> 35 <212> DNA <213> Artificial sequence <220> <223> XTOM7(noT) primers <400> 40 aaaaaactcg agtccccaaa gtaggctcaa aacag 35 <210> 41 <211> 924 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvHER2-TOM7-myc / His <400> 41 atggaagtgc aacttgttga gagtggcgga ggactggtcc aaccgggcgg ttcacttagg 60 ctctcatgtg cagcttcagg gttcacgttc acggactata caatggactg ggtgaggcaa 120 gcccctggta agggactgga gtgggttgct gacgttaacc ctaattccgg tgggtccatc 180 240. snowflake gattcaaggg ctttcagtcg snowflake aaacaccctc 300. tacctccaga tgaactcctt gcgggcagag gatacagcgg tctactattg cgcgagaaac ttgggaccaa gcttctactt cgactactgg gggcaagga cgcttgttac ggtttcaagc ggaggtggag gaagtggagg tggcggttcc ggcggtggcg gttcagatat acagatgacc 420 480. caatcaccca gttctcttag cgcgtctgta ggcgacaggg taaccataac ctgcaaggcg tcccaggacg tgtcaattgg agttgcctgg tatcagcaaa aacctgggaa agctccgaag 540 ctcctgattt acagcgcatc ttaccgatat actggtgtcc cttcaaggtt cagtggcagt 600 ggatctggga cagactttac gcttactatc agcagtctgc aacctgagga tttcgcgacc tactactgtc agcagtatta catctatccg tacacgttcg gtcaaggtac aaaggtagaa ataaaacgca cttttgccat tcgctggggc tttatccctc ttgtgattta cctgggattt 780. aagaggggtg cagatcccgg aatgcctgaa ccaactgttt tgagcctact ttggggactc 840. 900. 900. 900. 900. 900. 900. 900. 900. 900. 900. 900 ggtcatcatc accatcacca ttga 924 <210> 42 <211> 760 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvMEL <400> 42 ccgcggtggt acggacattg tgatgaccca gtctcaaaaa ttcatgtcca catcagtagg 60 agacagggtc agcgtcacct gcaaggccag tcagaatgtg gatactaatg tagcctggta 120 tcaacaaaaa ccagggcaat ctcctgaacc actgcttttc tcggcatcct accgttacac 180 tggagtccct gatcgcttca caggcagtgg atctgggaca gatttcactc tcaccatcag 240 caatgtgcag tctgaagact tggcagagta tttctgtcag caatataaca gctatcctct 300 gacgttcggt ggaggcacca agctggagat caaaggctcc accagcggca gcggtaagcc 360 aggctccggc gaaggcagca ccaaaggcga agtgaaggtt gaggagtctg gaggaggctt 420 ggtgcaacct ggaggatcca tgaaactctc ctgtgttgtc tctggattca ctttcggtaa 480 ttactggatg aactgggtcc gccagtctcc agagaagggg cttgagtgga ttgcagaaat 540 tagattgaaa tccaataatt ttgcaagata ttatgcggag tctgtgaaag ggaggttcac catctcaaga gatgattcca aaagtagtgt ctacctgcaa atgatcaacc tagagctga agatactggc atttattact gtaccagtta tggtaactac gttgggcact attttgacca 720 ctggggccaa ggcaccactc tcaccgtctc cctttgggga 760 <210> 43 <211> 1137 <212> DNA <213> The snowstorm <220> <223> The UB-scFvMEL-TOM7 system is active <400> 43 atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atgcaaatct tcgtcaaaac tctaacaggg aagactaa ccctagaggt tgaaccatcc gacactattg aaaacgtcaa agctaaaatt caagataag aaggtatccc tccggatcag cagagattga tttttgctgg tagcaacta cagagatggta gaaccttgtc tgactacaac atccaaaagg aatctactct tcacttggtg ttgagactcc gcggtggtac ggacattgtg atgacccagt ctcaaaaatt catgtccaca tcagtaggag acagggtcag cgtcacctgc aaggccagtc agaatgtgga tactaatgta gcctggtatc aacaaaaacc agggcaatct 420 cctgaaccac tgcttttctc ggcatcctac cgttacactg gagtccctga tcgcttcaca 480 ggcagtggat ctgggacaga tttcactctc accatcagca atgtgcagtc tgaagacttg 540 gcagagtatt tctgtcagca atataacagc tatcctctga cgttcggtgg aggcaccaag 600 ctggagatca aaggctccac cagcggcagc ggtaagccag gctccggcga aggcagcacc 660 aaaggcgaag tgaaggttga ggagtctgga ggaggcttgg tgcaacctgg aggatccatg 720 aaactctcct gtgttgtctc tggattcact ttcggtaatt actggatgaa ctgggtccgc 780 cagtctccag agaaggggct tgagtggatt gcagaaatta gattgaaatc caataatttt 840 gcaagatatt atgcggagtc tgtgaaaggg aggttcacca tctcaagaga tgattccaaa 900 agtagtgtct acctgcaaat gatcaaccta agagctgaag atactggcat ttattactgt 960 accagttatg gtaactacgt tgggcactat tttgaccact ggggccaagg caccactctc 1020 accgtctcct catttgccat tcgctggggc tttatccctc ttgtgattta cctgggattt 1080 aagaggggtg cagatcccgg aatgcctgaa ccaactgttt tgagcctact ttgggga 1137 <210> 44 <211> 36 <212> DNA <213> Artificial sequence <220> <223> RscFvMEL primers <400> 44 aaaaaagaat tcatgaaaac aagtaaccca ggagtg 36 <210> 45 <211> 939 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvMEL-TOM7-myc / His <400> 45 atgacggaca ttgtgatgac ccagtctcaa aaattcatgt ccacatcagt aggagacagg 60 gtcagcgtca cctgcaaggc cagtcagaat gtggatacta atgtagcctg gtatcaacaa 120 aaaccagggc aatctcctga accactgctt ttctcggcat cctaccgtta cactggagtc 180 cctgatcgct tcacaggcag tggatctggg acagatttca ctctcaccat cagcaatgtg 240 cagtctgaag acttggcaga gtatttctgt cagcaatata acagctatcc tctgacgttc 300 ggtggaggca ccaagctgga gatcaaaggc tccaccagcg gcagcggtaa gccaggctcc 360 ggcgaaggca gcaccaaagg cgaagtgaag gttgaggagt ctggaggagg cttggtgcaa 420 cctggaggat ccatgaaact ctcctgtgtt gtctctggat tcactttcgg taattactgg 480 atgaactggg tccgccagtc tccagagaag gggcttgagt ggattgcaga aattagattg 540 aaatccaata attttgcaag atattatgcg gagtctgtga aagggaggtt caccatctca 600 agagatgatt ccaaaagtag tgtctacctg caaatgatca acctaagagc tgaagatact 660 ggcatttatt actgtaccag ttatggtaac tacgttgggc actattttga ccactggggc 720 caaggcacca ctctcaccgt ctcctcattt gccattcgct ggggctttat ccctcttgtg 780 atttacctgg gatttaagag gggtgcagat cccggaatgc ctgaaccaac tgttttgagc 840 ctactttggg gactcgagtc tagagggccc ttcgaacaaa aactcatctc agaagaggat 900 ctgaatatgc ataccggtca tcatcaccat caccattga 939 <210> 46 <211> 750 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvPD-L1 <400> 46 atggacatcg tgatgagcca gtctcccagc agcctggctg tgtctgctgg ggagaaggtg 60 accatgtcct gcaagagctc ccagtccctg ctgaacagcc gcaccaggaa gaactacctg 120 gcctggtacc agcagaagcc aggccagagc cccaagctcc tcatctactg ggccagcacc 180 cgggagagcg gggtgcctga ccgcttcact ggaagtggca gcggcacaga cttcaccctg 240 accatcagct ctgtgcaggc cgaggacctg gcagtgtact actgccagca aagctatgat 300 gtggtgacat ttggagctgg caccaagctg gagctgaagg gaggtggcgg aagcgggggt 360 ggaggatccg ggggcggcgg aagccaggtc caggtgcagc agagcggggc tgagctggcc 420 gagcccgggg cctctgtgaa gatgagctgc aaggcttctg gctacatctt caccagctac 480 tggatgcact ggctcaagca gaggcctggg caggggctgg agtggatcgg ctatatcaac 540 cccagcagtg actacaatga atattctgag aagttcatgg acaaagccac cctgactgct 600 gacaaggcca gcaccaccgc ctacatgcag ctgatcagcc tgacctcaga ggacagcgct 660 gtgtactact gtgcccggag cggctggctg gtgcacgggg actattattt tgattattgg 720 ggccagggca ccacactgac agtgagcagc 750 <210> 47 <211> 948 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvPD-L1-TOM7-myc / His <400> 47 atggacatcg tgatgagcca gtctcccagc agcctggctg tgtctgctgg ggagaaggtg 60 accatgtcct gcaagagctc ccagtccctg ctgaacagcc gcaccaggaa gaactacctg 120 gcctggtacc agcagaagcc aggccagagc cccaagctcc tcatctactg ggccagcacc 180 cgggagagcg gggtgcctga ccgcttcact ggaagtggca gcggcacaga cttcaccctg 240 accatcagct ctgtgcaggc cgaggacctg gcagtgtact actgccagca aagctatgat 300 gtggtgacat ttggagctgg caccaagctg gagctgaagg gaggtggcgg aagcgggggt 360 ggaggatccg ggggcggcgg aagccaggtc caggtgcagc agagcggggc tgagctggcc 420 gagcccgggg cctctgtgaa gatgagctgc aaggcttctg gctacatctt caccagctac 480 tggatgcact ggctcaagca gaggcctggg caggggctgg agtggatcgg ctatatcaac 540 cccagcagtg actacaatga atattctgag aagttcatgg acaaagccac cctgactgct 600 gacaaggcca gcaccaccgc ctacatgcag ctgatcagcc tgacctcaga ggacagcgct 660 gtgtactact gtgcccggag cggctggctg gtgcacgggg actattattt tgattattgg 720 ggccagggca ccacactgac agtgagcagc ctcgagtttg ccattcgctg gggctttatc 780 cctcttgtga tttacctggg atttaagagg ggtgcagatc ccggaatgcc tgaaccaact 840 gttttgagcc tactttgggg actcgagtct agagggccct tcgaacaaaa actcatctca 900 gaagaggatc tgaatatgca taccggtcat catcaccatc accattga 948 <210> 48 <211> 395 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of p53 <400> 48 Arg Gly Gly Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu 1 5 10 15 Ser Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn 20 25 30 Val Leu Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser 35 40 45 Pro Asp Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu 50 55 60 Ala Pro Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala 65 70 75 80 Ala Pro Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser 85 90 95 Ser Ser Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg 100 105 110 Leu Gly Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr 115 120 125 Ser Pro Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro 130 135 140 Val Gln Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg 145 150 155 160 Ala Met Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg 165 170 175 Arg Cys Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro 180 185 190 Pro Gln His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu 195 200 205 Asp Asp Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro 210 215 220 Pro Glu Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys 225 230 235 240 Asn Ser Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile 245 250 255 Ile Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe 260 265 270 Glu Val Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu 275 280 285 Glu Asn Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly 290 295 300 Ser Thr Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro 305 310 315 320 Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly 325 330 335 Arg Glu Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu 340 345 350 Lys Asp Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser 355 360 365 Ser His Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys 370 375 380 Leu Met Phe Lys Thr Glu Gly Pro Asp Ser Asp 385 390 395 <210> 49 <211> 488 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of UB-p53 <400> 49 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr 20 25 30 Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala 35 40 45 Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile 50 55 60 Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn 65 70 75 80 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly 85 90 95 Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln Glu 100 105 110 Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu Ser 115 120 125 Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp Asp 130 135 140 Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro Arg 145 150 155 160 Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro Thr 165 170 175 Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser Val 180 185 190 Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly Phe 195 200 205 Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro Ala 210 215 220 Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln Leu 225 230 235 240 Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met Ala 245 250 255 Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys Pro 260 265 270 His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln His 275 280 285 Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp Arg 290 295 300 Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu Val 305 310 315 320 Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser Ser 325 330 335 Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr Leu 340 345 350 Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val Arg 355 360 365 Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn Leu 370 375 380 Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr Lys 385 390 395 400 Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys Lys 405 410 415 Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu Arg 420 425 430 Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala 435 440 445 Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His Leu 450 455 460 Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met Phe 465 470 475 480 Lys Thr Glu Gly Pro Asp Ser Asp 485 <210> 50 <211> 504 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of TOM70-UB-p53 <400> 50 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr Gln Ile Phe 20 25 30 Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser 35 40 45 Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 50 55 60 Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp 65 70 75 80 Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His 85 90 95 Leu Val Leu Arg Leu Arg Gly Gly Glu Glu Pro Gln Ser Asp Pro Ser 100 105 110 Val Glu Pro Pro Leu Ser Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu 115 120 125 Leu Pro Glu Asn Asn Val Leu Ser Pro Leu Pro Ser Gln Ala Met Asp 130 135 140 Asp Leu Met Leu Ser Pro Asp Asp Ile Glu Gln Trp Phe Thr Glu Asp 145 150 155 160 Pro Gly Pro Asp Glu Ala Pro Arg Met Pro Glu Ala Ala Pro Arg Val 165 170 175 Ala Pro Ala Pro Ala Ala Pro Thr Pro Ala Ala Pro Ala Pro Ala Pro 180 185 190 Ser Trp Pro Leu Ser Ser Ser Val Pro Ser Gln Lys Thr Tyr Gln Gly 195 200 205 Ser Tyr Gly Phe Arg Leu Gly Phe Leu His Ser Gly Thr Ala Lys Ser 210 215 220 Val Thr Cys Thr Tyr Ser Pro Ala Leu Asn Lys Met Phe Cys Gln Leu 225 230 235 240 Ala Lys Thr Cys Pro Val Gln Leu Trp Val Asp Ser Thr Pro Pro Pro 245 250 255 Gly Thr Arg Val Arg Ala Met Ala Ile Tyr Lys Gln Ser Gln His Met 260 265 270 Thr Glu Val Val Arg Arg Cys Pro His His Glu Arg Cys Ser Asp Ser 275 280 285 Asp Gly Leu Ala Pro Pro Gln His Leu Ile Arg Val Glu Gly Asn Leu 290 295 300 Arg Val Glu Tyr Leu Asp Asp Arg Asn Thr Phe Arg His Ser Val Val 305 310 315 320 Val Pro Tyr Glu Pro Pro Glu Val Gly Ser Asp Cys Thr Thr Ile His 325 330 335 Tyr Asn Tyr Met Cys Asn Ser Ser Cys Met Gly Gly Met Asn Arg Arg 340 345 350 Pro Ile Leu Thr Ile Ile Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu 355 360 365 Gly Arg Asn Ser Phe Glu Val Arg Val Cys Ala Cys Pro Gly Arg Asp 370 375 380 Arg Arg Thr Glu Glu Glu Asn Leu Arg Lys Lys Gly Glu Pro His His 385 390 395 400 Glu Leu Pro Pro Gly Ser Thr Lys Arg Ala Leu Pro Asn Asn Thr Ser 405 410 415 Ser Ser Pro Gln Pro Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr 420 425 430 Leu Gln Ile Arg Gly Arg Glu Arg Phe Glu Met Phe Arg Glu Leu Asn 435 440 445 Glu Ala Leu Glu Leu Lys Asp Ala Gln Ala Gly Lys Glu Pro Gly Gly 450 455 460 Ser Arg Ala His Ser Ser His Leu Lys Ser Lys Lys Gly Gln Ser Thr 465 470 475 480 Ser Arg His Lys Lys Leu Met Phe Lys Thr Glu Gly Pro Asp Ser Asp 485 490 495 Leu Glu His His His His His His 500 <210> 51 <211> 519 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of TOM70-(GGGGS)3-UB-p53 <400> 51 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr Gly Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ile Phe Val 35 40 45 Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp 50 55 60 Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro 65 70 75 80 Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly 85 90 95 Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu 100 105 110 Val Leu Arg Leu Arg Gly Gly Glu Glu Pro Gln Ser Asp Pro Ser Val 115 120 125 Glu Pro Pro Leu Ser Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu 130 135 140 Pro Glu Asn Asn Val Leu Ser Pro Leu Pro Ser Gln Ala Met Asp Asp 145 150 155 160 Leu Met Leu Ser Pro Asp Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro 165 170 175 Gly Pro Asp Glu Ala Pro Arg Met Pro Glu Ala Ala Pro Arg Val Ala 180 185 190 Pro Ala Pro Ala Ala Pro Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser 195 200 205 Trp Pro Leu Ser Ser Ser Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser 210 215 220 Tyr Gly Phe Arg Leu Gly Phe Leu His Ser Gly Thr Ala Lys Ser Val 225 230 235 240 Thr Cys Thr Tyr Ser Pro Ala Leu Asn Lys Met Phe Cys Gln Leu Ala 245 250 255 Lys Thr Cys Pro Val Gln Leu Trp Val Asp Ser Thr Pro Pro Pro Gly 260 265 270 Thr Arg Val Arg Ala Met Ala Ile Tyr Lys Gln Ser Gln His Met Thr 275 280 285 Glu Val Val Arg Arg Cys Pro His His Glu Arg Cys Ser Asp Ser Asp 290 295 300 Gly Leu Ala Pro Pro Gln His Leu Ile Arg Val Glu Gly Asn Leu Arg 305 310 315 320 Val Glu Tyr Leu Asp Asp Arg Asn Thr Phe Arg His Ser Val Val Val 325 330 335 Pro Tyr Glu Pro Pro Glu Val Gly Ser Asp Cys Thr Thr Ile His Tyr 340 345 350 Asn Tyr Met Cys Asn Ser Ser Cys Met Gly Gly Met Asn Arg Arg Pro 355 360 365 Ile Leu Thr Ile Ile Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly 370 375 380 Arg Asn Ser Phe Glu Val Arg Val Cys Ala Cys Pro Gly Arg Asp Arg 385 390 395 400 Arg Thr Glu Glu Glu Asn Leu Arg Lys Lys Gly Glu Pro His His Glu 405 410 415 Leu Pro Pro Gly Ser Thr Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser 420 425 430 Ser Pro Gln Pro Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu 435 440 445 Gln Ile Arg Gly Arg Glu Arg Phe Glu Met Phe Arg Glu Leu Asn Glu 450 455 460 Ala Leu Glu Leu Lys Asp Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser 465 470 475 480 Arg Ala His Ser Ser His Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser 485 490 495 Arg His Lys Lys Leu Met Phe Lys Thr Glu Gly Pro Asp Ser Asp Leu 500 505 510 Glu His His His His His His 515 <210> 52 <211> 444 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of TOM70-(GGGGS)3-p53 <400> 52 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr Gly Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Glu Pro Gln 35 40 45 Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln Glu Thr Phe Ser Asp 50 55 60 Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu Ser Pro Leu Pro Ser 65 70 75 80 Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp Asp Ile Glu Gln Trp 85 90 95 Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro Arg Met Pro Glu Ala 100 105 110 Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro Thr Pro Ala Ala Pro 115 120 125 Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser Val Pro Ser Gln Lys 130 135 140 Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly Phe Leu His Ser Gly 145 150 155 160 Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro Ala Leu Asn Lys Met 165 170 175 Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln Leu Trp Val Asp Ser 180 185 190 Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met Ala Ile Tyr Lys Gln 195 200 205 Ser Gln His Met Thr Glu Val Val Arg Arg Cys Pro His His Glu Arg 210 215 220 Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln His Leu Ile Arg Val 225 230 235 240 Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp Arg Asn Thr Phe Arg 245 250 255 His Ser Val Val Val Pro Tyr Glu Pro Pro Glu Val Gly Ser Asp Cys 260 265 270 Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser Ser Cys Met Gly Gly 275 280 285 Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr Leu Glu Asp Ser Ser 290 295 300 Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val Arg Val Cys Ala Cys 305 310 315 320 Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn Leu Arg Lys Lys Gly 325 330 335 Glu Pro His His Glu Leu Pro Pro Gly Ser Thr Lys Arg Ala Leu Pro 340 345 350 Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys Lys Pro Leu Asp Gly 355 360 365 Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu Arg Phe Glu Met Phe 370 375 380 Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala Gln Ala Gly Lys 385 390 395 400 Glu Pro Gly Gly Ser Arg Ala His Ser Ser His Leu Lys Ser Lys Lys 405 410 415 Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met Phe Lys Thr Glu Gly 420 425 430 Pro Asp Ser Asp Leu Glu His His His His His His 435 440 <210> 53 <211> 525 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of UB-p53-TOM7 <400> 53 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr 20 25 30 Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala 35 40 45 Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile 50 55 60 Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn 65 70 75 80 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly 85 90 95 Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln Glu 100 105 110 Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu Ser 115 120 125 Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp Asp 130 135 140 Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro Arg 145 150 155 160 Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro Thr 165 170 175 Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser Val 180 185 190 Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly Phe 195 200 205 Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro Ala 210 215 220 Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln Leu 225 230 235 240 Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met Ala 245 250 255 Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys Pro 260 265 270 His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln His 275 280 285 Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp Arg 290 295 300 Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu Val 305 310 315 320 Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser Ser 325 330 335 Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr Leu 340 345 350 Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val His 355 360 365 Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn Leu 370 375 380 Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr Lys 385 390 395 400 Arg Ala Leu Ser Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys Lys 405 410 415 Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu Arg 420 425 430 Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala 435 440 445 Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His Leu 450 455 460 Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met Phe 465 470 475 480 Lys Thr Glu Gly Pro Asp Ser Asp Leu Glu Phe Ala Ile Arg Trp Gly 485 490 495 Phe Ile Pro Leu Val Ile Tyr Leu Gly Phe Lys Arg Gly Ala Asp Pro 500 505 510 Gly Met Pro Glu Pro Thr Val Leu Ser Leu Leu Trp Gly 515 520 525 <210> 54 <211> 421 <212> PRT <213> Artificial sequence <220> <223> p53-myc / His amino acid sequence <400> 54 Met Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln 1 5 10 15 Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu 20 25 30 Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp 35 40 45 Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro 50 55 60 Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro 65 70 75 80 Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser 85 90 95 Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly 100 105 110 Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro 115 120 125 Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln 130 135 140 Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met 145 150 155 160 Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys 165 170 175 Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln 180 185 190 His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp 195 200 205 Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu 210 215 220 Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser 225 230 235 240 Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr 245 250 255 Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val 260 265 270 Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn 275 280 285 Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr 290 295 300 Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys 305 310 315 320 Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu 325 330 335 Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp 340 345 350 Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His 355 360 365 Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met 370 375 380 Phe Lys Thr Glu Gly Pro Asp Ser Asp Leu Glu Ser Arg Gly Pro Phe 385 390 395 400 Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Gly His 405 410 415 His His His His His 420 <210> 55 <211> 230 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of Granzyme B <400> 55 Arg Gly Gly Ile Ile Gly Gly His Glu Ala Lys Pro His Ser Arg Pro 1 5 10 15 Tyr Met Ala Tyr Leu Met Ile Trp Asp Gln Lys Ser Leu Lys Arg Cys 20 25 30 Gly Gly Phe Leu Ile Gln Asp Asp Phe Val Leu Thr Ala Ala His Cys 35 40 45 Trp Gly Ser Ser Ile Asn Val Thr Leu Gly Ala His Asn Ile Lys Glu 50 55 60 Gln Glu Pro Thr Gln Gln Phe Ile Pro Val Lys Arg Pro Ile Pro His 65 70 75 80 Pro Ala Tyr Asn Pro Lys Asn Phe Ser Asn Asp Ile Met Leu Leu Gln 85 90 95 Leu Glu Arg Lys Ala Lys Arg Thr Arg Ala Val Gln Pro Leu Arg Leu 100 105 110 Pro Ser Asn Lys Ala Gln Val Lys Pro Gly Gln Thr Cys Ser Val Ala 115 120 125 Gly Trp Gly Gln Thr Ala Pro Leu Gly Lys His Ser His Thr Leu Gln 130 135 140 Glu Val Lys Met Thr Val Gln Glu Asp Arg Lys Cys Glu Ser Asp Leu 145 150 155 160 Arg His Tyr Tyr Asp Ser Thr Ile Glu Leu Cys Val Gly Asp Pro Glu 165 170 175 Ile Lys Lys Thr Ser Phe Lys Gly Asp Ser Gly Gly Pro Leu Val Cys 180 185 190 Asn Lys Val Ala Gln Gly Ile Val Ser Tyr Gly Arg Asn Asn Gly Met 195 200 205 Pro Pro Arg Ala Cys Thr Lys Val Ser Ser Phe Val His Trp Ile Lys 210 215 220 Lys Thr Met Lys Arg Tyr 225 230 <210> 56 <211> 354 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of TOM70-(GGGGS)3-UB-granzyme B <400> 56 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr Gly Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ile Phe Val 35 40 45 Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp 50 55 60 Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro 65 70 75 80 Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly 85 90 95 Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu 100 105 110 Val Leu Arg Leu Arg Gly Gly Ile Ile Gly Gly His Glu Ala Lys Pro 115 120 125 His Ser Arg Pro Tyr Met Ala Tyr Leu Met Ile Trp Asp Gln Lys Ser 130 135 140 Leu Lys Arg Cys Gly Gly Phe Leu Ile Arg Asp Asp Phe Val Leu Thr 145 150 155 160 Ala Ala His Cys Trp Gly Ser Ser Ile Asn Val Thr Leu Gly Ala His 165 170 175 Asn Ile Lys Glu Gln Glu Pro Thr Gln Gln Phe Ile Pro Val Lys Arg 180 185 190 Pro Ile Pro His Pro Ala Tyr Asn Pro Lys Asn Phe Ser Asn Asp Ile 195 200 205 Met Leu Leu Gln Leu Glu Arg Lys Ala Lys Arg Thr Arg Ala Val Gln 210 215 220 Pro Leu Arg Leu Pro Ser Asn Lys Ala Gln Val Lys Pro Gly Gln Thr 225 230 235 240 Cys Ser Val Ala Gly Trp Gly Gln Thr Ala Pro Leu Gly Lys His Ser 245 250 255 His Thr Leu Gln Glu Val Lys Met Thr Val Gln Glu Asp Arg Lys Cys 260 265 270 Glu Ser Asp Leu Arg His Tyr Tyr Asp Ser Thr Ile Glu Leu Cys Val 275 280 285 Gly Asp Pro Glu Ile Lys Lys Thr Ser Phe Lys Gly Asp Ser Gly Gly 290 295 300 Pro Leu Val Cys Asn Lys Val Ala Gln Gly Ile Val Ser Tyr Gly Arg 305 310 315 320 Asn Asn Gly Met Pro Pro Arg Ala Cys Thr Lys Val Ser Ser Phe Val 325 330 335 His Trp Ile Lys Lys Thr Met Lys Arg Tyr Leu Glu His His His His 340 345 350 His His <210> 57 <211> 360 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of UB-Granzyme B-TOM7 <400> 57 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr 20 25 30 Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala 35 40 45 Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile 50 55 60 Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn 65 70 75 80 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly 85 90 95 Ile Ile Gly Gly His Glu Ala Lys Pro His Ser Arg Pro Tyr Met Ala 100 105 110 Tyr Leu Met Ile Trp Asp Gln Lys Ser Leu Lys Arg Cys Gly Gly Phe 115 120 125 Leu Ile Arg Asp Asp Phe Val Leu Thr Ala Ala His Cys Trp Gly Ser 130 135 140 Ser Ile Asn Val Thr Leu Gly Ala His Asn Ile Lys Glu Gln Glu Pro 145 150 155 160 Thr Gln Gln Phe Ile Pro Val Lys Arg Pro Ile Pro His Pro Ala Tyr 165 170 175 Asn Pro Lys Asn Phe Ser Asn Asp Ile Met Leu Leu Gln Leu Glu Arg 180 185 190 Lys Ala Lys Arg Thr Arg Ala Val Gln Pro Leu Arg Leu Pro Ser Asn 195 200 205 Lys Ala Gln Val Lys Pro Gly Gln Thr Cys Ser Val Ala Gly Trp Gly 210 215 220 Gln Thr Ala Pro Leu Gly Lys His Ser His Thr Leu Gln Glu Val Lys 225 230 235 240 Met Thr Val Gln Glu Asp Arg Lys Cys Glu Ser Asp Leu Arg His Tyr 245 250 255 Tyr Asp Ser Thr Ile Glu Leu Cys Val Gly Asp Pro Glu Ile Lys Lys 260 265 270 Thr Ser Phe Lys Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Lys Val 275 280 285 Ala Gln Gly Ile Val Ser Tyr Gly Arg Asn Asn Gly Met Pro Pro Arg 290 295 300 Ala Cys Thr Lys Val Ser Ser Phe Val His Trp Ile Lys Lys Thr Met 305 310 315 320 Lys Arg Tyr Leu Glu Phe Ala Ile Arg Trp Gly Phe Ile Pro Leu Val 325 330 335 Ile Tyr Leu Gly Phe Lys Arg Gly Ala Asp Pro Gly Met Pro Glu Pro 340 345 350 Thr Val Leu Ser Leu Leu Trp Gly 355 360 <210> 58 <211> 189 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of RKIP <400> 58 Arg Gly Gly Pro Val Asp Leu Ser Lys Trp Ser Gly Pro Leu Ser Leu 1 5 10 15 Gln Glu Val Asp Glu Gln Pro Gln His Pro Leu His Val Thr Tyr Ala 20 25 30 Gly Ala Ala Val Asp Glu Leu Gly Lys Val Leu Thr Pro Thr Gln Val 35 40 45 Lys Asn Arg Pro Thr Ser Ile Ser Trp Asp Gly Leu Asp Ser Gly Lys 50 55 60 Leu Tyr Thr Leu Val Leu Thr Asp Pro Asp Ala Pro Ser Arg Lys Asp 65 70 75 80 Pro Lys Tyr Arg Glu Trp His His Phe Leu Val Val Asn Met Lys Gly 85 90 95 Asn Asp Ile Ser Ser Gly Thr Val Leu Ser Asp Tyr Val Gly Ser Gly 100 105 110 Pro Pro Lys Gly Thr Gly Leu His Arg Tyr Val Trp Leu Val Tyr Glu 115 120 125 Gln Asp Arg Pro Leu Lys Cys Asp Glu Pro Ile Leu Ser Asn Arg Ser 130 135 140 Gly Asp His Arg Gly Lys Phe Lys Val Ala Ser Phe Arg Lys Lys Tyr 145 150 155 160 Glu Leu Arg Ala Pro Val Ala Gly Thr Cys Tyr Gln Ala Glu Trp Asp 165 170 175 Asp Tyr Val Pro Lys Leu Tyr Glu Gln Leu Ser Gly Lys 180 185 <210> 59 <211> 313 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of TOM70-(GGGGS)3-UB-RKIP <400> 59 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr Gly Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ile Phe Val 35 40 45 Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp 50 55 60 Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro 65 70 75 80 Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly 85 90 95 Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu 100 105 110 Val Leu Arg Leu Arg Gly Gly Pro Val Asp Leu Ser Lys Trp Ser Gly 115 120 125 Pro Leu Ser Leu Gln Glu Val Asp Glu Gln Pro Gln His Pro Leu His 130 135 140 Val Thr Tyr Ala Gly Ala Ala Val Asp Glu Leu Gly Lys Val Leu Thr 145 150 155 160 Pro Thr Gln Val Lys Asn Arg Pro Thr Ser Ile Ser Trp Asp Gly Leu 165 170 175 Asp Ser Gly Lys Leu Tyr Thr Leu Val Leu Thr Asp Pro Asp Ala Pro 180 185 190 Ser Arg Lys Asp Pro Lys Tyr Arg Glu Trp His His Phe Leu Val Val 195 200 205 Asn Met Lys Gly Asn Asp Ile Ser Ser Gly Thr Val Leu Ser Asp Tyr 210 215 220 Val Gly Ser Gly Pro Pro Lys Gly Thr Gly Leu His Arg Tyr Val Trp 225 230 235 240 Leu Val Tyr Glu Gln Asp Arg Pro Leu Lys Cys Asp Glu Pro Ile Leu 245 250 255 Ser Asn Arg Ser Gly Asp His Arg Gly Lys Phe Lys Val Ala Ser Phe 260 265 270 Arg Lys Lys Tyr Glu Leu Arg Ala Pro Val Ala Gly Thr Cys Tyr Gln 275 280 285 Ala Glu Trp Asp Asp Tyr Val Pro Lys Leu Tyr Glu Gln Leu Ser Gly 290 295 300 Lys Leu Glu His His His His His His 305 310 <210> 60 <211> 405 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of PTEN <400> 60 Arg Gly Gly Thr Ala Ile Ile Lys Glu Ile Val Ser Arg Asn Lys Arg 1 5 10 15 Arg Tyr Gln Glu Asp Gly Phe Asp Leu Asp Leu Thr Tyr Ile Tyr Pro 20 25 30 Asn Ile Ile Ala Met Gly Phe Pro Ala Glu Arg Leu Glu Gly Val Tyr 35 40 45 Arg Asn Asn Ile Asp Asp Val Val Arg Phe Leu Asp Ser Lys His Lys 50 55 60 Asn His Tyr Lys Ile Tyr Asn Leu Cys Ala Glu Arg His Tyr Asp Thr 65 70 75 80 Ala Lys Phe Asn Cys Arg Val Ala Gln Tyr Pro Phe Glu Asp His Asn 85 90 95 Pro Pro Gln Leu Glu Leu Ile Lys Pro Phe Cys Glu Asp Leu Asp Gln 100 105 110 Trp Leu Ser Glu Asp Asp Asn His Val Ala Ala Ile His Cys Lys Ala 115 120 125 Gly Lys Gly Arg Thr Gly Val Met Ile Cys Ala Tyr Leu Leu His Arg 130 135 140 Gly Lys Phe Leu Lys Ala Gln Glu Ala Leu Asp Phe Tyr Gly Glu Val 145 150 155 160 Arg Thr Arg Asp Lys Lys Gly Val Thr Ile Pro Ser Gln Arg Arg Tyr 165 170 175 Val Tyr Tyr Tyr Ser Tyr Leu Leu Lys Asn His Leu Asp Tyr Arg Pro 180 185 190 Val Ala Leu Leu Phe His Lys Met Met Phe Glu Thr Ile Pro Met Phe 195 200 205 Ser Gly Gly Thr Cys Asn Pro Gln Phe Val Val Cys Gln Leu Lys Val 210 215 220 Lys Ile Tyr Ser Ser Asn Ser Gly Pro Thr Arg Arg Glu Asp Lys Phe 225 230 235 240 Met Tyr Phe Glu Phe Pro Gln Pro Leu Pro Val Cys Gly Asp Ile Lys 245 250 255 Val Glu Phe Phe His Lys Gln Asn Lys Met Leu Lys Lys Asp Lys Met 260 265 270 Phe His Phe Trp Val Asn Thr Phe Phe Ile Pro Gly Pro Glu Glu Thr 275 280 285 Ser Glu Lys Val Glu Asn Gly Ser Leu Cys Asp Gln Glu Ile Asp Ser 290 295 300 Ile Cys Ser Ile Glu Arg Ala Asp Asn Asp Lys Glu Tyr Leu Val Leu 305 310 315 320 Thr Leu Thr Lys Asn Asp Leu Asp Lys Ala Asn Lys Asp Lys Ala Asn 325 330 335 Arg Tyr Phe Ser Pro Asn Phe Lys Val Lys Leu Tyr Phe Thr Lys Thr 340 345 350 Val Glu Glu Pro Ser Asn Pro Glu Ala Ser Ser Ser Thr Ser Val Thr 355 360 365 Pro Asp Val Ser Asp Asn Glu Pro Asp His Tyr Arg Tyr Ser Asp Thr 370 375 380 Thr Asp Ser Asp Pro Glu Asn Glu Pro Phe Asp Glu Asp Gln His Thr 385 390 395 400 Gln Ile Thr Lys Val 405 <210> 61 <211> 529 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of TOM70-(GGGGS)3-UB-PTEN <400> 61 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr Gly Gly Gly 20 25 30 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ile Phe Val 35 40 45 Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp 50 55 60 Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro 65 70 75 80 Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly 85 90 95 Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu 100 105 110 Val Leu Arg Leu Arg Gly Gly Thr Ala Ile Ile Lys Glu Ile Val Ser 115 120 125 Arg Asn Lys Arg Arg Tyr Gln Glu Asp Gly Phe Asp Leu Asp Leu Thr 130 135 140 Tyr Ile Tyr Pro Asn Ile Ile Ala Met Gly Phe Pro Ala Glu Arg Leu 145 150 155 160 Glu Gly Val Tyr Arg Asn Asn Ile Asp Asp Val Val Arg Phe Leu Asp 165 170 175 Ser Lys His Lys Asn His Tyr Lys Ile Tyr Asn Leu Cys Ala Glu Arg 180 185 190 His Tyr Asp Thr Ala Lys Phe Asn Cys Arg Val Ala Gln Tyr Pro Phe 195 200 205 Glu Asp His Asn Pro Pro Gln Leu Glu Leu Ile Lys Pro Phe Cys Glu 210 215 220 Asp Leu Asp Gln Trp Leu Ser Glu Asp Asp Asn His Val Ala Ala Ile 225 230 235 240 His Cys Lys Ala Gly Lys Gly Arg Thr Gly Val Met Ile Cys Ala Tyr 245 250 255 Leu Leu His Arg Gly Lys Phe Leu Lys Ala Gln Glu Ala Leu Asp Phe 260 265 270 Tyr Gly Glu Val Arg Thr Arg Asp Lys Lys Gly Val Thr Ile Pro Ser 275 280 285 Gln Arg Arg Tyr Val Tyr Tyr Tyr Ser Tyr Leu Leu Lys Asn His Leu 290 295 300 Asp Tyr Arg Pro Val Ala Leu Leu Phe His Lys Met Met Phe Glu Thr 305 310 315 320 Ile Pro Met Phe Ser Gly Gly Thr Cys Asn Pro Gln Phe Val Val Cys 325 330 335 Gln Leu Lys Val Lys Ile Tyr Ser Ser Asn Ser Gly Pro Thr Arg Arg 340 345 350 Glu Asp Lys Phe Met Tyr Phe Glu Phe Pro Gln Pro Leu Pro Val Cys 355 360 365 Gly Asp Ile Lys Val Glu Phe Phe His Lys Gln Asn Lys Met Leu Lys 370 375 380 Lys Asp Lys Met Phe His Phe Trp Val Asn Thr Phe Phe Ile Pro Gly 385 390 395 400 Pro Glu Glu Thr Ser Glu Lys Val Glu Asn Gly Ser Leu Cys Asp Gln 405 410 415 Glu Ile Asp Ser Ile Cys Ser Ile Glu Arg Ala Asp Asn Asp Lys Glu 420 425 430 Tyr Leu Val Leu Thr Leu Thr Lys Asn Asp Leu Asp Lys Ala Asn Lys 435 440 445 Asp Lys Ala Asn Arg Tyr Phe Ser Pro Asn Phe Lys Val Lys Leu Tyr 450 455 460 Phe Thr Lys Thr Val Glu Glu Pro Ser Asn Pro Glu Ala Ser Ser Ser 465 470 475 480 Thr Ser Val Thr Pro Asp Val Ser Asp Asn Glu Pro Asp His Tyr Arg 485 490 495 Tyr Ser Asp Thr Thr Asp Ser Asp Pro Glu Asn Glu Pro Phe Asp Glu 500 505 510 Asp Gln His Thr Gln Ile Thr Lys Val Leu Glu His His His His His 515 520 525 His <210> 62 <211> 246 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvHER2 <400> 62 Arg Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 1 5 10 15 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 20 25 30 Thr Asp Tyr Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn 50 55 60 Gln Arg Phe Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn 65 70 75 80 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser 130 135 140 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys 145 150 155 160 Lys Ala Ser Gln Asp Val Ser Ile Gly Val Ala Trp Tyr Gln Gln Lys 165 170 175 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr 180 185 190 Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 195 200 205 Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr 210 215 220 Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys 225 230 235 240 Val Glu Ile Lys Arg Thr 245 <210> 63 <211> 374 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of UB-scFvHER2-TOM7 <400> 63 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr 20 25 30 Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala 35 40 45 Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile 50 55 60 Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn 65 70 75 80 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly 85 90 95 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 100 105 110 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 115 120 125 Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 130 135 140 Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 145 150 155 160 Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr 165 170 175 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 180 185 190 Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 195 200 205 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 210 215 220 Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser 225 230 235 240 Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser 245 250 255 Gln Asp Val Ser Ile Gly Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys 260 265 270 Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val 275 280 285 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 290 295 300 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln 305 310 315 320 Tyr Tyr Ile Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 325 330 335 Lys Arg Thr Phe Ala Ile Arg Trp Gly Phe Ile Pro Leu Val Ile Tyr 340 345 350 Leu Gly Phe Lys Arg Gly Ala Asp Pro Gly Met Pro Glu Pro Thr Val 355 360 365 Leu Ser Leu Leu Trp Gly 370 <210> 64 <211> 307 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvHER2-TOM7-myc / His <400> 64 Met Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp 20 25 30 Tyr Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45 Val Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg 50 55 60 Phe Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 130 135 140 Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala 145 150 155 160 Ser Gln Asp Val Ser Ile Gly Val Ala Trp Tyr Gln Gln Lys Pro Gly 165 170 175 Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly 180 185 190 Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 195 200 205 Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220 Gln Tyr Tyr Ile Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu 225 230 235 240 Ile Lys Arg Thr Phe Ala Ile Arg Trp Gly Phe Ile Pro Leu Val Ile 245 250 255 Tyr Leu Gly Phe Lys Arg Gly Ala Asp Pro Gly Met Pro Glu Pro Thr 260 265 270 Val Leu Ser Leu Leu Trp Gly Leu Glu Ser Arg Gly Pro Phe Glu Gln 275 280 285 Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Gly His His His 290 295 300 His His His 305 <210> 65 <211> 251 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvMEL <400> 65 Arg Gly Gly Thr Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser 1 5 10 15 Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn 20 25 30 Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro 35 40 45 Glu Pro Leu Leu Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp 50 55 60 Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn 85 90 95 Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly 100 105 110 Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys 115 120 125 Gly Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 130 135 140 Gly Ser Met Lys Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asn 145 150 155 160 Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp 165 170 175 Ile Ala Glu Ile Arg Leu Lys Ser Asn Asn Phe Ala Arg Tyr Tyr Ala 180 185 190 Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser 195 200 205 Ser Val Tyr Leu Gln Met Ile Asn Leu Arg Ala Glu Asp Thr Gly Ile 210 215 220 Tyr Tyr Cys Thr Ser Tyr Gly Asn Tyr Val Gly His Tyr Phe Asp His 225 230 235 240 Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 245 250 <210> 66 <211> 378 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of UB-scFvMEL-TOM7 <400> 66 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr 20 25 30 Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala 35 40 45 Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile 50 55 60 Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn 65 70 75 80 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly 85 90 95 Thr Asp Ile Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 100 105 110 Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn 115 120 125 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Glu Pro Leu Leu 130 135 140 Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 145 150 155 160 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 165 170 175 Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 180 185 190 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr Ser Gly 195 200 205 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys 210 215 220 Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys 225 230 235 240 Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asn Tyr Trp Met Asn 245 250 255 Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile Ala Glu Ile 260 265 270 Arg Leu Lys Ser Asn Asn Phe Ala Arg Tyr Tyr Ala Glu Ser Val Lys 275 280 285 Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu 290 295 300 Gln Met Ile Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr 305 310 315 320 Ser Tyr Gly Asn Tyr Val Gly His Tyr Phe Asp His Trp Gly Gln Gly 325 330 335 Thr Thr Leu Thr Val Ser Ser Phe Ala Ile Arg Trp Gly Phe Ile Pro 340 345 350 Leu Val Ile Tyr Leu Gly Phe Lys Arg Gly Ala Asp Pro Gly Met Pro 355 360 365 Glu Pro Thr Val Leu Ser Leu Leu Trp Gly 370 375 <210> 67 <211> 312 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvMEL-TOM7-myc / His <400> 67 Met Thr Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser 1 5 10 15 Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp 20 25 30 Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Glu Pro 35 40 45 Leu Leu Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe 50 55 60 Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val 65 70 75 80 Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr 85 90 95 Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr 100 105 110 Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu 115 120 125 Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 130 135 140 Met Lys Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asn Tyr Trp 145 150 155 160 Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile Ala 165 170 175 Glu Ile Arg Leu Lys Ser Asn Asn Phe Ala Arg Tyr Tyr Ala Glu Ser 180 185 190 Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val 195 200 205 Tyr Leu Gln Met Ile Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr 210 215 220 Cys Thr Ser Tyr Gly Asn Tyr Val Gly His Tyr Phe Asp His Trp Gly 225 230 235 240 Gln Gly Thr Thr Leu Thr Val Ser Ser Phe Ala Ile Arg Trp Gly Phe 245 250 255 Ile Pro Leu Val Ile Tyr Leu Gly Phe Lys Arg Gly Ala Asp Pro Gly 260 265 270 Met Pro Glu Pro Thr Val Leu Ser Leu Leu Trp Gly Leu Glu Ser Arg 275 280 285 Gly Pro Phe Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His 290 295 300 Thr Gly His His His His His His 305 310 <210> 68 <211> 250 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvPD-L1 <400> 68 Met Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala 1 5 10 15 Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn 20 25 30 Ser Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly 35 40 45 Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly 50 55 60 Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 65 70 75 80 Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln 85 90 95 Gln Ser Tyr Asp Val Val Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gln Val Gln Val Gln Gln Ser Gly Ala Glu Leu Ala Glu Pro Gly Ala 130 135 140 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 145 150 155 160 Trp Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 165 170 175 Gly Tyr Ile Asn Pro Ser Ser Asp Tyr Asn Glu Tyr Ser Glu Lys Phe 180 185 190 Met Asp Lys Ala Thr Leu Thr Ala Asp Lys Ala Ser Thr Thr Ala Tyr 195 200 205 Met Gln Leu Ile Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 210 215 220 Ala Arg Ser Gly Trp Leu Val His Gly Asp Tyr Tyr Phe Asp Tyr Trp 225 230 235 240 Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 245 250 <210> 69 <211> 315 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvPD-L1-TOM7-myc / His <400> 69 Met Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala 1 5 10 15 Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn 20 25 30 Ser Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly 35 40 45 Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly 50 55 60 Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 65 70 75 80 Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln 85 90 95 Gln Ser Tyr Asp Val Val Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gln Val Gln Val Gln Gln Ser Gly Ala Glu Leu Ala Glu Pro Gly Ala 130 135 140 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 145 150 155 160 Trp Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 165 170 175 Gly Tyr Ile Asn Pro Ser Ser Asp Tyr Asn Glu Tyr Ser Glu Lys Phe 180 185 190 Met Asp Lys Ala Thr Leu Thr Ala Asp Lys Ala Ser Thr Thr Ala Tyr 195 200 205 Met Gln Leu Ile Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 210 215 220 Ala Arg Ser Gly Trp Leu Val His Gly Asp Tyr Tyr Phe Asp Tyr Trp 225 230 235 240 Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Leu Glu Phe Ala Ile Arg 245 250 255 Trp Gly Phe Ile Pro Leu Val Ile Tyr Leu Gly Phe Lys Arg Gly Ala 260 265 270 Asp Pro Gly Met Pro Glu Pro Thr Val Leu Ser Leu Leu Trp Gly Leu 275 280 285 Glu Ser Arg Gly Pro Phe Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 290 295 300 Asn Met His Thr Gly His His His His His His 305 310 315 <210> 70 <211> 15 <212> DNA <213> Artificial sequence <220> <223> Linker <400> 70 ggggsggggs ggggs 15 <210> 71 <211> 75 <212> PRT <213> Artificial sequence <220> <223> amino acid sequence of ubiquitin <400> 71 Gln Leu Phe Val Lys Thr Leu Thr Gly Lys Thr Val Thr Leu Glu Val 1 5 10 15 Glu Ser Ser Asp Thr Ile Asp Asn Val Lys Ser Lys Ile Gln Asp Lys 20 25 30 Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln 35 40 45 Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser 50 55 60 Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly 65 70 75 <210> 72 <211> 225 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding ubiquitin <400> 72 caacttttcg tcaaaactct aacagggaag actgtaaccc tagaggttga atcttccgac 60 actattgaca acgtcaaaag taaaattcaa gataaagaag gtatccctcc ggatcagcag 120 agattgatttttgctggtaa gcaactagaa gatggtagaa ccttgtctga ctacaacatc 180 caaaaggaat ctactcttca cttggtgttg agactccgcg gtggt 225 <210> 73 <211> 400 <212> PRT <213> Artificial sequence <220> <223> amino acid sequence of p53 <400> 73 Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln Glu 1 5 10 15 Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu Ser 20 25 30 Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp Asp 35 40 45 Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro Arg 50 55 60 Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Ala Pro Thr 65 70 75 80 Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser Val 85 90 95 Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly Phe 100 105 110 Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro Ala 115 120 125 Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln Leu 130 135 140 Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met Ala 145 150 155 160 Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys Pro 165 170 175 His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln His 180 185 190 Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp Arg 195 200 205 Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu Val 210 215 220 Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser Ser 225 230 235 240 Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr Leu 245 250 255 Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val Arg 260 265 270 Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn Leu 275 280 285 Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr Lys 290 295 300 Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys Lys 305 310 315 320 Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu Arg 325 330 335 Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala 340 345 350 Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His Leu 355 360 365 Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met Phe 370 375 380 Lys Thr Glu Gly Pro Asp Ser Asp Leu Glu His His His His His His 385 390 395 400 <210> 74 <211> 1203 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding p53 <400> 74 gaggagccgc agtcagatcc tagcgtcgag ccccctctga gtcaggaaac attttcagac 60 ctgtggaaac tacttcctga aaacaacgtt ctgtccccct tgccgtccca agcaatggat 120 gatttgatgc tgtccccgga cgatattgaa caatggttca ctgaagaccc aggtccagat 180 gaagctccca gaatgccaga ggctgctccc cgcgtggccc ctgcaccagc agctcctaca 240 ccggcggccc ctgcaccagc cccctcctgg cccctgtcat cttctgtccc ttcccagaaa 300 acctaccagg gcagctacgg tttccgtctg ggcttcttgc attctgggac agccaagtct 360 gtgacttgca cgtactcccc tgccctcaac aagatgtttt gccaactggc caagacctgc 420 cctgtgcagc tgtgggttga ttccacaccc ccgcccggca cccgcgtccg cgccatggcc 480 atctacaagc agtcacagca catgacggag gttgtgaggc gctgccccca ccatgagcgc 540 tgctcagata gcgatggtct ggcccctcct cagcatctta tccgagtgga aggaaatttg 600 cgtgtggagt atttggatga cagaaacact tttcgacata gtgtggtggt gccctatgag 660 ccgcctgagg ttggctctga ctgtaccacc atccactaca actacatgtg taacagttcc 720 tgcatgggcg gcatgaaccg gaggcccatc ctcaccatca tcacactgga agactccagt 780 ggtaatctac tgggacggaa cagctttgag gtgcgtgttt gtgcctgtcc tgggagagac 840 cggcgcacag aggaagagaa tctccgcaag aaaggggagc ctcaccacga gctgccccca 900 gggagcacta agcgagcact gcccaacaac accagctcct ctccccagcc aaagaagaaa 960 ccactggatg gagaatattt cacccttcag atccgtgggc gtgagcgctt cgagatgttc 1020 cgagagctga atgaggcctt ggaactcaag gatgcccagg ctgggaagga gccagggggg 1080 agcagggctc actccagcca cctgaagtcc aaaaagggtc agtctacctc ccgccataaa 1140 aaactcatgt tcaagacaga agggcctgac tcagacctcg agcaccacca ccaccaccac 1200 tag 1203 <210> 75 <211> 29 PRT Artificial sequence <220> TOM70 from Saccharomyces cerevisiae <400> 75 Met Lys Ser Phe Ile Thr Arg Asn Lys Thr Ala Ile Phe Ala Thr Val 1 5 10 15 Ala Ala Thr Gly Thr Ala Ile Gly Ala Tyr Tyr Tyr Tyr 20 25 <210> 76 <211> 60 <212> PRT <213> Artificial sequence <220> <223> TOM70 for people <400> 76 Met Ala Ala Ser Lys Pro Val Glu Ala Ala Val Val Ala Ala Ala Val 1 5 10 15 Pro Ser Ser Gly Ser Gly Val Gly Gly Gly Gly Thr Ala Gly Pro Gly 20 25 30 Thr Gly Gly Leu Pro Arg Trp Gln Leu Ala Leu Ala Val Gly Ala Pro 35 40 45 Leu Leu Leu Gly Ala Gly Ala Ile Tyr Leu Trp Ser 50 55 60 <210> 77 <211> 29 <212> PRT <213> Artificial sequence <220> <223> TOM20 of brewing yeast <400> 77 Met Ser Gln Ser Asn Pro Ile Leu Arg Gly Leu Ala Ile Thr Thr Ala 1 5 10 15 Ile Ala Ala Leu Ser Ala Thr Gly Tyr Ala Ile Tyr Phe 20 25 <210> 78 <211> twenty four <212> PRT <213> Artificial sequence <220> <223> TOM20 for people <400> 78 Met Val Gly Arg Asn Ser Ala Ile Ala Ala Gly Val Cys Gly Ala Leu 1 5 10 15 Phe Ile Gly Tyr Cys Ile Tyr Phe 20 <210> 79 <211> twenty two <212> PRT <213> Artificial sequence <220> <223> OM45 of brewing yeast <400> 79 Met Ser Ser Arg Ile Ile Val Gly Ser Ala Ala Leu Ala Ala Ala Ile 1 5 10 15 Thr Ala Ser Ile Met Val 20 <210> 80 <211> twenty three <212> PRT <213> Artificial sequence <220> <223> TOM5 of brewing yeast <400> 80 Ala Ala Tyr Val Ala Ala Phe Leu Trp Val Ser Pro Met Ile Trp His 1 5 10 15 Leu Val Lys Lys Gln Trp Lys 20 <210> 81 <211> twenty four <212> PRT <213> Artificial sequence <220> <223> TOM5 for people <400> 81 Ile Arg Asn Phe Leu Ile Tyr Val Ala Leu Leu Arg Val Thr Pro Phe 1 5 10 15 Ile Leu Lys Lys Leu Asp Ser Ile 20 <210> 82 <211> 41 <212> PRT <213> Artificial sequence <220> <223> TOM7 of brewing yeast <400> 82 Ile Leu Thr Leu Thr His Asn Val Ala His Tyr Gly Trp Ile Pro Phe 1 5 10 15 Val Leu Tyr Leu Gly Trp Ala His Thr Ser Asn Arg Pro Asn Phe Leu 20 25 30 Asn Leu Leu Ser Pro Leu Pro Ser Val 35 40 <210> 83 <211> 35 <212> PRT <213> Artificial sequence <220> <223> TOM7 for people <400> 83 Phe Ala Ile Arg Trp Gly Phe Ile Pro Leu Val Ile Tyr Leu Gly Phe 1 5 10 15 Lys Arg Gly Ala Asp Pro Gly Met Pro Glu Pro Thr Val Leu Ser Leu 20 25 30 Leu Trp Gly 35 <210> 84 <211> 55 <212> PRT <213> Artificial sequence <220> <223> TOM22 from Saccharomyces cerevisiae <400> 84 Leu Ala Trp Thr Leu Thr Thr Thr Ala Leu Leu Leu Gly Val Pro Leu 1 5 10 15 Ser Leu Ser Ile Leu Ala Glu Gln Gln Leu Ile Glu Met Glu Lys Thr 20 25 30 Phe Asp Leu Gln Ser Asp Ala Asn Asn Ile Leu Ala Gln Gly Glu Lys 35 40 45 Asp Ala Ala Ala Thr Ala Asn 50 55 <210> 85 <211> 60 <212> PRT <213> Artificial sequence <220> <223> Human TOM22 <400> 85 Ala Ala Leu Trp Ile Gly Thr Thr Ser Phe Met Ile Leu Val Leu Pro 1 5 10 15 Val Val Phe Glu Thr Glu Lys Leu Gln Met Glu Gln Gln Gln Gln Leu 20 25 30 Gln Gln Arg Gln Ile Leu Leu Gly Pro Asn Thr Gly Leu Ser Gly Gly 35 40 45 Met Pro Gly Ala Leu Pro Ser Leu Pro Gly Lys Ile 50 55 60 <210> 86 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Fis1 of brewer's yeast <400> 86 Gly Val Val Val Ala Gly Gly Val Leu Ala Gly Ala Val Ala Val Ala 1 5 10 15 Ser Phe Phe Leu Arg Asn Lys Arg Arg 20 25 <210> 87 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Human Fis1 <400> 87 Gly Leu Val Gly Met Ala Ile Val Gly Gly Met Ala Leu Gly Val Ala 1 5 10 15 Gly Leu Ala Gly Leu Ile Gly Leu Ala Val Ser Lys Ser Lys Ser 20 25 30 <210> 88 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Human Bcl-2α <400> 88 Leu Ser Leu Lys Thr Leu Leu Ser Leu Ala Leu Val Gly Ala Cys Ile 1 5 10 15 Thr Leu Gly Ala Tyr Leu Gly His Lys 20 25 <210> 89 <211> 19 <212> PRT <213> Artificial sequence <220> <223> VAMP1 of brewer's yeast <400> 89 Met Ile Met Leu Gly Ala Ile Cys Ala Ile Ile Val Val Val Ile Val 1 5 10 15 Arg Arg Asp <210> 90 <211> twenty two <212> PRT <213> Artificial sequence <220> <223> Human VAMP1 <400> 90 Met Met Ile Met Leu Gly Ala Ile Cys Ala Ile Ile Val Val Val Ile 1 5 10 15 Val Ile Tyr Phe Phe Thr 20 <210> 91 <211> 60 <212> DNA <213> Artificial sequence <220> <223> P53-Promoter-S <400> 91 gggcatgctc gggcatgccc gggcatgctc gggcatgccc gggcatgctc gggcatgccc 60 60 <210> 92 <211> 60 <212> DNA <213> Artificial sequence <220> <223> P53 - Promoter - AS <400> 92 gggcatgccc gagcatgccc gggcatgccc gagcatgccc gggcatgccc gagcatgccc 60 60 <210> 93 <211> 945 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvPDL1-myc-TOM7 <400> 93 atggacatcg tgatgagcca gtctcccagc agcctggctg tgtctgctgg ggagaaggtg 60 accatgtcct gcaagagctc ccagtccctg ctgaacagcc gcaccaggaa gaactacctg 120 gcctggtacc agcagaagcc aggccagagc cccaagctcc tcatctactg ggccagcacc 180 cgggagagcg gggtgcctga ccgcttcact ggaagtggca gcggcacaga cttcaccctg 240 accatcagct ctgtgcaggc cgaggacctg gcagtgtact actgccagca aagctatgat 300 gtggtgacat ttggagctgg caccaagctg gagctgaagg gaggtggcgg aagcgggggt 360 ggaggatccg ggggcggcgg aagccaggtc caggtgcagc agagcggggc tgagctggcc 420 gagcccgggg cctctgtgaa gatgagctgc aaggcttctg gctacatctt caccagctac 480 tggatgcact ggctcaagca gaggcctggg caggggctgg agtggatcgg ctatatcaac 540 cccagcagtg actacaatga atattctgag aagttcatgg acaaagccac cctgactgct 600 gacaaggcca gcaccaccgc ctacatgcag ctgatcagcc tgacctcaga ggacagcgct 660 gtgtactact gtgcccggag cggctggctg gtgcacgggg actattattt tgattattgg 720 ggccagggca ccacactgac agtgagcagc gaacaaaaac tcatctcaga agaggatctg 780 gtgaagctga gcaaagaggc caagcagaga ctacagcagc tcttcaaggg gagccagttt 840 gccattcgct ggggctttat ccctcttgtg atttacctgg gatttaagag gggtgcagat 900 cccggaatgc ctgaaccaac tgttttgagc ctactttggg gataa 945 <210> 94 <211> 314 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvPDL1-myc-TOM7 <400> 94 Met Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala 1 5 10 15 Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn 20 25 30 Ser Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly 35 40 45 Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly 50 55 60 Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 65 70 75 80 Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln 85 90 95 Gln Ser Tyr Asp Val Val Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Gln Val Gln Val Gln Gln Ser Gly Ala Glu Leu Ala Glu Pro Gly Ala 130 135 140 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 145 150 155 160 Trp Met His Trp Leu Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 165 170 175 Gly Tyr Ile Asn Pro Ser Ser Asp Tyr Asn Glu Tyr Ser Glu Lys Phe 180 185 190 Met Asp Lys Ala Thr Leu Thr Ala Asp Lys Ala Ser Thr Thr Ala Tyr 195 200 205 Met Gln Leu Ile Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 210 215 220 Ala Arg Ser Gly Trp Leu Val His Gly Asp Tyr Tyr Phe Asp Tyr Trp 225 230 235 240 Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Glu Gln Lys Leu Ile Ser 245 250 255 Glu Glu Asp Leu Val Lys Leu Ser Lys Glu Ala Lys Gln Arg Leu Gln 260 265 270 Gln Leu Phe Lys Gly Ser Gln Phe Ala Ile Arg Trp Gly Phe Ile Pro 275 280 285 Leu Val Ile Tyr Leu Gly Phe Lys Arg Gly Ala Asp Pro Gly Met Pro 290 295 300 Glu Pro Thr Val Leu Ser Leu Leu Trp Gly 305 310 <210> 95 <211> 732 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvHER2 <400> 95 atggaagtgc aacttgttga gagtggcgga ggactggtcc aaccgggcgg ttcacttagg 60 ctctcatgtg cagcttcagg gttcacgttc acggactata caatggactg ggtgaggcaa gccctggta agggactgga gtggggttgct gacgttaacc ctaattccgg tgggtccatc 180 240. 240. 240. 240. 240. 240. 240. 240 300. tacctccaga tgaactcctt gcgggcagag gatacagcgg tctactattg cgcgagaaac ttgggaccaa gcttctactt cgactactgg gggcaagga cgcttgttac ggtttcaagc ggaggtggag gaagtggagg tggcggttcc ggcggtggcg gttcagatat acagatgacc 420 480. caatcaccca gttctcttag cgcgtctgta ggcgacaggg taaccataac ctgcaaggcg tcccaggacg tgtcaattgg agttgcctgg tatcagcaaa aacctgggaa agctccgaag 540 ctcctgattt acagcgcatc ttaccgatat actggtgtcc cttcaaggtt cagtggcagt 600 ggatctggga cagactttac gcttactatc agcagtctgc aacctgagga tttcgcgacc tactactgtc agcagtatta catctatccg tacacgttcg gtcaaggtac aaaggtagaa ataaaacgca ct <210> 96 <211> 244 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvHER2 <400> 96 Met Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp 20 25 30 Tyr Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45 Val Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg 50 55 60 Phe Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 130 135 140 Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala 145 150 155 160 Ser Gln Asp Val Ser Ile Gly Val Ala Trp Tyr Gln Gln Lys Pro Gly 165 170 175 Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly 180 185 190 Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 195 200 205 Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220 Gln Tyr Tyr Ile Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu 225 230 235 240 Ile Lys Arg Thr <210> 97 <211> 927 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvHER2-myc-TOM7 <400> 97 atggaagtgc aacttgttga gagtggcgga ggactggtcc aaccgggcgg ttcacttagg 60 ctctcatgtg cagcttcagg gttcacgttc acggactata caatggactg ggtgaggcaa 120 gccctggta agggactgga gtggggttgct gacgttaacc ctaattccgg tgggtccatc 180 240. snowflake gattcaaggg ctttcagtcg snowflake aaacaccctc 300. tacctccaga tgaactcctt gcgggcagag gatacagcgg tctactattg cgcgagaaac ttgggaccaa gcttctactt cgactactgg gggcaagga cgcttgttac ggtttcaagc ggaggtggag gaagtggagg tggcggttcc ggcggtggcg gttcagatat acagatgacc 420 480. caatcaccca gttctcttag cgcgtctgta ggcgacaggg taaccataac ctgcaaggcg tcccaggacg tgtcaattgg agttgcctgg tatcagcaaa aacctgggaa agctccgaag 540 ctcctgattt acagcgcatc ttaccgatat actggtgtcc cttcaaggtt cagtggcagt 600 ggatctggga cagactttac gcttactatc agcagtctgc aacctgagga tttcgcgacc tactactgtc agcagtatta catctatccg tacacgttcg gtcaaggtac aaaggtagaa ataaaacgca ctgaacaaaa actcatctca gaagaggatc tggtgaagct gagacaaagag gccaagcaga gactacagca gctcttcaag gggagccagt ttgccattcg ctggggcttt 840 atccctcttg tgatttacct gggatttaag aggggtgcag atcccggaat gcctgaacca 900 actgttttga gcctactttg gggataa 927 <210> 98 <211> 308 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvHER2-myc-TOM7 <400> 98 Met Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp 20 25 30 Tyr Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45 Val Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg 50 55 60 Phe Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 130 135 140 Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala 145 150 155 160 Ser Gln Asp Val Ser Ile Gly Val Ala Trp Tyr Gln Gln Lys Pro Gly 165 170 175 Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly 180 185 190 Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 195 200 205 Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220 Gln Tyr Tyr Ile Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu 225 230 235 240 Ile Lys Arg Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Val Lys 245 250 255 Leu Ser Lys Glu Ala Lys Gln Arg Leu Gln Gln Leu Phe Lys Gly Ser 260 265 270 Gln Phe Ala Ile Arg Trp Gly Phe Ile Pro Leu Val Ile Tyr Leu Gly 275 280 285 Phe Lys Arg Gly Ala Asp Pro Gly Met Pro Glu Pro Thr Val Leu Ser 290 295 300 Leu Leu Trp Gly 305 <210> 99 <211> 726 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvMSLN <400> 99 atgcaagtgc agctcgtcca gtctggggct gaggtgaaga ggcctggagc cagtgttcag 60 gtgtcctgcc gggcctctgg ctacagcatc aacacctact atatgcagtg ggtgcggcag 120 gcccctgggg ccggcctgga gtggatgggc gtcatcaatc ccagcggggt gacctcctat 180 gcccagaagt tccagggccg cgtgactctc accaatgaca ccagcaccaa cacagtctac 240 atgcagctga acagcctcac ttcagctgac acagctgtgt actactgtgc ccgctgggcc 300 ctgtggggag actttggcat ggatgtgtgg ggcaagggca ctctggtgac agtgagcagt 360 ggagggggcg gcagcggtgg cggtggaagt ggcggaggag gcagtgacat ccagatgacc 420 cagagcccct ccacactgtc tgcttccatc ggggacagag tcaccatcac ctgccgcgcc 480 agcgagggca tctaccactg gctggcctgg taccagcaga aaccaggaaa agcccccaag 540 ctgctgattt acaaggcctc ctccctggct tcaggcgccc caagccgctt cagcggctcc 600 ggctctggaa cagacttcac cctgacaatc agcagcctgc agccagatga ttttgccacc 660 tattactgcc agcagtactc caactacccc ctgaccttcg gcgggggcac caagttggag 720 atcaag 726 <210> 100 <211> 242 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvMSLN <400> 100 Met Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly 1 5 10 15 Ala Ser Val Gln Val Ser Cys Arg Ala Ser Gly Tyr Ser Ile Asn Thr 20 25 30 Tyr Tyr Met Gln Trp Val Arg Gln Ala Pro Gly Ala Gly Leu Glu Trp 35 40 45 Met Gly Val Ile Asn Pro Ser Gly Val Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Leu Thr Asn Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Ala Leu Trp Gly Asp Phe Gly Met Asp Val Trp Gly Lys 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 130 135 140 Thr Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Arg Ala 145 150 155 160 Ser Glu Gly Ile Tyr His Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly 165 170 175 Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Ala Ser Gly 180 185 190 Ala Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 195 200 205 Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220 Gln Tyr Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu 225 230 235 240 Ile Lys <210> 101 <211> 921 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence encoding scFvMSLN-myc-TOM7 <400> 101 atgcaagtgc agctcgtcca gtctggggct gaggtgaaga ggcctggagc cagtgttcag 60 gtgtcctgcc gggcctctgg ctacagcatc aacacctact atatgcagtg ggtgcggcag 120 gcccctgggg ccggcctgga gtggatgggc gtcatcaatc ccagcggggt gacctcctat 180 gcccagaagt tccagggccg cgtgactctc accaatgaca ccagcaccaa cacagtctac 240 atgcagctga acagcctcac ttcagctgac acagctgtgt actactgtgc ccgctgggcc 300 ctgtggggag actttggcat ggatgtgtgg ggcaagggca ctctggtgac agtgagcagt 360 ggagggggcg gcagcggtgg cggtggaagt ggcggaggag gcagtgacat ccagatgacc 420 cagagcccct ccacactgtc tgcttccatc ggggacagag tcaccatcac ctgccgcgcc 480 agcgagggca tctaccactg gctggcctgg taccagcaga aaccaggaaa agcccccaag 540 ctgctgattt acaaggcctc ctccctggct tcaggcgccc caagccgctt cagcggctcc 600 ggctctggaa cagacttcac cctgacaatc agcagcctgc agccagatga ttttgccacc 660 tattactgcc agcagtactc caactacccc ctgaccttcg gcgggggcac caagttggag 720 atcaaggaac aaaaactcat ctcagaagag gatctggtga agctgagcaa agaggccaag 780 cagagactac agcagctctt caaggggagc cagtttgcca ttcgctgggg ctttatccct 840 cttgtgattt acctgggatt taagaggggt gcagatcccg gaatgcctga accaactgtt 900 ttgagcctac tttggggata a 921 <210> 102 <211> 306 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of scFvMSLN-myc-TOM7 <400> 102 Met Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly 1 5 10 15 Ala Ser Val Gln Val Ser Cys Arg Ala Ser Gly Tyr Ser Ile Asn Thr 20 25 30 Tyr Tyr Met Gln Trp Val Arg Gln Ala Pro Gly Ala Gly Leu Glu Trp 35 40 45 Met Gly Val Ile Asn Pro Ser Gly Val Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Leu Thr Asn Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Ala Leu Trp Gly Asp Phe Gly Met Asp Val Trp Gly Lys 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 130 135 140 Thr Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Arg Ala 145 150 155 160 Ser Glu Gly Ile Tyr His Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly 165 170 175 Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Ala Ser Gly 180 185 190 Ala Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 195 200 205 Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln 210 215 220 Gln Tyr Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu 225 230 235 240 Ile Lys Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Val Lys Leu Ser 245 250 255 Lys Glu Ala Lys Gln Arg Leu Gln Gln Leu Phe Lys Gly Ser Gln Phe 260 265 270 Ala Ile Arg Trp Gly Phe Ile Pro Leu Val Ile Tyr Leu Gly Phe Lys 275 280 285 Arg Gly Ala Asp Pro Gly Met Pro Glu Pro Thr Val Leu Ser Leu Leu 290 295 300 Trp Gly 305
Claims
1. A modified mitochondria containing an anticancer agent; in, The anticancer agent is combined with triphenylphosphine; The modified mitochondria are those that bind to a single-stranded variable region fragment that specifically binds to Her2. The amino acid sequence of the single-stranded variable region fragment that specifically binds to Her2 is shown in SEQ ID NO: 98; The anticancer agent mentioned is doxorubicin.
2. A pharmaceutical composition for the prevention or treatment of cancer, comprising modified mitochondria according to claim 1, wherein the modified mitochondria are the active ingredient of the pharmaceutical composition.
3. The use of the modified mitochondria according to claim 1 in the preparation of pharmaceutical compositions for treating cancer, in, The cancer is selected from any one of the following groups: breast cancer, lung cancer, and stomach cancer.
4. A method for preparing mitochondria comprising an anticancer agent, comprising: The anticancer agent and isolated mitochondria were mixed together; The anticancer agent is combined with triphenylphosphine; The isolated mitochondria are those that have bound to a single-stranded variable region fragment that specifically binds to Her2, and the amino acid sequence of the single-stranded variable region fragment that specifically binds to Her2 is shown in SEQ ID NO:
98. The anticancer agent mentioned is doxorubicin.
Citation Information
Patent Citations
Image processing method and apparatus using convolution neural network
KR1020190048279A
Modified mitochondria and use thereof
KR1020190124656A
Pharmaceutical composition for preventing hair loss and promoting hair growth comprising isolated mitochondria
KR102111321B1
KR20190124656A
